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I Abstract 
Keywords: hot melt extrusion, co-crystal, NIR, model shear, twin screw 
extrusion, quantification, partial least squares, solvent-free, continuous 
cocrystallisation. 
This project utilised a novel solvent-free continuous cocrystallisation (SFCC) 
method to manufacture pharmaceutical co-crystals. The objectives were to 
optimize the process towards achieving high co-crystal yields and to 
understand the behaviour of co-crystals under different conditions. Particular 
attention was paid to the development of near infrared (NIR) spectroscopy as 
a process analytical technology (PAT). 
Twin screw, hot melt extrusion was the base technique of the SFCC process. 
Changing parameters such as temperature, screw speed and screw 
geometry was important for improving the co-crystal yield. The level of 
mixing and shear was directly influenced by the screw geometry, whilst the 
screw speed was an important parameter for controlling the residence time 
of the material during hot melt extrusion. Ibuprofen – nicotinamide 1:1 co-
crystals and carbamazepine – nicotinamide 1:1 co-crystals were successfully 
manufactured using the SFCC method. 
Characterisation techniques were important for this project, and NIR 
spectroscopy proved to be a convenient, accurate analytical technique for 
identifying the formation of co-crystals along the extruder barrel. Separate 
thermal and model shear deformation studies were also carried out to 
determine the effect of temperature and shear on co-crystal formation for 
several different pharmaceutical co-crystal pairs. 
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Finally, NIR spectroscopy was used to create two partial least squares 
regression models, for predicting the 1:1 co-crystal yield of ibuprofen – 
nicotinamide and carbamazepine – nicotinamide, when in a powder mixture 
with the respective pure API. It is believed that the prediction models created 
in this project can be used to facilitate future in-line PAT studies of 
pharmaceutical co-crystals during different manufacturing processes. 
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III Abbreviations 
SFCC  Solvent-free continuous cocrystallisation 
API   Active pharmaceutical ingredient 
CBZ  Carbamazepine 
NIC   Nicotinamide 
IBU   Ibuprofen 
PM  Physical mixture 
CC   Co-crystal 
FDA   Food and drug administration 
CDER  Centre for drug evaluation and research 
NCE   New chemical entity 
HME   Hot melt extrusion 
EPSRC Engineering and physical sciences research council 
SEM  Scanning electron microscopy 
DSC  Differential scanning calorimetry 
NIR  Near infrared spectroscopy 
PXRD  Powder X-ray diffraction 
APS  Academy of pharmaceutical sciences 
BACG  British association for crystal growth 
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SNV  Standard normal variate 
SGS  Savitzky-Golay smoothing 
NS  Norris smoothing 
PLS   Partial least squares 
IQPC  The international quality and productivity centre  
PAT  Process analytical technology/tool 
QbD  Quality by design 
R&D  Research and development 
HPLC  High performance liquid chromatography 
USPC  The United States pharmacopeial convention 
RMSEC Root mean square error of calibration 
RMSEP Root mean square error of prediction 
RMSECV Root mean square error of cross validation 
R2  Correlation coefficient 
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IV Figure index 
Figure 2.1 An illustration of different solvent interactions with a crystal 
(Hilfiker 2006). 
Figure 2.2  A diagram showing the fundamental differences between 
polymorphs, co-crystals, salts and solvates/hydrates. 
Figure 2.3  The classification of multi-component solid forms. They can 
overlap with one another and they can exhibit polymorphism 
(Aitipamula et al. 2012). 
Figure 2.4  Common hydrogen bond synthons found in supramolecular 
assemblies. 
Figure 2.5  Solubility phase diagram of components A and B and co-crystal 
AB. The subscript ‘T’ is total concentration and [B]tr is the 
transition concentration. The four different regions are labelled 
I-IV (Nehm et al. 2006). 
Figure 2.6  A diagram of moisture sorption by a deliquescent material, Ds, 
dissolution of co-crystal components, and cocrystallisation of 
the components A and B (Jayasankar et al. 2007). 
Figure 2.7  A diagram of the mixed fusion Kofler method showing two 
components (A and B) coming in contact with each other to 
form a zone of mixing. Cocrystallisation can occur in this mixing 
zone (Berry et al. 2008). 
Figure 2.8  Four different screw operations used in twin screw extrusion 
(Dhumal et al. 2010). 
Figure 2.9  An illustration of an intermeshing co-rotating twin screw from 
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two different angles (Ghebre-Selassie and Martin 2003). 
Figure 2.10  Schematic representation of caffeine – maleic acid co-crystal 
formation using SFCC (Kulkarni et al. 2015). 
Figure 3.1  Carbamazepine diagram (Kelly and Rodríguez-Hornedo 2009). 
Figure 3.2  Ibuprofen diagram (Williams et al. 2012). 
Figure 3.3  Nicotinamide diagram (Chiarella et al. 2007). 
Figure 3.4  Salicylic acid diagram (Nordström and Rasmuson 2006). 
Figure 3.5  Caffeine diagram (Pinto and Diogo 2006). 
Figure 3.6  Maleic acid diagram (Database 2016). 
Figure 3.7 1:1 IBU-NIC co-crystal molecular structure. Hydrogen bonding 
is shown by light blue and red dashed lines. Source: 
Fleischman et al. (Fleischman et al. 2003) via Cambridge 
Structural Database (Allen 2002). 
Figure 3.8 1:1 CBZ-NIC co-crystal molecular structure. Hydrogen bonding 
is shown by light blue and red dashed lines. Source: Berry et 
al. (Berry et al. 2008) 2008 via Cambridge Structural Database 
(Allen 2002). 
Figure 3.9  Bragg’s law analogy. Two crystallographic planes are shown 
with spacing, d. Also two incident X-rays are drawn to show 
coherent scattering and their incident angle, Theta (θ) (Adapted 
from (Giacovazzo 2002)). 
Figure 3.10  A simplified diagram of differential scanning calorimetry. 
Figure 3.11  Photographs of screw geometry A and B situated in an open 
extruder barrel. 
Figure 3.12  Individual screw components used for screw geometries A and 
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B. Forward conveying screw (Left), broad end kneading 
component (Centre), narrow end kneading component (Right). 
Figure 3.13 Extruder barrel zones marked in pen. Zone 1 is where the 
material is fed into the barrel. 
Figure 4.1  DSC thermograms of carbamazepine (Form III) using heating 
ramps of 5°C and 10°C per minute. 
Figure 4.2  DSC thermograms of nicotinamide using heating ramps of 5°C 
and 10°C per minute. 
Figure 4.3  Modulated DSC thermograms of carbamazepine – 
nicotinamide physical mixtures at different molar ratios. 
Figure 4.4  Modulated DSC melting temperatures for 1:1 physical mixture 
(Eutectic), 1:1 co-crystal and carbamazepine form I plotted for 
each mol fraction of carbamazepine. 
Figure 4.5  Modulated DSC integrated melting peak energies for 1:1 
physical mixture (Eutectic), 1:1 co-crystal and carbamazepine 
form I plotted for each mol fraction of carbamazepine. 
Figure 4.6  A simple carbamazepine – nicotinamide binary phase diagram 
plotted using the modulated DSC endothermic melting points. 
Figure 4.7  Light microscope image of the Kofler method using ibuprofen 
and nicotinamide. 
Figure 4.8  A DSC thermogram of 1:1 carbamazepine – nicotinamide 
physical mixture using a heat-cool-heat method. Important 
events are labelled A to G. 
Figure 4.9  Bright field light microscopy images of 1:1 carbamazepine – 
nicotinamide physical mixture using a heat-cool-heat method. 
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Figure 4.10  Polarised light microscopy images of 1:1 carbamazepine – 
nicotinamide physical mixture using a heat-cool-heat method. 
Figure 4.11  PXRD spectra of 1:1 ibuprofen – nicotinamide physical mixture 
(PM) and the samples for Tmax 85°C (Run 1) and Tmax 90°C 
(Run 2). 
Figure 4.12  PXRD spectra of 1:1 nicotinamide – salicylic acid physical 
mixture (PM) and the samples for Tmax 115°C (Run 1) and Tmax 
120°C (Run 2) Tmax 120°C 10 rad/sec (Run 3). 
Figure 4.13  PXRD spectra of 1:1 caffeine – maleic acid physical mixture 
(PM) and the samples for Tmax 90°C (Run 1), Tmax 100°C (Run 
2) Tmax 100°C with alternating shear direction (Run 3), Tmax 
110°C (Run 4) and 2:1 PM initial material Tmax 100°C (Run 5). 
Figure 4.14  PXRD spectra of IBU-NIC 1:1 physical mixture subjected to no 
shear, 25% strain, 50% strain, 75% strain and 100% strain and 
held at 70°C for 10 minutes with a heating and cooling rate of 
20°C/min. The 1:1 physical mixture spectrum is also shown 
(PM). 
Figure 4.15  PXRD spectra of IBU-NIC 1:1 physical mixture subjected to no 
shear, 25% strain, 50% strain, 75% strain and 100% strain and 
held at 80°C for 10 minutes with a heating and cooling rate of 
20°C/min. The 1:1 physical mixture spectrum is also shown. 
Figure 4.16  PXRD spectra of IBU-NIC 1:1 physical mixture subjected to no 
shear, 25% strain, 50% strain, 75% strain and 100% strain and 
held at 90°C for 10 minutes with a heating and cooling rate of 
20°C/min. The 1:1 physical mixture spectrum is also shown. 
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Figure 4.17  DSC thermograms of the model shear deformation samples. 
Temperatures: 70, 80 and 90°C. Strain: 0, 25 and 50%. 
Figure 4.18  DSC thermograms of the model shear deformation samples. 
Temperatures: 70, 80 and 90°C. Strain: 75 and 100%. 
Figure 4.19  PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
25% strain and held at 70°C, 80°C and 90°C for 10 minutes 
with a heating and cooling rate of 20°C/min and an applied 
force of 5 N. 
Figure 4.20  PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
200% strain and held at 70°C, 75°C, 80°C, 85°C and 90°C for 
10 minutes with a heating and cooling rate of 20°C/min and an 
applied force of 1 N. 
Figure 4.21  PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
300% strain and held at 70°C, 75°C, 80°C, 85°C and 90°C for 
10 minutes with a heating and cooling rate of 20°C/min and an 
applied force of 1 N. 
Figure 5.1  PXRD spectra of A. ibuprofen, B. nicotinamide, C. IBU-NIC 1:1 
physical mixture and D. IBU-NIC 1:1 co-crystal (Microwave 
method section 3.2). 
Figure 5.2  DSC thermograms of A. ibuprofen, B. nicotinamide, C. IBU-NIC 
1:1 physical mixture and D. IBU-NIC 1:1 co-crystal (Microwave 
method section 3.2) heated at 10°C/min from 40°C to 220°C. 
Figure 5.3  PXRD spectra of A. IBU-NIC 1:1 physical mixture, B. extrudate 
T80 30 rpm, C. extrudate T80 20 rpm, D. extrudate T90 30 
rpm, E. extrudate T90 20 rpm, F. IBU-NIC 1:1 co-crystal 
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(Microwave method section 3.2).  
Figure 5.4  NIR spectra of ibuprofen, nicotinamide, 1:1 IBU-NIC physical 
mixture, 1:1 IBU-NIC co-crystal (Microwave method section 
3.2), extrudate T90 20 rpm 15% seed, extrudate T90 20 rpm 
15% seed, ground powder. All the spectra shown have been 
treated with SNV baseline correction. 
Figure 5.5 Second derivative NIR spectra of A. ibuprofen, B. nicotinamide, 
C. IBU-NIC 1:1 physical mixture, D. IBU-NIC 1:1 co-crystal 
(Microwave method section 3.2), E. extrudate T90 20 rpm 15% 
seed, F. extrudate T90 20 rpm 15% seed, ground powder. All 
the spectra shown have been treated with SNV baseline 
correction and Norris smoothing. 
Figure 5.6  PXRD spectra of A. carbamazepine (Form III), B. nicotinamide, 
C. CBZ-NIC 1:1 physical mixture and D. CBZ-NIC 1:1 co-
crystal (Solvent evaporation method section 3.3). 
Figure 5.7  DSC thermograms of A. carbamazepine (Form III), B. 
nicotinamide, C. CBZ-NIC 1:1 physical mixture and D. CBZ-
NIC 1:1 co-crystal (Solvent evaporation method section 3.3) 
heated at 10°C/min from 40°C to 220°C. 
Figure 5.8  PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. extrudate 
T125 20 rpm, C. extrudate T130 20 rpm, D. extrudate T135 20 
rpm, E. extrudate T140 20 rpm, F. CBZ-NIC 1:1 co-crystal 
(Solvent evaporation method section 3.3). 
Figure 5.9  PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. extrudate 
T110 20 rpm, C. extrudate T120 20 rpm, D. extrudate T125 20 
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rpm, E. extrudate T130 20 rpm, F. extrudate T135 20 rpm, G. 
extrudate T140 20 rpm, H. CBZ-NIC 1:1 co-crystal (Solvent 
evaporation method section 3.3). 
Figure 5.10  PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. extrudate 
T135 20 rpm, C. extrudate T140 20 rpm, D. extrudate T135 10 
rpm, E. extrudate T140 10 rpm, F. CBZ-NIC 1:1 co-crystal 
(Solvent evaporation method section 3.3). 
Figure 5.11  PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. zone 2 
sample, C. zone 6 sample, D. zone 7 sample, E. zone 8 
sample, F. zone 9 sample, G. extrudate sample, H. CBZ-NIC 
1:1 co-crystal (Solvent evaporation method section 3.3). 
Figure 5.12  PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. zone 2 
sample, C. zone 3 sample, D. zone 4 sample, E. zone 5 
sample, F. zone 6 sample, G. zone 7 sample, H. zone 8 
sample, I. zone 9 sample, J. zone 10 sample, K. extrudate 
sample, L. CBZ-NIC 1:1 co-crystal (Solvent evaporation 
method section 3.3). 
Figure 5.13  PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. zone 2 
sample, C. zone 3 sample, D. zone 4 sample, E. zone 5 
sample, F. zone 6 sample, G. zone 7 sample, H. zone 8 
sample, I. zone 9 sample, J. zone 10 sample, K. extrudate 
sample, L. CBZ-NIC 1:1 co-crystal (Solvent evaporation 
method section 3.3). 
Figure 5.14  Original (Top) and second derivative (Bottom) NIR spectra of 
carbamazepine, nicotinamide, CBZ-NIC 1:1 physical mixture 
xiv 
 
and CBZ-NIC 1:1 co-crystal (Solvent evaporation method 
section 3.3), All the spectra shown have been treated with SNV 
baseline correction. 
Figure 5.15  Original NIR spectra of A. 1:1 CBZ-NIC physical mixture, B. 
T120 SGB 20 rpm sample, C. T125 SGB 20 rpm sample, D. 
T130 SGB 20 rpm sample, E. T135 SGB 20 rpm sample, F. 
T140 SGB 20 rpm sample, G. T130 SGB 10 rpm sample, H. 
T135 SGB 10 rpm sample, I. T140 SGB 10 rpm sample, J. 1:1 
CBZ-NIC co-crystal (Solvent evaporation method section 3.3). 
Figure 5.16  Second derivative NIR spectra of 1:1 CBZ-NIC physical 
mixture, T130 SGB 20 rpm sample, T135 SGB 20 rpm sample, 
T140 SGB 20 rpm sample, T130 SGB 10 rpm sample, T135 
SGB 10 rpm sample, T140 SGB 10 rpm sample, 1:1 CBZ-NIC 
co-crystal (Solvent evaporation method section 3.3). 
Figure 5.17  Second derivative NIR region 4930 cm-1 to 5150 cm-1 spectra 
of 1:1 CBZ-NIC physical mixture, T130 SGB 20 rpm sample, 
T135 SGB 20 rpm sample, T140 SGB 20 rpm sample, T130 
SGB 10 rpm sample, T135 SGB 10 rpm sample, T140 SGB 10 
rpm sample, 1:1 CBZ-NIC co-crystal (Solvent evaporation 
method section 3.3). 
Figure 5.18  NIR spectra of samples taken from along the extruder barrel 
from zone 2 to the extruded material. A) T140 SGB 10 rpm, B) 
T140 SGB 20 rpm, C) T135 SGB 20 rpm. The arrows indicate 
the samples starting at zone 2 and finishing at the extruded 
material. The 1:1 carbamazepine nicotinamide physical mixture 
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is also included (The grey spectrum). 
Figure 5.19  Second derivative NIR regions: 5850 to 6000 cm-1, 6780 to 
6890 cm-1, 4050 to 4150 cm-1 and 4600 to 4700 cm-1. Spectra 
of 1:1 CBZ-NIC physical mixture, zone 2 to zone 10 and 
extruded samples and 1:1 CBZ-NIC co-crystal (Solvent 
evaporation method section 3.3) for three extrusion runs of 
T140 SGB 10 rpm (A), ), T140 SGB 20 rpm (B) and T135 GSB 
20 rpm (C). 
Figure 5.20  SEM image of carbamazepine (Form III) 400X (Left). SEM 
image of nicotinamide 200X (Right). 
Figure 5.21  SEM images of 1:1 carbamazepine nicotinamide physical 
mixture at 200X magnification (Left) and 2000X magnification 
(Right). 
Figure 5.22  SEM images of 1:1 carbamazepine nicotinamide co-crystal 
(Solvent evaporation method section 3.3) at 500X magnification 
(Left) and 3000X magnification (Right). 
Figure 5.23  SEM images of the carbamazepine nicotinamide extruded 
sample: T135 SGB 20 rpm at 500X magnification (Left) and 
1000X magnification (Right). 
Figure 5.24  SEM images of the carbamazepine nicotinamide extruded 
sample: T140 SGB 10 rpm at 1000X magnification (Left) and at 
3000X magnification (Right).  
Figure 5.25  SEM images of carbamazepine nicotinamide extruded sample: 
T140 SGB 10 rpm zone 8 at 3000X magnification (Left) and 
zone 9 at 3000X magnification (Right). 
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Figure 5.26  SEM images of carbamazepine nicotinamide extruded sample: 
T140 SGB 10 rpm zone 10 at 3000X magnification (Left) and a 
selected image from zone 8 at 1000X magnification (Right). 
Figure 5.27  PXRD spectra of carbamazepine (Form III) and extruded 
carbamazepine using screw geometry B, 10 rpm screw speed 
and temperature profile T150. 
Figure 5.28  DSC thermograms of carbamazepine (Form III) and extruded 
carbamazepine using screw geometry B, 10 rpm screw speed 
and temperature profile T150. 
Figure 5.29  PXRD spectra of nicotinamide and extruded nicotinamide using 
screw geometry B, 10 rpm screw speed and temperature 
profiles T140 and T150. 
Figure 5.30  DSC thermograms of nicotinamide and extruded nicotinamide 
using screw geometry B, 10 rpm screw speed and temperature 
profiles T140 and T150. 
Figure 5.31  HPLC iminostilbene analysis results. 
Figure 6.1  NIR spectra for ibuprofen, nicotinamide, IBU-NIC 1:1 physical 
mixture (PM) and IBU-NIC 1:1 co-crystal (CC) (Microwave 
method section 3.2). For this figure, the spectra were pre-
treated using SNV across the whole region 10000-4000 cm-1. 
Figure 6.2  Second derivative NIR spectra for ibuprofen, nicotinamide, IBU-
NIC 1:1 physical mixture (PM) and IBU-NIC 1:1 co-crystal (CC) 
(Microwave method section 3.2). For this figure, the spectra 
were pre-treated using SNV and Norris smoothing across the 
whole region 10000-4000 cm-1. 
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Figure 6.3  A to I show the nine different NIR regions. Second derivative 
NIR spectra for ibuprofen, 25%CC, 50%CC, 75%CC and 
100%CC. All spectra were pre-treated using SNV and Norris 
smoothing across the whole region 10000-4000 cm-1. 
Figure 6.4  IBU-NIC model: PLS regression Model 1. Using the region 
7450-7000 cm-1 and chemometrics second derivative, SNV and 
Norris smoothing. Both the calibration and validation data sets 
are plotted. 
Figure 6.5  IBU-NIC model: PLS regression Model 1. RMSECV values 
according to the number of factors used in the PLS regression. 
Figure 6.6  IBU-NIC model: PLS regression Model 1. First and second 
factor loadings for the spectral and concentration contribution 
of the calibration standards. 
Figure 6.7  IBU-NIC model: Model 1 residuals plot. Using the region 7450-
7000 cm-1 and chemometrics second derivative, SNV and 
Norris smoothing. 
Figure 6.8  IBU-NIC model:  second derivative NIR spectra over the region 
7450-7000 cm-1 with Norris smoothing of ibuprofen and the 
calibration samples with 25, 50, 75 and 100% 1:1 IBU-NIC CC. 
Figure 6.9  NIR spectra for carbamazepine (Form III), nicotinamide, CBZ-
NIC 1:1 physical mixture and CBZ-NIC 1:1 co-crystal (Solvent 
evaporation section 3.3). For this figure, the spectra were pre-
treated using SNV across the whole region 10000-4000 cm-1. 
Figure 6.10  Second derivative NIR spectra for carbamazepine (Form III), 
nicotinamide, CBZ-NIC 1:1 physical mixture and CBZ-NIC 1:1 
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co-crystal (Solvent evaporation section 3.3). For this figure, the 
spectra were pre-treated using SNV and Norris smoothing 
across the whole region 10000-4000 cm-1. 
Figure 6.11  A to I show the nine different NIR regions. Second derivative 
NIR spectra for carbamazepine (Form III), 25%CC, 50%CC, 
75%CC and 100%CC. All spectra were pre-treated using SNV 
and Norris smoothing across the whole region 10000-4000 cm-
1. 
Figure 6.12  CBZ-NIC model: PLS regression Model 2. Using the region 
9000-8500 cm-1 and chemometrics second derivative, SNV and 
SG smoothing. 
Figure 6.13  CBZ-NIC model: PLS regression Model 2. RMSECV values 
according to the number of factors used in the PLS regression. 
Figure 6.14  CBZ-NIC model: PLS regression Model 2. First and second 
factor loadings for the spectral and concentration contribution 
of the calibration standards. 
Figure 6.15  CBZ-NIC model: Model 2 residuals plot. Using the region 9000-
8500 cm-1 and chemometrics second derivative, SNV and SG 
smoothing.  
Figure 6.16  CBZ-NIC model:  second derivative NIR spectra over the 
region 9000-8500 cm-1 with SG smoothing of carbamazepine 
(Form III) and the calibration samples with 25, 50, 75 and 100% 
1:1 CBZ-NIC co-crystal. 
Figure A.1  Light microscopy images of 1:1 ibuprofen – nicotinamide 
physical mixture shear cell run 1. Showing the starting material 
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(Left), after 8 minutes of shear (Centre) and post shear 33°C 
(Right). 
Figure A.2  Light microscopy images of 1:1 ibuprofen – nicotinamide 
physical mixture shear cell run 2. Showing the starting material 
(Left), the material at 85°C pre shear (Centre) and post shear 
30°C (Right). 
Figure A.3  Light microscopy images of 1:1 nicotinamide – salicylic acid 
physical mixture shear cell run 1. Showing the starting material 
(Left), after 2 minutes of shear (Centre) and after 8 minutes of 
shear (Right). 
Figure A.4  Light microscopy images of 1:1 nicotinamide – salicylic acid 
physical mixture shear cell run 2. Showing the starting material 
(Left), after 2 minutes isothermal at 120°C (Centre) and after 8 
minutes of shear (Right). 
Figure A.5  Light microscopy images of 1:1 nicotinamide – salicylic acid 
physical mixture shear cell run 3. Showing the starting material 
(Left), after 2 minutes isothermal at 120°C (Centre) and after 8 
minutes of shear (Right). 
Figure A.6  Light microscopy images of 1:1 caffeine - maleic acid physical 
mixture shear cell run 1. Showing the starting material (Left), 
after 6 minutes of shear (Centre) and post shear 35°C (Right). 
Figure A.7  Light microscopy images of 1:1 caffeine - maleic acid physical 
mixture shear cell run 2. Showing the starting material (Left), 
after 2 minutes of shear (Centre) and after 8 minutes of shear 
(Right). 
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Figure A.8  Light microscopy images of 1:1 caffeine - maleic acid physical 
mixture shear cell run 3. Showing the starting material (Left), 
after 2 minutes of shear (Centre) and after 8 minutes of shear 
(Right). 
Figure A.9  Light microscopy images of 1:1 caffeine - maleic acid physical 
mixture shear cell run 4. Showing the starting material (Left), 
after 2 minutes of shear (Centre) and after 8 minutes of shear 
(Right). 
Figure 
A.10  
Light microscopy images of 2:1 caffeine - maleic acid physical 
mixture shear cell run 5. Showing the starting material (Left), 
after 2 minutes of shear (Centre) and after 8 minutes of shear 
(Right). 
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V Table index 
Table 2.1  Outcome of twin screw extrusion experiments performed with 
theophylline – citric acid system (Daurio et al. 2011). A: 
anhydrous, M: monohydrate, AC: anhydrous co-crystal, HC: 
hydrated co-crystal. 
Table 2.2  Component solubilities and co-crystal solubilities (Good and 
Rodríguez-Hornedo 2009). 
Table 2.3  Drugs on the market and in the R&D pipeline and their 
Biopharmaceutics Classification System class (Thayer 2010). 
Table 3.1  Temperature profiles for hot melt extrusion. Each zone 
represents a controlled heating area along the extruder barrel. 
The code indicates the maximum temperature. 
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The invention of high-throughput screening of therapeutically active 
ingredients has led to an increase in the number of poorly soluble APIs by 
approximately 25-40% since it has been introduced (Maniruzzaman et al. 
2013). Additionally, 70% of new chemical entities (NCE’s), that are yet to 
reach the market, are poorly soluble (Sanphui et al. 2012). The solubility of 
an API is critical for achieving acceptable, controlled bioavailability when a 
drug is administered to a patient. However, it is not commonplace to find an 
API with relatively good aqueous solubility, so instead, a large proportion of 
pharmaceutical research is now focused on modifying existing APIs to 
improve their solubility and other important physico-chemical properties such 
as stability, dissolution rate, bioavailability and compressibility. 
The crystal structure, morphology, and particle size are all important factors 
that can have a large influence on an APIs performance. Different crystal 
forms of an API generally affect the physico-chemical properties and stability, 
whereas the crystal morphology and particle size are more likely to affect the 
dosage form used and the manufacturing stage (Stieger and Liebenberg 
2012). Entropy, enthalpy, non-covalent interactions (Hydrogen bonding, Van 
der Waals interactions, π-π stacking and electrostatic interactions) and 
molecular assemblies are all determining factors for the different crystal 
forms an API can achieve (Rodrı́guez-Spong et al. 2004). The 
thermodynamics and kinetics of a system ultimately dictate the preferred 
crystal form and its stability under specified conditions. 
Well known alternative API crystal forms include polymorphs (Llinàs and 
Goodman 2008), salts (Banerjee et al. 2005), solvates and hydrates (Douillet 
et al. 2012). Pharmaceutical co-crystals, consisting of an API and a co-
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former, are relatively new crystal forms that can be utilised for API solubility 
enhancement (McNamara et al. 2006). There are several published methods 
for synthesizing co-crystals including solution crystallisation (Gagniere et al. 
2009), slow evaporation from solution (Weyna et al. 2009), solvent drop 
grinding (Weyna et al. 2009), neat grinding (Sanphui et al. 2012), slurry 
crystallisation (Takata et al. 2008), ultrasound assisted cocrystallisation 
(Aher et al. 2010) and hot melt extrusion (Dhumal et al. 2010). 
Hot melt extrusion (HME) is a well-established manufacturing technique; 
however, its use in pharmaceutical research is relatively new. Typically, there 
is no requirement to use a solvent with this technique and it can be easily 
scaled depending on the quantities that are desired. It can successfully 
achieve cocrystallisation of an API and co-former (Dhumal et al. 2010) and 
can deliver continuous crystallisation which is now highly sought after in the 
pharmaceutical industry. 
This project utilised HME as a solvent-free continuous cocrystallisation 
(SFCC) technique for the formation of pharmaceutical co-crystals. 
Parameters including temperature, screw speed and screw configuration 
were explored to achieve the highest co-crystal purity possible and the 
extrudates were characterized using several different analytical techniques. 
The project was designed to fundamentally understand the extrusion 
process, including investigating the mechanisms of co-crystal formation 
using combinations of model shear deformation experiments. Additionally, 
near infrared (NIR) spectroscopy was used to predict co-crystal purity using 
partial least squares linear regression. ThermoFisher Scientific provided 
insight and knowledge for creating the co-crystal prediction models. 
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2.1 The current state of pharmaceutical research 
Pharmaceutical research, whether undertaken by private companies or by 
publicly funded institutions, is constantly evolving with the aim of becoming 
more efficient. The current industrial landscape has favoured alliances 
between companies, and partnerships between companies and institutions 
(DiMasi et al. 2016), to increase knowledge transfer and to outsource 
specific research. 
Whilst the pharmaceutical sector has been pushing for efficiency, the number 
of targets for therapeutic agents has significantly increased due to the 
molecular makeup of diseases being uncovered by innovative advances in 
technology. This has led to a fall in productivity attributed to diminishing 
returns in the “knowledge production function” (Pammolli et al. 2011). 
It is possible, that in the past, research and development (R&D) has 
consumed the easier therapeutic targets (Evenson 1993). However, there is 
little doubt that new research prospects cause a net increase in the 
complexity of current R&D. The rising “burden of knowledge” has economic 
implications, but it can be overcome by knowledge transfer and efficient 
practices (Jones 2009). 
Thorough assessments of the continuing technological advances made by 
the pharmaceutical sector are increasingly being carried out to evaluate the 
therapeutic merits of new APIs (Pammolli et al. 2011). Considering recent 
reviews of the value of the novelty of APIs and the associated financial 
returns for pharmaceutical firms, it has come to light that directing R&D 
towards novel targets currently has a high risk of failure and lower returns 
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compared to R&D which focuses on improving known APIs or formulations 
(Ma and Zemmel 2002). The total risk-adjusted costs of R&D for a “high-
novelty approach” could be 40% higher than a “low-novelty approach”. 
Therefore it is vital for the pharmaceutical industry to head towards 
significant improvements in processes and technologies in order to decrease 
the risks involved and improve returns (Ma and Zemmel 2002). 
A recent study conducted in 2016 investigated the R&D costs of 106 new 
drugs from 10 different biopharmaceutical companies (DiMasi et al. 2016). 
The study showed that the most recent estimate of the “average out-of-
pocket cost per approved new compound” was $1395 million, and when 
adding the estimated post-approval R&D costs, this figure rose to $2870 
million. 
Any effective, proven innovation to pharmaceutical science, processes or 
manufacturing methods can have an impact on the R&D costs and the 
general efficiency of current R&D practises. 
2.2 Crystal structures of APIs 
Crystal engineering has been an important part of pharmaceutical R&D and 
can provide researchers with many directions for their research to explore. In 
the early developmental stages of drug compounds, increasing attention is 
being paid to material properties, including the effect of different crystal forms 
(Peterson et al. 2006). APIs are intrinsically valuable materials and crystal 
engineering is one way to realise their full potential (Almarsson and 
Zaworotko 2004). 
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APIs with poor properties, such as poor solubility, are somewhat responsible 
for the drop in R&D output since the early 1990s (Gardner et al. 2004). 
Additionally, the physical properties often cause new drug approvals to be 
delayed by regulatory bodies (CDER 2007). Therefore it is essential for 
pharmaceutical companies to explore and understand API crystal forms and 
their inherent physical properties. 
Understanding crystal structures was important for this project as it was 
centred on the knowledge of how different crystal forms can influence the 
physico-chemical properties of an API. In the pharmaceutical industry, the 
crystal structure is a fundamental factor in the commercial success or failure 
of an API. Both the intermolecular and intramolecular interactions are 
important if one wants to manipulate API properties. The enhancement of the 
physico-chemical properties of an API is common practice for 
pharmaceutical companies who are looking to improve solubility, stability and 
bioavailability. 
Crystals have long-range order and have repeating molecular patterns. Well 
known API crystal forms include polymorphs (Llinàs and Goodman 2008), 
salts (Banerjee et al. 2005), solvates and hydrates (Douillet et al. 2012). 
Polymorphs are crystalline structures that have different arrangements and 
conformations of the molecules within the crystal lattice. They generally have 
different melting points and crystal habits. Polymorphism denotes a crystal 
system where a substance can exist with different unit cells whilst having the 
exact same elemental composition. Each unique polymorph can exhibit 
different physico-chemical properties to each other. This is because of 
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differences in size, morphology, symmetry, number of molecules within the 
unit cell, packing, and void volumes (Brittain 2009). 
Polymorphs have different lattice energies (Enthalpies) and this causes them 
to possess different physico-chemical properties such as solubility. To be 
soluble, the free energy of solvation must exceed the lattice free energy of 
the solid plus the free energy of cavity formation in the solvent for the 
solvation process to be spontaneous. The enthalpy and entropy change 
determines the ostwald free energy change, therefore the difference in the 
lattice energies must imply that the solubility of the crystal forms are different. 
An unstable polymorph has an increased solubility due to an increase in the 
lattice energy (Brittain 2009). 
A study conducted in 2000 demonstrates the differences in physico-chemical 
properties polymorphs can have. Solubility tests of carbamazepine forms I, III 
and dihydrate found that their intrinsic dissolution rates were 61.8, 67.4 and 
41.8 µg/cm2/min using a JP13 1st fluid dissolution medium at 37°C and their 
solubilities were 460.2, 501.9 and 311.1 µg/mL respectively. 
When a substance consists of sufficiently basic and acidic components, it 
can form a salt. Salt formation involves a proton-transfer or a neutralization 
reaction (Berge et al. 1977). A pharmaceutical salt is formed when an API 
forms a sufficiently strong ionic interaction with an oppositely charged ionic 
molecule (Kumar et al. 2007). Charged ionic groups in the API and 
counterion molecule generate an intermolecular coulombic force of attraction 
(Bhattachar et al. 2006). 
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It is estimated that over half of the approved APIs in the United States of 
America are pharmaceutical salts (Saal and Becker 2013). They can 
possess good aqueous solubility compared to co-crystals as described by a 
study conducted in 2005 (Bhatt et al. 2005) where saccharin was used as a 
weak acid and was able to protonate different APIs. However, 
pharmaceutical salts can suffer from toxicological problems such as changes 
in the pharmacokinetics compared to the API on its own which ultimately 
leads to different toxicokinetics, and problems can be caused by the 
counterion itself (Saal and Becker 2013). Typically, for newly developed 
APIs, the toxicology of the salt forms are not known. The time required to 
solve this issue is inevitably a hindrance to its development. 
Solvates are sometimes considered as pseudopolymorphs because they are 
different crystalline forms of the API with the inclusion of a solvent within the 
crystal lattice (Stoichiometric or non-stoichiometric) (Chadha et al. 2010). 
When the solvent is water, the crystal form is called a hydrate. Approximately 
one in three APIs can exist in a hydrate form (Breimer 1980). Both solvates 
and hydrates can be useful when they are thermodynamically stable as the 
solvate form can enhance the solubility, stability and bioavailability of the API 
(Sheth and Grant 2005, De Armas et al. 2007). 
Solvent molecules can interact with crystalline materials in various ways. 
These include liquid inclusion, surface adsorption, absorption in disordered 
regions and as part of the crystal structure itself. Figure 2.1 illustrates these 
interactions. The majority of these associations are generally considered as 
nuisances when trying to develop a stable crystalline form and solvates are 
rarely selected for development. A solvate can only be selected for 
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development by a pharmaceutical company if it is stable and has a lower 
than tolerated potential daily exposure of the solvent to the patient (Douillet 
et al. 2012). 
 
Figure 2.1  An illustration of different solvent interactions with a crystal 
(Hilfiker 2006). 
If there is no long range order in a solid phase, then the substance is referred 
to as an amorphous material (Mandic 2012). Typically, amorphous solids 
have no molecular packing or well-defined molecular conformations. There 
are some desirable properties of amorphous solids, such as high solubility, 
high dissolution rates and they can sometimes have better compression 
characteristics than their alternative crystal forms (Yu 2001). Past studies 
have even treated the amorphous form of an API as a polymorph of the 
crystalline forms (Haleblian and McCrone 1969). The downside to 
amorphous solids, is they can be highly hygroscopic and they are generally 
metastable forms which suffer from poor kinetic stability (Mandic 2012). 
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Crystal engineering has rapidly evolved and is now seen as synonymous 
with supramolecular synthesis (Vishweshwar et al. 2006). Multi-component 
crystalline systems assemble through non-covalent forces and when they 
form a single crystalline phase, they are referred to as co-crystals 
(Rodrıǵuez-Spong et al. 2004). 
2.3 Co-crystal definitions, nomenclature 
Co-crystals can be described as a crystalline phase with multiple distinct 
molecular constituents that are normally linked by intermolecular bonds. 
Historically, co-crystals have been referred to as molecular complexes 
(Blagden et al. 2007, Aitipamula et al. 2012). There are numerous published 
definitions to help distinguish co-crystals from polymorphs, salts, hydrates, 
solvates and amorphous materials. They are discussed in this section along 
with the nomenclature. 
The International Quality and Productivity Centre (IQPC) held a meeting in 
Amsterdam in 2006 which featured intellectual property lawyers, university 
academics and individuals from international pharmaceutical companies. The 
purpose was to establish a definition for co-crystals with their intellectual 
property potential in mind. The end result was the following definition: 
“crystalline entities with at least two different components constituting the unit 
cell and interacting by hydrogen bonds”. Additional appendices were 
required to state that co-crystals are not “salts where the strength of the 
interaction is so strong that the linkage is between two oppositely-charged 
ions” and that “cocrystallisation is different from coprecipitation, eutectic 
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formation, solid solution, or dispersion” (Lara-Ochoa and Espinosa-Perez 
2007). 
Zaworotko presented a different co-crystal definition for more practical uses. 
The definition was: “A co-crystal is a multiple component crystal in which all 
components are solid under ambient conditions when in their pure form. 
These components consist of a target molecule or ion and a molecular co-
crystal former(s); when in a co-crystal, they coexist at the molecular level 
within a single crystal” (Shan and Zaworotko 2008). This definition was more 
detailed than the one produced by the IQPC and it served more purpose in 
scientific research as opposed to patent law. 
An interesting proposal by Lara-Ochoa (Lara-Ochoa and Espinosa-Pérez 
2007) expressed the need for a definition which describes the type of 
interaction stabilising the co-crystal. They proposed the following definition: 
“A crystal constituted by heterosynthons, stabilized by hydrogen bonds or 
other types of non-valency intermolecular interactions, and in which all the 
component synthons are solid under ambient conditions, when in their pure 
form.” 
In 2013, the Food and Drug Administration (FDA) collaborated with the 
United States Department of Health and Human services and the Center for 
Drug Evaluation and Research (CDER) to publish the Regulatory 
Classification of Pharmaceutical Co-Crystals – Guidance for Industry (FDA 
2013). The FDA approved definition for a co-crystal was as follows: 
‘Crystalline material composed of two or more molecules within the same 
crystal lattice’. The definition for a pharmaceutical co-crystal was ‘a 
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dissociable “API-excipient” molecular complex, with a neutral guest 
compound being the excipient’ (Brittain 2013). 
Co-crystal nomenclature has also been debated over recent years. Desiraju 
has stated that issues with the nomenclature of a new subject are a 
necessary evil which helps to fine-tune what is accurate and what needs to 
be discarded. In an article published in CrystEngComm in 2003 (Desiraju 
2003), Desiraju argued that the word ‘crystal’ is too important and too 
meaningful to be used in this context however he conceded that the term co-
crystal has become very popular and may well be used regardless of its 
controversial nature. The term ‘molecular-complex’ was thought to be more 
appropriate because the term ‘co-crystal’ implied that the structure has 
commonalities between its crystal structure and that of the crystal structure 
of the individual components. 
In a response to Desiraju, Dunitz disputed the ‘molecular-complex’ term and 
reasoned that it had too broad a meaning just as how Desiraju described the 
word ‘crystal’ (Dunitz 2003). Dunitz argued that the term ‘co-crystal’ had 
good reasons to be popular and that it aptly describes a crystal containing 
more than one single component. 
Bond (2007) suggested that both Desiraju and Dunitz were well intentioned 
however missed the point about the fact that ‘co-crystal’ should be nothing 
more than a synonym and the term ‘multi-component molecular crystal’ was 
a more accurate term to use. However, he acknowledged that the term ‘co-
crystal’ would be difficult to displace, considering its popularity. 
15 
 
Various other authors have entered into the co-crystal nomenclature debate 
in recent years (Zukerman-Schpector and Tiekink 2008, Almarsson et al. 
2012, Kelley et al. 2013). 
This project was centred on pharmaceutical co-crystals; therefore it was 
necessary to distinguish co-crystals from other pharmaceutical solid forms. 
Figure 2.2 illustrates the differences between each solid form in terms of their 
components. 
 
Figure 2.2 A diagram showing the fundamental differences between 
polymorphs, co-crystals, salts and solvates/hydrates. 
A total of 46 scientists working in the field of pharmaceutical co-crystals 
published an article in 2012 (Aitipamula et al. 2012) to classify co-crystals in 
pharmaceutical sciences from a regulatory perspective. Figure 2.3 was taken 
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from this study to highlight the difficulties involved in defining multi-
component solid forms. The different forms can overlap with one another and 
each form can exhibit polymorphism. This was an effective way of describing 
the complexity of solid forms. 
 
Figure 2.3 The classification of multi-component solid forms. They can 
overlap with one another and they can exhibit polymorphism 
(Aitipamula et al. 2012). 
2.4 Co-crystal design 
Weak intermolecular interactions can play an important role in controlling 
material properties because they can provide alternative crystal forms, and 
different forms can exhibit different solubilities, crystal morphologies and 
other important properties. Carefully designed systems can achieve 
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favourable, complimentary hydrogen bonding between the molecules. 
However, such systems can also form hydrogen-bonded molecular 
aggregates, which are also known as supramolecular assemblies. These 
aggregates/assemblies can enhance critical physico-chemical properties of 
pharmaceutical APIs, such as solubility and stability, and are therefore a key 
part of designing a co-crystal. 
Etter (1991) described some general rules when choosing suitable hydrogen-
bonding components in organic chemistry. Below is a summary of these 
rules: 
- All good proton donors and acceptors are used in hydrogen bonding 
- The best hydrogen bond donor and the best hydrogen bond acceptor will 
prefer to hydrogen bond with one another 
Different hydrogen bonded synthons can be created by the formation of 
hydrogen bonds between different molecules. Figure 2.4 shows some 
examples of these synthons. The synthons can be classified as 
homosynthons or heterosynthons depending on the arrangement of the 
functional groups involved in the bonding. Homosynthons have the same or 
similar interacting functional groups whereas heterosynthons have different 
interacting functional groups. For example, an amide-amide interaction is a 
homosynthon and an acid-amide is a heterosynthon. 
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Figure 2.4 Common hydrogen bond synthons found in supramolecular 
assemblies. 
In multi component co-crystals, homosynthons are the most common 
synthon. It should be noted that heterosynthons can be formed in both a 
single component crystal and a multi component co-crystal. The interacting 
molecules that form a synthon can be called homomers or heteromers to 
describe the type of molecular aggregate they have formed. If both 
molecules are the same then the aggregate is called a homomer, 
alternatively, a heteromer aggregate forms a multi component co-crystal. 
Multiple hydrogen bonding possibilities, dipoles, ionic states and steric or 
conformational limitations can cause problems when trying to model co-
crystals and can cause conflict with the principles already discussed 
(Deshpande et al. 2012). Complicated systems will always have some 
exceptions to the guidelines. Halogen bonds have also been used in co-
crystal design and can even be used in combination with hydrogen bonds 
(Aakeröy et al. 2008). However, heteromeric NH…O, OH…O and NH…N 
hydrogen-bonding remains the primary method for designing and 
synthesizing co-crystals (Wood et al. 2014). 
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2.5 Mechanisms of co-crystal formation 
To understand the fundamentals of co-crystal behaviour and discipline, the 
mechanisms which have been proposed for their formation were reviewed. 
There are four methods of co-crystal formation found in the literature. These 
include the reaction crystallisation method, the eutectic and vapour phase 
method, the deliquescence method and the thermal fusion method. 
The reaction crystallisation method proposes that the chemical potential is 
the main driving force of crystallisation which allows for the rapid and 
effective formation of co-crystals under ambient conditions. The theory states 
that the difference between the chemical potential at equilibrium and at a 
supersaturated state is an important marker. It can predict if cocrystallisation 
will spontaneously occur or not. 
At equilibrium, the sum of a co-crystal component’s chemical potentials (Or 
molar free energies) is equal to that of the solution. The molar free energy of 
a co-crystal AmBn in equilibrium with the solution phase is given by equation 
2.1: 
GAmBn = Gsolution = mG
L
A + nG
L
B = mµA + nµB    (Eq. 2.1) 
Equation 2.2 describes the chemical potential (each component has the 
activity ai): 
µi = µ
0
i + RTlnai        (Eq. 2.2) 
where µ0i is the chemical potential of the reference state for i. 
Combining equations 2.1 and 2.2 gives equation 2.3 and 2.4: 
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ΔGAmBn = ΔGsolution = RT(mlnaA + nlnaB)    (Eq. 2.3) 
exp(ΔGAmBn / RT) = (aA)
m(aB)
n = Ksp     (Eq. 2.4) 
Where Ksp is the solubility product of the co-crystal. 
Another part of this theory relies on the solubility phase diagram for the 
crystal, A, and the co-crystal, AB. Figure 2.5 shows an example of a co-
crystal solubility phase diagram. 
 
Figure 2.5 Solubility phase diagram of components A and B and co-
crystal AB. The subscript ‘T’ is total concentration and [B]tr is the 
transition concentration. The four different regions are labelled I-IV 
(Nehm et al. 2006). 
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The solubility phase diagram in figure 2.5 has four labelled phase regions I, 
II, III and IV. Region I describes the area where the solution is 
supersaturated with respect to A and under saturated with respect to AB, 
therefore any AB crystals will spontaneously transform into form A crystals in 
this region. Region II describes a region where the solution is supersaturated 
with respect to both forms A and AB; this is where AB will precipitate out of 
the solution as it is the most thermodynamically stable phase. In region III, 
both A and AB are undersaturated in the solution, and no phase will 
precipitate out of the solution. Finally, in region IV, the solution is 
supersaturated with respect to AB and undersaturated with respect to A, 
therefore form A will transform to crystalline form AB. 
There were some assumptions required for interpreting the solubility phase 
diagram in figure 2.5. It was assumed that B was more soluble than A; AB 
was more soluble than A in a stoichiometric solution, no complexation or 
ionization of the components takes place in the solution, and the solubility of 
A is independent of the concentration of B in the solution. 
A crucial part of the phase diagram shown in figure 2.5 was the point where 
the solubility of the drug A and co-crystal AB intersected. This was the 
eutectic point and the co-crystal solubility can be calculated from this point 
using the concentrations of the drug and co-former (Nehm et al. 2006). 
In 2006, a research group proposed that when the co-crystal form is added 
to a solution in excess of the stoichiometric composition, it reduces the 
solubility of the co-crystal (Rodríguez-Hornedo et al. 2006). It was explained 
by considering the equilibrium equation of the reaction of a binary co-crystal 
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when dissociating in a solution of its API and co-former. The equilibrium 
constant for this reaction is proportional to the thermodynamic activity 
product of the API and co-former. The co-crystal solubility can therefore be 
predicted by the solubility product if the activity of the solid is constant or 
equal to 1. 
The reaction theory proposes that cocrystallisation in solid-liquid systems is 
initiated by the effect of nonstoichiometric concentrations of the co-crystal 
components causing the reduction of the solubility of the co-crystal to be 
crystallised (Rodríguez-Hornedo et al. 2006). 
The second proposed mechanism for cocrystallisation was the eutectic and 
vapour phase theory. This theory sets out to explain why, during processes 
such as mechanical grinding of an API and co-former, the reactants can melt 
to form the co-crystal form at temperatures below the individual melting 
points of the components (Chadwick et al. 2007). It is unknown exactly what 
the cause of this phenomenon is however it has been suggested that vapour 
diffusion could provide a mass transfer mechanism because kinetic data has 
shown that the reaction is diffusion controlled (Rastogi et al. 1962). It has 
also been proposed that additional degrees of freedom, the enhancing of 
molecular collisions and the formation of co-crystal seeds play an important 
role when a study was conducted where the rate of cocrystallisation was 
significantly increased upon the addition on small amounts of solvent (Shan 
et al. 2002) 
Another proposal for the eutectic effect was that if the crystal lattice of each 
component allows for long-range anisotropic molecular migrations, the 
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molecules can undergo gas-solid, solid-solid, thermal, photochemical and 
catalysed reactions (Kaupp 2003). 
With regards to the mechanical grinding technique in particular, the eutectic 
effect was explained by the mechanical act of grinding causing a high 
interfacial area between the initial solid phases where a liquid phase can 
form. Additional grinding and shear experienced by the material then 
facilitated contact between the liquid and solid phases which caused 
nucleation and growth of the co-crystal phase (Chadwick et al. 2007). 
Thirdly, the deliquescence mediated cocrystallisation method has been 
proposed for describing the formation of co-crystals in a solution. It is based 
on the deliquescent and hydroscopic properties of the co-crystal 
components. The proposed process is displayed in the diagram in figure 2.6. 
Examples of such components include sucrose, fructose and citric acid 
(Jayasankar et al. 2007). The deliquescent material absorbs moisture at a 
characteristic relative humidity. This causes it to dissolve and coat the 
surrounding particles with the solution. Finally, solution-mediated 
cocrystallisation occurs if two or more co-crystal components are in close 
proximity with each other. 
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Figure 2.6 A diagram of moisture sorption by a deliquescent material, 
Ds, dissolution of co-crystal components, and cocrystallisation of the 
components A and B (Jayasankar et al. 2007). 
The driving force for solid blends containing deliquescent materials depends 
on the rate of moisture sorption, the dissolution rate of the co-crystal 
components, and the supersaturation of those components in the solution 
phase. It was demonstrated that moisture can generate co-crystals when 
exposed to deliquescent conditions. 
The thermal fusion method for cocrystallisation describes the use of 
temperature alone for forming co-crystals and was first described by 
Lehmann (1888). It is a useful technique for studying the thermal behaviour 
of co-crystals and their individual components. The mixed fusion Kofler 
method, as it is now known, has been utilised by researchers to visualise the 
formation of a co-crystal when the two components meet on a glass slide 
(Berry et al. 2008). The basic methodology of the Kofler method is illustrated 
in figure 2.7. The highest melting point component, A, is melted and re-
crystallised, next, the lower melting point component B is heated and allowed 
to melt and is brought into contact with component A to create a zone of 
mixing, where cocrystallisation can occur. 
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Figure 2.7 A diagram of the mixed fusion Kofler method showing two 
components (A and B) coming in contact with each other to form a 
zone of mixing. Cocrystallisation can occur in this mixing zone (Berry 
et al. 2008). 
When combined with any kind of microscopy which has heating capabilities, 
the mixed fusion Kofler method is a powerful technique which can probe 
crystal properties and morphology under heating and when in contact with a 
co-former. The differential scanning calorimetry technique can also be used 
to accurately characterise the changes a material is experiencing upon 
heating under set conditions. The method involves heating small quantities of 
the appropriate stoichiometric amounts of the co-crystal components in the 
DSC pan up to a temperature which causes cocrystallisation to occur. 
2.6 Co-crystal preparation techniques 
There are a large number of reported methods for co-crystal synthesis. It is 
not easy to design a co-crystal that will be successful because a heteromeric 
system will only form if it is the most thermodynamically stable system 
(Providing the kinetics allow the transition) when compared to the homomeric 
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systems (Vishweshwar et al. 2006, Blagden et al. 2007). Intermolecular 
bonding is the key for the successful synthesis of co-crystals. 
Reported methods for the preparation of co-crystals include: solution 
crystallisation or solution mediated phase transformation (Leyssens et al. 
2014), solution evaporation (Weyna et al. 2009), solid-state grinding, liquid 
assisted grinding, polymer assisted grinding (Hasa et al. 2015), solvent-drop 
grinding (Trask et al. 2004), hot stage microscopy (Berry et al. 2008), hot 
melt extrusion (Moradiya et al. 2014), spray drying (Patil et al. 2014), freeze 
drying (Eddleston et al. 2013) and ultrasound assisted cocrystallisation (Kaur 
Bhangu et al. 2016). Hot melt extrusion is an increasingly popular 
cocrystallisation technique which will be discussed in more detail in the next 
section. 
2.7 Hot melt extrusion 
Hot melt extrusion formed a large part of this project. The technology 
surrounding extrusion and a general background review are presented in 
sub-section 2.71. The use of extrusion technology for manufacturing 
pharmaceutical co-crystals is also discussed in sub-section 2.72. 
2.71 Background 
Hot melt extrusion was originally developed for processing foods and plastics 
and rubber (Breitenbach 2002, Chokshi and Zia 2010). There are two main 
types: single screw and twin screw. For both single and twin screw designs, 
granules or powder is fed into the screw typically using a hopper. The 
material is then conveyed along the barrel where it is heated and subjected 
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to pressure and shear depending on the screw configuration and processing 
conditions. In most extruders, the depth of the screw flight is reduced to 
increase the pressure for compacting the material as it travels along the 
screw. At the end of the barrel, the material passes through a die which 
moulds it into a chosen shape (Crawford 1981). Extrusion technology was 
significantly developed towards the end of the 19th century to provide a 
continuous process for producing polymers of uniform shape and size (White 
et al. 2003). 
Most commercial extruders are now built with a modular design to make it 
easier to modify the extruder with attachments, to achieve better control, to 
facilitate maintenance and to allow for in-line process analytical technology 
(PAT) tools for analysing the process (Chokshi and Zia 2010). Single screw 
extrusion uses a single screw housed within the barrel; alternatively, twin 
screw extrusion uses two complimentary screws. The screws can be custom 
made to provide a certain level of mixing, shear and conveying. 
Screw design and configuration plays an important role in extrusion. The 
configuration can influence the mixing intensity, shear and how the material 
is conveyed along the barrel. The modification of screw configurations also 
allows the extruder to perform functions such as mixing, blending and 
dissolution (Breitenbach 2002). In figure 2.8, photographs of the most 
common screw operations that can be used are shown from a 16 mm co-
rotating twin screw extruder (Pharmalab, Thermo Scientific, UK). There can 
be forward conveying, staggered mixing, dispersive mixing and discharge 
screw functionalities. 
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Figure 2.8 Four different screw operations used in twin screw extrusion 
(Dhumal et al. 2010). 
The sequence of screw components along the barrel is called a screw 
configuration. For the Pharmalab extruder, mixing components can be 
placed at 0°, 30°, 60° and 90° to each other. However, other extruder models 
can have different mixing components which are tailored for specific needs, 
for example, reverse mixing elements for increasing the pressure (Whelan 
and Dunning 1988, Ghebre-Selassie and Martin 2003). In general, when the 
mixing components are at 0° to each other, this allows for dispersive mixing 
of the material. At 30°, 60°, and 90°, the mixing components allow staggered 
mixing. The mixing components can also be positioned to create reverse flow 
which creates higher shear experienced by the material in the barrel. 
The forward conveying screw elements are important as they convey the 
material along the extruder barrel, through zones which are set at different 
temperatures. They also deliver the material to the mixing zones, depending 
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on the screw configuration, and provide a net forwarding pressure. The 
mixing elements promote either dispersive or distributive (Staggered) mixing. 
Dispersive mixing is primarily used for breaking down aggregates and 
normally has a longer length mixing zone compared to distributive mixing. 
Dispersive mixing can hold the material in a pressure trap, for a certain 
period of time, which squeezes, elongates, and shears the material. 
Alternatively, distributive mixing regions are designed to separate the 
material into smaller units. Distributive mixing zones can be further sub-
classified due to their directional trait; they can forward convey, reverse 
convey or be completely neutral. This directional trait is determined by the 
angles at which the individual kneading elements are placed to one another 
and whether the element is in the clockwise or anticlockwise direction 
compared to the one before it. For example, if the kneading elements were 
positioned at 30° to each other in a clockwise direction, and the screw is 
rotated in a clockwise direction, this would be a distributive, forward 
conveying mixing zone. If the kneading elements are positioned at 90° to one 
another, this would create a neutral, distributive mixing zone. If the kneading 
elements were at 30° in an anticlockwise direction, and the screw is still spun 
in a clockwise direction, this would be a reverse, distributive mixing zone. 
When positioned at 0° to each other, this is a neutral mixing zone, and is 
exactly the same as a dispersive mixing zone.  
Single-screw extruders were developed for injection moulding of polymers 
and food and are used primarily as a melting device (Eitzlmayr et al. 2014). 
For highly viscous materials, and for specialised mixing capabilities, twin 
screw extrusion is preferred. In twin screw extrusion, two screws are 
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involved. In the majority of cases, the screws are made to be identical to 
each other in terms of their configuration. Mixing zones cannot be positioned 
at different points along each screw, they must both have the mixing zones 
at the same position, otherwise the screws will not complement each other 
geometrically (Ghebre-Selassie and Martin 2003). 
Twin screw extruders can have either co-rotating screws, which rotate in the 
same direction, or counter-rotating screws, which rotate in opposite 
directions to one another. Counter-rotating screws offer good material 
conveying and provide high shear because the material is squeezed through 
the small gap between the screws, however this can cause air entrapment, 
high pressures and can only be operated at slow speeds (Lim and White 
1994). If the pressure increases between the two screws, this can cause 
barrel wall scraping by the screws, and ultimately damage to the extruder. 
Co-rotating screws usually have an intermeshing design. Figure 2.9 
illustrates a forward conveying screw zone where both screws are 
intermeshing. This intermeshing design allows the screws to self-wipe as 
they rotate which is very useful as the screws can self-clean themselves and 
they don’t allow material to build up within the extruder barrel. Co-rotating 
screws can be operated at much higher screw speeds than counter-rotating 
screws and they do not suffer from mechanical wearing as much as counter-
rotating screws because they do not experience an outward pushing effect 
from a build-up of pressure between the screws. Co-rotational screw 
configurations are much more flexible than those for counter-rotating screws 
and they can be specifically tailored for a desired effect, such as intense 
mixing (Ghebre-Selassie and Martin 2003). Another advantage of a co-
31 
 
rotating, intermeshing, twin screw extruder is the material has a minimised 
residence time within the extruder whilst achieving the desired operations 
such as conveying, melting and sufficient mixing. 
 
Figure 2.9 An illustration of an intermeshing co-rotating twin screw 
from two different angles (Ghebre-Selassie and Martin 2003). 
Due to the inherent nature of the self-wiping screws in twin screw extruders, 
emphasis has been put on the solvent-free extrusion capabilities in recent 
years (Kleinebudde 2011, Eitzlmayr et al. 2014). Solvent-free extrusion is 
important as it is seen as being more environmentally friendly (Dhumal et al. 
2010) and there are no issues regarding solvents needing to be evaporated 
in post-processing stages (Krause et al. 2009). 
Variable-speed drives are used to turn the extruder screws. The gearing 
controls the speed, in rotations per minute (rpm), and in a twin screw 
extruder, the distribution gear absorbs any load from the screws and 
maintains the angular timing of the screws. The length to diameter ratio is an 
important term, and is simply the length of the screw divided by the diameter 
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of the screw. Intermeshing twin screw extruders can have an L/D ratio of up 
to approximately 60:1 and non-intermeshing twin screw extruders can 
achieve 100:1 or longer because there are no intermesh clearance 
constraints. A single screw extruder would normally have an L/D ratio of 36:1 
or shorter (Ghebre-Sellassie and Martin 2007). The outer diameter (OD) 
refers to the full diameter of each screw and the inside diameter (ID) refers to 
the OD minus the depth of flight. The OD/ID ratio is important because it is 
used to calculate the free volume within an extruder when added to the 
space between the screws and the gaps between the screw and barrel wall. 
Therefore, the flight of depth is critical for achieving the perfect balance 
between the free volume and the torque. The transfer of energy that the 
material is exposed to by the extruder is directly impacted by this balance. 
Finally, residence time of material within the extruder barrel can directly 
affect the properties of the material; the residence time can vary significantly 
depending on the extrusion conditions. 
Computer modelling of the extrusion process has always been a goal for 
extrusion science and extruder manufacturing companies (Tayeb et al. 
1989). Recent efforts have focused on 1D modelling as it has the power to 
provide crucial data about flow and stress on the extruder components and 
also for determining mixing modes and rates (Eitzlmayr and Khinast 2015). 
There are limitations to the modelling, as authors admit that a 3D model 
would be preferred, however this would require more computational effort 
(Eitzlmayr et al. 2014). 
In the last decade, hot melt extrusion technology has evolved and a 
transition has been made to pharmaceutical science (Crowley et al. 2007). 
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Hot melt extrusion can be used to prepare pharmaceutical delivery systems, 
including granules (Gryczke et al. 2011), pellets (Bialleck and Rein 2011, 
Roblegg et al. 2011), sustained release (Almeida et al. 2011, Vithani et al. 
2013) and rapid release (Perissutti et al. 2002) dosage matrices and many 
other devices. The technology can also be utilised for polymorphic 
transformation of APIs (Kulkarni et al. 2013, Kulkarni et al. 2015). 
2.72 Extruding co-crystal pairs 
Pharmaceutical co-crystals can be prepared using twin screw, hot melt 
extrusion when subjected to the correct conditions (Temperature, shear, 
residence time and sufficient mixing) (Dhumal et al. 2010) without the use of 
binders, polymers or solvents. 
As discussed in section 2.5, the right conditions are required for 
cocrystallisation to be spontaneous. The conditions must thermodynamically 
favour co-crystal formation. Hot melt extrusion technology provides a 
process where the temperature, pressure, shear and mixing intensity 
amongst other parameters can be accurately controlled. Adjusting these 
parameters, allows for the process to be optimised to favour a certain 
reaction, transformation or other desired effects. An advantage of using 
extrusion is that no solvent is needed to facilitate the conversion to co-crystal 
(Dhumal et al. 2010) and is thus considered a green technology.  
Ibuprofen – nicotinamide co-crystals were made using twin screw, hot melt 
extrusion by Dhumal et al. (2010). Ibuprofen and nicotinamide were blended 
and sufficiently mixed in a 1:1 molar ratio before being loaded into a 
gravimetric twin-screw feeder. The feeder fed the materials into the 
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Pharmalab 16 mm co-rotating twin screw extruder (40:1 L/D) (Thermo 
Scientific, UK) which was operated without a die. Their study found that a 
long residence time was important for increasing the 1:1 co-crystal yield. The 
residence time of the material was controlled by the screw speed; 20 rpm, 30 
rpm and 40 rpm. Equally as important was the temperature; if situated above 
the eutectic point of the two raw materials a good co-crystal yield was 
obtained. The most effective temperature profile involved heating the 
material from 25 to 90°C from zone 2 to zone 7 of the extruder barrel. The 
maximum temperature of 90°C was situated where the main mixing zone of 
the screw was positioned. Finally, at zone 10, the temperature was reduced 
to 80°C. The effectiveness of this temperature profile relied on the 
temperature being adequately above the eutectic point of the raw materials 
to cause partial melting, without causing any degradation. Finally, the screw 
geometry played an important role in forming the co-crystals. The group used 
three different configurations: low shear, medium shear and high shear. This 
nomenclature relates to the number, length and type of mixing zones that 
were positioned along the screws with the low shear screws having no 
mixing zones, and the high shear screws having five separate mixing zones. 
Overall, the team were able to prove that all three parameters, residence 
time, temperature and screw geometry, were important for controlling the co-
crystal yield using twin screw extrusion. 
Similarly, four case studies were undertaken by Daurio et al.  (2011) to see 
whether twin screw, hot melt extrusion could be used for manufacturing co-
crystals. The co-crystal systems they investigated were caffeine – oxalic 
acid, nicotinamide – trans cinnamic acid, carbamazepine – saccharin and 
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theophylline – citric acid. The extruder they used for their experiments was a 
Prism Pharmalab 16 mm twin screw extruder (25:1 L/D). It has three 
controlled temperature zones along the barrel and an additional temperature 
control for the die. However, the die was not needed and was therefore 
disconnected for the study. The screw geometry they used was designed to 
be a high shear, high mixing operation, with alternating forward conveying 
and 90° mixing zones along the full length of each screw. 
For the caffeine – oxalic acid system, Daurio et al. (2011) blended and mixed 
the material in a 2:1 molar ratio. To study the effect of mixing, the material 
was extruded using two screw geometries; one solely consisting of forward 
mixing elements, the other as described in the paragraph above, high mixing. 
No 2:1 co-crystals formed when applying the forward conveying screw, 
however, when using the mixing screw, the co-crystal formed at 25°C and 
75°C. The authors stated that the eutectic formation may not be the 
mechanism controlling co-crystal formation in this co-crystal system. Next, 
the team collected samples from the beginning, middle and end of the 
extruder barrel and analysed them using PXRD. They found a metastable 
caffeine – oxalic acid co-crystal polymorph situated in the middle of the 
barrel. Finally, they studied the effect of material residence time on co-crystal 
formation. The screw speed was set to 25, 50, 75, 100 and 250 rpm and 
from looking at the PXRD patterns, they determined that the slowest screw 
speed was the optimal setting for co-crystal formation. However, they noted 
that residence time did not play a significant role in increasing co-crystal 
formation because it was only at 250 rpm were they found incomplete co-
crystal formation. 
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Concerning the nicotinamide – trans cinnamic acid co-crystal system, Daurio 
et al. (2011) blended and mixed the components in a 1:1 molar ratio. The 
first study they conducted involved investigating the effect of temperature on 
co-crystal formation by extruding the physical mixture at 75 rpm with 
temperatures of 80, 90, 100 and 110°C. Only at 110°C was full co-crystal 
conversion achieved. At 120°C, the large amount of torque suffered by the 
extruder precluded the run. The authors state that for this co-crystal system, 
eutectic formation is involved. 
For the carbamazepine – saccharin co-crystal system, Daurio et al. (2011) 
blended and mixed the raw materials in a 1:1 molar ratio. Extrusion was 
carried out at 50°C and 190°C using a screw speed of 25 rpm. Near 
complete co-crystal formation (97%) was only observed in the sample 
processed at 190°C. They chose 190°C because this is very close to the 
melting point of carbamazepine. To investigate the effect of the presence of 
water during extrusion of the material, the team decided to add 
approximately 5 mL of water to 10.4 g of 1:1 physical mixture of anhydrous 
carbamazepine and saccharin and then extruded this at 100°C. 100°C was 
chosen to rid the end product of water. For this sample, an 87% co-crystal 
yield was achieved. The authors suggest that this method could be more 
optimized to increase the co-crystal yield and recommend that using 
hydrated starting materials could also have a similar effect. Finally, the 
researchers tried to make form II of the 1:1 co-crystal by adding ethanol 
during extrusion. However, they were only able to produce form I. This 
proves that by utilizing the effect of catalytic solvents during extrusion, they 
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were able to lower the processing temperatures required for formation of the 
form I co-crystal. 
A theophylline – citric acid system was also studied by Daurio et al. (2011) 
using twin screw extrusion. They blended and mixed the anhydrous and 
monohydrated forms of the materials in 1:1 molar ratios ready for extrusion. 
The experiment details are shown in table 2.1. Both the hydrated and 
anhydrous co-crystals were formed using different combinations of the 
starting components. At the high temperature, the anhydrous co-crystals 
were formed, as was expected, regardless of the starting components. They 
concluded that when extrusion was carried out at 20°C, water resided within 
the crystal lattice of the co-crystal, however, in the case of 50°C, the water 
aided the formation of the anhydrous co-crystal. Similarly, the water aided 
the formation of the anhydrous co-crystal at 153°C but was unable to help 
the material to reach full conversion due to evaporation. An additional 
ethanol assisted run, concluded that the anhydrous co-crystal was formed. 
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Table 2.1 Outcome of twin screw extrusion experiments performed with 
theophylline – citric acid system (Daurio et al. 2011). A: anhydrous, M: 
monohydrate, AC: anhydrous co-crystal, HC: hydrated co-crystal. 
# Theophylline Citric 
acid 
Type of 
extrusion 
Temperature 
(°C) 
Product 
1 A A Neat 153 
AC + 
unreacted 
2 A M Neat 153 
AC + 
unreacted 
3 M A Neat 153 
AC + 
unreacted 
4 A M Neat 50 AC 
5 A A Ethanol-assisted 20 AC 
6 A M Neat 20 HC 
7 A M Water-assisted 20 HC 
 
In 2010, Medina et al. (2010) attempted using twin screw extrusion to 
manufacture 2:1 caffeine – oxalic acid and 1:1 AMG 517 – sorbic acid co-
crystals. The appropriate stoichiometric blends of the starting materials were 
fed into a ThermoScientific Pharmalab 16 mm co-rotating twin screw 
extruder for processing. For both systems, a high intensity mixing screw 
geometry was used. The temperature used for the caffeine – oxalic acid 
system was 75°C for each temperature controlled zone along the extruder 
barrel and the screw speed was set at 100 rpm. For the AMG 517 – sorbic 
acid system, the temperature was 115°C throughout the barrel, and the 
screw speed was 25 rpm. No die was used for both systems and a forward 
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conveying screw featuring no mixing elements was used as a control. PXRD 
confirmed that both co-crystals were successfully manufactured using the 
aforementioned settings and when the control conditions were employed, no 
co-crystals were formed in either system. The authors conclude the results 
by stating that efficient mixing and close material packing during twin screw 
extrusion are critical for providing surface contact between the raw 
components and thus, facilitating co-crystal formation. 
Kulkarni et al. (Kulkarni et al. 2015) presented a study where the 
stoichiometry of the caffeine – maleic acid co-crystal was controlled using 
twin screw, hot melt extrusion. The team used a ThermoScientific Pharmalab 
16 mm co-rotating twin screw extruder (40:1 L/D). The findings are presented 
in figure 2.10. 
 
Figure 2.10 Schematic representation of caffeine – maleic acid co-
crystal formation using SFCC (Kulkarni et al. 2015). 
The findings from the study confirmed that hot melt extrusion was able to 
successfully form 2:1 caffeine – maleic acid co-crystals where other 
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crystallisation techniques had failed. The extrusion process was also capable 
of converting the 1:1 co-crystals into 2:1 co-crystals and conversion from 2:1 
to 1:1 was achieved by seeding with the phase pure 1:1 co-crystal (15% w/w) 
at zone 6 of the extruder barrel. 
In this section, many examples of cocrystallisation via hot melt extrusion 
were presented. It is an increasingly popular technique which has great 
potential for the pharmaceutical sector as a whole.  
2.8 Applications of co-crystals 
Pharmaceutical co-crystals have been celebrated for their ability to improve 
the physicochemical properties of an API without disrupting the functionality 
of the API molecule itself (Schultheiss and Newman 2009). Highly 
symmetrical, rigid, low molecular weight molecules which can form strong 
intermolecular interactions have a high probability of being able to 
cocrystallise with suitable co-formers (Stahly 2007). Co-crystals are 
“underutilised solids that greatly expand the possibilities for finding a 
developable solid form of an API” according to Stahly (2007). 
In the current literature, there are many examples where cocrystallisation has 
provided a means of improving API solubility and dissolution rates. Chow et 
al. (2012) reported that 1:1 ibuprofen – nicotinamide co-crystals and 1:1 
flurbiprofen – nicotinamide co-crystals can have improved tableting 
behaviour, hygroscopicity and dissolution performance compared to 
ibuprofen and flurbiprofen on their own. Similarly, Yan et al. (2012) reported 
that cocrystallising agomelatine with glycolic acid, isonicotinamide, methyl-4-
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hydroxybenzoate and urea improves the APIs aqueous solubility compared 
to agomelatine form I and II. 
A large study was conducted by Good and Rodriguez-Hornedo (2009) to 
compare the solubilities of the API and co-formers to their co-crystal forms. 
Their findings are shown in table 2.2. For some co-crystal forms, the co-
crystal solubilities were lower than the solubility of the API on its own. The 
research team found that the co-crystal solubility increased with the solubility 
of the components. They also found that if the co-former solubility is 
approximately 10-fold higher than the API, this generally leads to a co-crystal 
form which has a higher solubility than the API. 
Table 2.2 Component solubilities and co-crystal solubilities (Good and 
Rodríguez-Hornedo 2009). 
Co-crystal 
(drug – co-
former) 
A:B co-
crystal 
stoichiometry 
(drug − co-
former) 
Solvent 
Sco-former 
(M) 
Sdrug (M) 
Co-crystal 
solubility 
(M) 
CBZ-MLN 2:1 water 1.5 × 10+1 4.6 × 10−4 5.9 × 10−3 
CBZ-GTA 1:1 water 1.0 × 10+1 4.6 × 10−4 5.4 × 10−2 
CBZ-NCT 1:1 water 7.5 × 100 4.6 × 10−4 7.0 × 10−2 
THP-NCT 1:1 water 7.5 × 100 3.1 × 10−2 4.5 × 10−1 
CBZ-OXA 2:1 water 1.3 × 100 4.6 × 10−4 1.3 × 10−3 
CBZ-SUC 2:1 water 5.4 × 10−1 4.6 × 10−4 1.2 × 10−3 
CBZ-SAC 1:1 water 1.8 × 10−2 4.6 × 10−4 1.2 × 10−3 
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CAF-SLC 1:1 water 1.4 × 10−2 1.1 × 10−1 2.9 × 10−2 
THP-SLC 1:1 water 1.4 × 10−2 3.1 × 10−2 1.3 × 10−2 
CBZ-SLC 1:1 water 1.4 × 10−2 4.6 × 10−4 9.1 × 10−4 
CBZ-GTA 1:1 IPA 3.6 × 100 5.0 × 10−2 2.2 × 10−1 
THP-NCT 1:1 IPA 6.3 × 10−1 3.0 × 10−3 4.8 × 10−2 
CBZ-NCT 1:1 IPA 6.3 × 10−1 5.0 × 10−2 6.1 × 10−2 
CBZ-SAC 1:1 IPA 1.6 × 10−1 5.0 × 10−2 2.0 × 10−2 
CBZ-SUC 2:1 IPA 5.5 × 10−1 5.0 × 10−2 8.8 × 10−3 
CBZ-GTA 1:1 EtOH 2.8 × 100 1.4 × 10−1 3.1 × 10−1 
THP-NCT 1:1 EtOH 1.1 × 100 1.8 × 10−2 7.6 × 10−2 
CBZ-NCT 1:1 EtOH 1.1 × 100 1.4 × 10−1 1.5 × 10−1 
CBZ-SAC 1:1 EtOH 2.4 × 10−1 1.4 × 10−1 6.5 × 10−2 
CBZ-SUC 2:1 EtOH 8.1 × 10−1 1.4 × 10−1 4.5 × 10−2 
CBZ-GTA 1:1 EtOAc 1.0 × 100 4.9 × 10−2 9.4 × 10−2 
CBZ-SAC 1:1 EtOAc 1.8 × 10−1 4.9 × 10−2 5.0 × 10−2 
THP-NCT 1:1 EtOAc 1.1 × 10−1 6.2 × 10−3 1.4 × 10−2 
CBZ-NCT 1:1 EtOAc 1.1 × 10−1 4.9 × 10−2 2.6 × 10−2 
CBZ-SUC 2:1 EtOAc 4.6 × 10−2 4.9 × 10−2 2.0 × 10−3 
 
The solubility of a co-crystal is thought to be determined by the strength of 
the crystal lattice and the solubility of the individual components (Thakuria et 
al. 2013). Therefore, one can theoretically alter the solubility of an API by 
cocrystallisation with a carefully selected co-former, as evidenced in table 
2.2. The co-crystal lattice strength/energy has complete control of the 
solubility when in solvents with a small resistance to solvation or in an ideal 
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solution where solvent-solute interactions equal those of solvent-solvent 
interactions. However, drug hydrophobicity plays a major role in determining 
the aqueous solubility of the co-crystal (Lu et al. 2008). Co-crystals which 
involve hydrophobic components can have reduced solubilities compared to 
what would be expected if the solubility was solely calculated from the lattice 
energy. 
Approximately 40% of marketed drugs have low solubility and up to 90% 
may not make it to market due to solubility issues (Thayer 2010). The data in 
table 2.3 highlights this problem. Over the past decade, there have been 
many patent application filings for pharmaceutical co-crystals which possess 
improved solubility and stability (Miroshnyk et al. 2009). It is clear that co-
crystal forms can provide a route for the enhancement of the solubility of 
APIs and they offer a new hope for poorly soluble drugs. 
Table 2.3 Drugs on the market and in the R&D pipeline and their 
Biopharmaceutics Classification System class (Thayer 2010). 
BCS class Solubility Permeability 
% Drugs on 
market 
% Drugs in 
R&D 
pipeline 
I High High 35 5-10 
II Low High 30 60-70 
III High Low 25 5-10 
IV low low 10 10-20 
 
Cocrystallisation has also been proven as a viable technique for modifying 
the melting point and thermal stability of APIs (Thakuria et al. 2013). 
Vishweshwar et al. (2003) reported that the melting point of isonicotinamide 
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– aliphatic dicarboxylic acid co-crystals exhibited a similar trend to that of the 
pure co-formers. As they changed the number of diacids from odd to even, 
the melting point increased. Bond (2006) observed a similar trend with the 
melting point when studying 2:1 n-alkyl carboxylic acid – pyrazine co-crystals 
and comparing with the melting point of the pure n-alkyl carboxylic acids. The 
melting point of the co-formers increased from 285 to 315 Kelvin as the chain 
length was extended from C1 to C13, while the co-crystal forms had the 
opposite effect on the melting temperature. Finally, Trask et al. (2005) were 
able to improve the hydration stability of caffeine by cocrystallising the API 
with oxalic acid. They achieved “complete stability to humidity over a period 
of several weeks”. 
2.9 NIR spectroscopy 
Near infrared spectroscopy played a key role in this study. It was utilised due 
to its ability to characterise materials in a practical and rapid way. In this 
section, the background of NIR is discussed along with the PAT applications 
of this technology. 
2.91 Background 
The near infrared region of the electromagnetic spectrum is defined as the 
wavenumber range of 12820 – 3959 cm-1 by the American Society of Testing 
and Materials (ASTM) (ASTM 2012). The earliest reported use of NIR 
spectroscopy as an analytical tool was in the 1950s. Following the invention 
of computers that were capable of processing NIR spectra, the technique 
was expanded and became increasingly popular in various scientific fields 
(Blanco and Villarroya 2002). 
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NIR spectroscopy can provide spectra for solid and liquid samples without 
any pre-treatment of the samples being required (Blanco and Villarroya 
2002). It can be used in-line with continuous technologies and it is a rapid 
technique which can provide multivariate qualitative (Blanco et al. 1998), 
quantitative (Long 2009), physical and chemical (Reich 2005). 
Absorption bands in the NIR spectrum mainly correspond to overtone bands 
and combination bands of fundamental molecular vibrations. One of the 
simplest ways of describing the vibration of molecules is by using the 
harmonic oscillator model (Eq. 2.5) which calculates the energy of the 
different equally spaced energy levels (Blanco and Villarroya 2002). 
𝑬𝒗𝒊𝒃  =  (𝒖 + 
𝟏
𝟐
) 
𝒉
𝟐𝝅
√
𝒌
𝝁
       (Eq. 2.5)  
Where u is the vibrational quantum number, µ is the reduced mass of the 
bonding atoms, and Planck’s constant h and the force constant k are used. 
The harmonic oscillator model only allows transitions between consecutive 
energy levels which cause the dipole moment to change (Eq. 2.6) (Blanco 
and Villarroya 2002). 
∆𝑬𝒗𝒊𝒃  =  ∆𝑬𝒓𝒂𝒅  = 𝒉𝒗       (Eq. 2.6)  
Where v is the fundamental vibrational frequency of the bond (Which 
produces an absorption band in the mid IR region). The harmonic oscillator 
model does not take into account the coulombic repulsion between atoms or 
even the dissociation of molecular bonds, and therefore it is not an accurate 
representation of the behaviour of real molecules. Molecular behaviour can 
be described more accurately by an anharmonic oscillator model. This is 
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because the energy curve of an oscillating molecule is affected by 
intramolecular interactions, and therefore the equilibrium position vibrations 
are non-symmetric. The energy levels are not equally spaced in the 
anharmonic model (Eq. 2.7) (Blanco and Villarroya 2002). 
∆𝑬𝒗𝒊𝒃  = 𝒉𝒗 [𝟏 − (𝟐𝒖 + ∆𝒖 + 𝟏)𝒚]     (Eq. 2.7)  
The difference between the energy levels decreases with increasing 
vibrational quantum number, u. Where y is the anharmonicity factor. The 
anharmonic nature of the transitions between molecular vibrational energy 
states gives rise to overtone absorption bands situated at multiples of the 
fundamental vibrational frequencies. 
Combination absorption bands are produced by polyatomic molecules where 
more than one vibrational mode can interfere with each other and cause 
simultaneous energy changes. Overtone bands are typically located between 
12820 and 5000 cm-1 (Wavenumber). Combination bands are typically 
located between 5263 and 4000 cm-1 (Wavenumber) (Blanco and Villarroya 
2002).  
As the hydrogen atom is the lightest, it exhibits the largest vibrations and the 
most exaggerated anharmonic behaviour. Common absorption bands that 
occur in the NIR region are usually overtones and combinations of vibrations 
of the following functional groups: -CH, -OH, -NH and -SH (Reich 2005). 
Absorption bands for C=O, C-C and C-Cl are produced in the spectrum but 
are notably weaker. The frequency and intensity of NIR absorption bands are 
directly affected by anharmonicity and Fermi resonance.  
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When two NIR absorption bands of a molecule, which have the same 
frequency due to possessing a similar energy, do not overlay and sum up 
with one another but instead split into two peaks of higher and lower 
frequencies, this is called Fermi resonance (Fermi 1931). Intermolecular 
hydrogen bonding and dipole interactions must also be considered because 
they too can alter the vibrational energy states, causing existing absorption 
bands to shift or creating new ones. 
Hydrogen bonding has the same effect of increasing the mass of the 
vibrating hydrogen atom. This leads to a reduction of mechanical 
anharmonicity of the hydrogen bond vibration and therefore leads to a 
reduced absorption intensity of the resulting NIR band (Siesler 2008). This 
phenomenon is important to this study because hydrogen bonding plays an 
essential role in forming co-crystals. In conclusion, crystal phases can be 
successfully determined by using NIR spectroscopy, and small changes to 
the molecular structure can be observed. 
2.92 PAT applications 
One of the aims of this study was to develop a co-crystal yield prediction 
model using NIR. The hope was to gather and analyse spectral data which 
could provide important co-crystal information. The findings of this model 
could then eventually be used for future in-line NIR monitoring of 
pharmaceutical co-crystal manufacturing techniques such as hot melt 
extrusion. NIR spectroscopy provided an accurate characterisation technique 
which could be used to reach this goal due to its inherent advantages over 
other methods as discussed in section 2.91. 
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NIR spectroscopy has important implications for PAT tools. In 2004, the US 
Food and Drug Administration (FDA) published a PAT guidance document 
called “PAT – A Framework for Innovative Pharmaceutical Development, 
Manufacturing, and Quality Assurance” (Afnan 2004). It was designed to 
encourage the voluntary development and implementation of innovative 
technologies in the pharmaceutical sector which are effective and efficient. 
The report recommended using analytical techniques to help understand 
manufacturing processes to ensure quality and consistency.  
In 2008, a conference on harmonisation was held in Geneva, Switzerland 
where it was concluded that PAT tools were an opportunity for more flexible 
regulatory approaches for pharmaceuticals (ICH 2008a). The conference 
also encouraged the use of quality by design (QbD) which encompasses 
PAT tools (ICH 2008b). 
The PAT approach involves understanding a process or technique combined 
with the analysis and monitoring of the process, usually in real-time. The 
objective is to guarantee acceptable final product quality using a defined 
methodology. It allows research groups to control, adapt and fix processes 
more quickly and efficiently instead of only analysing the end product and 
making their decisions from further down the line (Read et al. 2010). 
Kelly et al. (Kelly et al. 2012) demonstrated in 2012 that NIR can be used as 
an in-line PAT tool during the formation of ibuprofen - nicotinamide co-
crystals using hot melt extrusion. The team were able to identify key band 
shifts and band formations relating to the co-crystal form; particularly in the 
region 5200-4700 cm-1, when comparing the spectra of processed samples 
49 
 
to the 1:1 physical mixture of the starting components. Similarly, Moradiya et 
al. (2014) used NIR for in-line characterisation during the HME of 
carbamazepine - cinnamic acid co-crystals allowing for the determination of 
the position along the extruder barrel where co-crystal formation commenced 
by identifying key NIR band shifting. 
A case study, in 2014, using furosemide - adenine co-crystals was used to 
demonstrate a chemometric assisted NIR spectral analysis method with 
principal component analysis (PCA) which was able to pinpoint 
cocrystallisation nucleation and solvent evaporation events during a solvent 
evaporation method (Sarraguça et al. 2014). From this case study, further 
studies were conducted by Sarraguça et al. where they monitored 
cocrystallisation using NIR spectroscopy for furosemide - nicotinamide and 
furosemide - p-aminobenzioc acid co-crystals during a solvent evaporation 
technique (Sarraguça et al. 2015, Sarraguça et al. 2015). Carbamazepine - 
saccharin co-crystals (Lee et al. 2015) and indomethacin - saccharin co-
crystals (Chun et al. 2014) have also been monitored during antisolvent 
cocrystallisation using NIR spectroscopy. 
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CHAPTER 3 MATERIALS AND METHODS 
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3.1 Materials 
Carbamazepine form III (Figure 3.1) was purchased from Sigma Aldrich. It 
has the chemical formula C15H12N2O and molecular weight 236.27 g/mol. 
 
Figure 3.1 Carbamazepine diagram (Kelly and Rodríguez-Hornedo 
2009). 
Racemic ibuprofen (Figure 3.2) was purchased from Sigma Aldrich. It has 
the chemical formula C13H18O2 and molecular weight 206.28 g/mol. 
 
 
Figure 3.2 Ibuprofen diagram (Williams et al. 2012). 
Nicotinamide (Figure 3.3) was purchased from Sigma Aldrich. It has the 
chemical formula C6H6N2O and molecular weight 122.12 g/mol. 
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Figure 3.3 Nicotinamide diagram (Chiarella et al. 2007). 
Salicylic acid (Figure 3.4) was purchased from Sigma Aldrich. It has the 
chemical formula C7H6O3 and molecular weight 138.12 g/mol. 
 
 
Figure 3.4 Salicylic acid diagram (Nordström and Rasmuson 2006). 
Caffeine (Figure 3.5) was purchased from Sigma Aldrich. It has the chemical 
formula C8H10N4O2 and molecular weight 194.19 g/mol. 
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Figure 3.5 Caffeine diagram (Pinto and Diogo 2006). 
Maleic acid (Figure 3.6) was purchased from Sigma Aldrich. It has the 
chemical formula C4H4O4 and molecular weight 116.07 g/mol. 
 
Figure 3.6 Maleic acid diagram (Database 2016). 
All the above materials were a minimum of 98% purity. No further purification 
of the materials was performed. The solvents used for solution crystallisation 
were ethanol (99% analytical grade) and methanol (99% analytical grade). 
3.2 Preparation of ibuprofen – nicotinamide co-crystals 
Solvent mediated co-crystallisation was carried out using a microwave 
reactor (Monowave 300, Anton Paar GmbH, Austria).  1:1 equimolar weights 
of ibuprofen and nicotinamide, totalling 0.820 g, was mixed with 82 µL of 
diluted water in a 30 mL capacity glass tube. The temperature was set to 
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80°C and samples were subjected to microwave irradiation with a holding 
time of 5 minutes and were then cooled at 10°C/min to 40°C and held for 1 
minute. For chapter 6, the preparation of this co-crystal was carried out by 
the PhD student Abdolati Alwati. The resulting co-crystal molecular structure 
is shown in figure 3.7.  
 
Figure 3.7 1:1 IBU-NIC co-crystal molecular structure. Hydrogen 
bonding is shown by light blue and red dashed lines. Source: 
Fleischman et al. (Fleischman et al. 2003) via Cambridge Structural 
Database (Allen 2002). 
The hydrogen bonding patterns are well documented for the 1:1 IBU-NIC co-
crystal. The racemic ibuprofen binds to nicotinamide via an acid-pyridine 
motif, before a pair of dimers come together through an amide-amide motif 
between the nicotinamide molecules. Finally an amide-acid motif forms 
between the nicotinamide and the ibuprofen to create a ‘supramolecular 
macrocycle structure’ (Blagden et al. 2008). 
3.3 Preparation of carbamazepine – nicotinamide co-crystals 
Solvent evaporation was carried out based on the method reported by 
Shayanfar et al. (2014) in 2014. 1:1 equimolar weights of carbamazepine 
(2.363 g, 0.01 mol) and nicotinamide (1.221 g, 0.01 mol) were dissolved in 
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20 mL of absolute ethanol. The mixture was gently heated and manually 
stirred with a glass rod for 30 minutes. The mixture was then left for 72 hours 
at room temperature to allow for evaporation of the solvent. The resulting co-
crystal molecular structure is shown in figure 3.8.  
 
Figure 3.8 1:1 CBZ-NIC co-crystal molecular structure. Hydrogen 
bonding is shown by light blue and red dashed lines. Source: Berry et 
al. (Berry et al. 2008) 2008 via Cambridge Structural Database (Allen 
2002). 
In this 1:1 co-crystal, a translation related hydrogen-bonding pattern exists 
between the nicotinamide molecules and the carbamazepine molecules. The 
donors and acceptors of both amide groups are fulfilled but the nitrogen atom 
within the ring structure of nicotinamide does not form any strong hydrogen 
bonds. The crystal packing suggests hydrophobic interlocking rows with 
π…π interactions between the carbamazepine and the nicotinamide rings 
(Fleischman et al. 2003). 
There are reported studies which suggest there are other polymorphic forms 
of the 1:1 carbamazepine – nicotinamide co-crystal (Seefeldt et al. 2007, 
Porter III et al. 2008), however these forms are thought to be unstable and 
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can only form under specially controlled conditions. In this thesis, there was 
no indication of this alternative polymorphic form when observing the powder 
X-ray diffraction characterisation of samples. 
3.4 Powder X-ray diffraction 
X-ray scattering occurs when an X-ray is absorbed by an atom and excites 
another electron within that atom and the incident energy is then re-
irradiated. Coherent scattering (Elastic) occurs when the incident X-ray 
photon changes direction when it comes into contact with an atom and none 
of its energy is transferred to an electron. Finally, incoherent scattering is 
when some energy from the incident X-ray photon is lost when it collides with 
the atom and the emitted X-ray has a lower energy and becomes out of 
phase with the incident X-ray. In any case, waves scattering from one or 
more objects will expand in space until they come in contact with each other, 
causing constructive or destructive interference. A periodic array of 
molecules within a crystal that coherently scatter radiation, and as a result 
cause constructive interference at certain angles, is called diffraction 
(Giacovazzo 2002). 
The diffraction of a crystal phase is unique because the angles of diffraction 
are directly affected by the periodic arrays within the lattice. Bragg’s law 
explains this phenomenon in figure 3.9. In Bragg’s law, the crystallographic 
planes are described by Miller indices h, k and l. The incident X-rays are 
monochromatic and in phase with one another and they reflect from different 
crystallographic planes within the crystal lattice. In figure 3.9, the X-ray that 
interacts with the lower plane has to travel further than the one above it and 
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this difference is equal to the wavelength (λ) and causes constructive 
interference. Similarly, if an X-ray interacted with a third plane, the extra 
distance travelled will be equal to 2λ (Klug and Alexander 1974). 
 
Figure 3.9 Bragg’s law analogy. Two crystallographic planes are shown 
with spacing, d. Also two incident X-rays are drawn to show coherent 
scattering and their incident angle, theta (θ) (Adapted from (Giacovazzo 
2002)). 
This theory leads to the Bragg equation (Eq. 3.1): 
nλ = 2dhklsinθ        (Eq. 3.1) 
Where n is the plane, λ is the wavelength, dhkl is the distance between the 
planes and θ is the incidence angle of the X-ray beam. 
In this study, the crystallinity of the raw and extruded material was 
determined using a Bruker D8 X-ray diffractometer provided by the Analytical 
Centre at the University of Bradford. Scans from 2-40° (2θ) with a 0.01° step 
width and a 1s time count were carried out for most samples using CuKα1 
radiation (1.5406 Ang wavelength). The receiving slit was 1° and the 
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scattering slit, 0.2°. The diffracted X-rays were collected by a detector and 
were arranged into a 2 dimensional pattern showing the position (2θ) and 
intensity of each reflection. The composition of the powder was predicted by 
comparing the obtained peaks to X-ray diffraction data for known molecules. 
3.5 Differential scanning calorimetry 
Differential thermal analysis involves two thermometers attached by a 
thermocouple, where one thermometer is used as a reference while the other 
measures the temperature of a sample. The difference between the 
temperature of the reference and the sample provides thermal information 
about the sample (Richardson and Charsley 1998). Differential scanning 
calorimetry (DSC) measures the difference in the heat flow instead of the 
difference in temperature and a simple diagram of a DSC arrangement is 
shown in figure 3.10. 
 
Figure 3.10 A simplified diagram of differential scanning calorimetry. 
For all thermal analysis studies, including modulated DSC, samples with a 
typical mass between 3 mg and 8 mg, were subjected to heating profiles 
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using a Q2000 Differential Scanning Calorimeter (Thermal Analysis 
Instruments, UK). The standard heating profile used was a temperature ramp 
typically starting from 40°C, the end temperature varied depending on the 
material being analysed. The default heating rate used was 10°C/min unless 
otherwise specified. As the temperature increased, the heat flow was 
recorded in mW and was converted to W/g in most cases. This technique 
was able to accurately determine the melting point of each individual 
material, as well as obtain the eutectic point for the co-crystal pairs studied. 
3.6 Scanning electron microscopy 
SEM images were taken using an FEI Quanta 400 Scanning Electron 
Microscope (Cambridge, UK) under a high vacuum using an acceleration 
voltage of 20 kV and spot size 3.0. The accompanying software was XTM 
microscope control software version 2.3. Samples were mounted on 
aluminium pin-stubs (Agar Scientific, Stansted, UK) using self-adhesive 
carbon stickers (Agar Scientific) and were coated with a layer of gold 
approximately 30 nm thick. The stubs were then placed on the SEM stage 
before being placed under a vacuum. The objective of using scanning 
electron microscopy was to observe the particle morphology of the individual 
materials and the co-crystals manufactured using hot melt extrusion and 
solution crystallisation. 
3.7 Model shear deformation 
Rheology is the study of the flow and the deformation of matter and in theory, 
it can be used experimentally to predict and understand the effect of shear 
stress and shear strain on a material. Quantitative measurements of viscosity 
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or other rheological values from rheological experiments is only possible if 
studying suitable materials such as polymers or liquids. In this study, solid 
pharmaceutical powders were used. So collecting typical rheological data 
was not possible. 
Nonetheless, a rotational rheometer can be used as an instrument which can 
apply a known amount of shear to a variety of materials, including solid 
powders. It can also heat and cool the material to a range of temperatures 
whilst applying the shear. 
In order to investigate the effect of shear force on co-crystal formation in this 
study, model shear deformation experiments, using a rotational rheometer, 
were designed. Model shear deformation was performed using an Anton 
Paar MCR rheometer equipped with parallel bottom and top plates (25 mm 
diameter). The heating and cooling rate used for all samples was 20°C/min. 
The top temperature was held for 10 minutes to mimic the time the material 
would spend, on average, inside the extruder barrel during extrusion. 
Different levels of strain were applied during the heating, hold and cooling of 
the sample and the direction of shear was set to oscillation mode, therefore, 
once the strain limit had been reached the direction would reverse. The 
oscillatory mode was chosen over the continuous mode in an attempt to 
keep as much of the material in contact with the upper and lower rheometer 
plates as possible during the applied shear. 
For the ibuprofen – nicotinamide pair in chapter 4, the maximum 
temperatures used were 70, 80 and 90°C with a holding time of 10 minutes. 
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The strain was set to 0, 25, 50, 75, 100, 200 and 300% and the 
heating/cooling rate was 20°C/min. 
By varying the temperature at which shear is applied to the material, and by 
changing the strain limit, the effect of both parameters on the co-crystal yield 
can be discovered. The results can then be compared to what is observed 
when using hot melt extrusion and can be used to determine the effect of 
shear on co-crystal formation. 
3.8 Twin screw, hot melt extrusion 
The hot melt extrusion technique provided a base technology for continuous 
cocrystallisation. A 16 mm co-rotating twin screw extruder (Pharmalab, 
Thermo Scientific, UK) with a length-to-diameter ratio of 40:1 was used and 
was operated without a die. The die was not necessary when extruding the 
powder materials because under high temperatures, the die can clog up and 
can prevent the material from being extruded. The powder materials were 
fed into the extruder at an approximate rate of 0.2 Kg/h by hand into a 
feeding funnel. Typically, 10-20 g of material was used per extrusion run. 
Several different temperature profiles, screw geometries and screw speeds 
were used to improve the co-crystal yield and were designed around the 
thermal data gathered for the subject materials. 
3.81 Temperature profiles 
Table 3.1 displays the temperature profiles used during hot melt extrusion of 
all materials in this study. The temperature codes indicate the maximum 
temperature achieved along the extruder barrel, for example, T140 describes 
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the temperature profile which started at 25°C at zone 2, reached 140°C at 
zone 7-8 and ended on 125°C at zone 10. For this project, the maximum 
temperature for each profile was positioned at zone 7 and zone 8 to allow for 
gradual heating from zone 2, whilst allowing for a slight decrease in the 
temperature towards the end of the extruder barrel. 
Table 3.1 Temperature profiles for hot melt extrusion. Each zone 
represents a controlled heating area along the extruder barrel. The 
code indicates the maximum temperature. 
Code Temperature (°C) 
 
Zone 
2 
Zone 
3 
Zone 
4 
Zone 
5 
Zone 
6 
Zone 
7 
Zone 
8 
Zone 
9 
Zone 
10 
T80 25 40 50 70 75 80 80 80 70 
T90 25 40 50 75 80 90 90 80 80 
T110 25 40 60 85 100 110 110 100 100 
T120 25 40 60 85 105 120 120 110 110 
T125 25 40 70 90 120 125 125 120 110 
T130 25 40 80 110 125 130 130 125 120 
T135 25 50 100 120 130 135 135 130 120 
T140 25 50 100 125 135 140 140 135 125 
T150 25 60 110 135 145 150 150 145 135 
 
A range of temperatures for each co-crystal pair where used to monitor the 
effect of temperature on the co-crystal yield. The majority of the temperature 
profiles used were purposely designed to heat the material in the extruder 
barrel beyond the eutectic point of the system.  
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3.82 Screw Geometry 
There were two screw geometries adopted for this study: screw geometry A 
and screw geometry B. Images of each screw geometry are shown in figure 
3.11. Screw geometry A is a basic design featuring one mixing zone. This 
mixing zone consists of kneading screw elements angled at 30, 60 or 90° 
and is designed for mixing the material in the barrel at zone 7 and zone 8. 
Screw geometry B is a more complex screw geometry. It features three 
separate mixing zones positioned between zone 5 and zone 8. Screw 
geometry B provides more mixing capacity than geometry A and it also 
provides some dispersive mixing zones (0°) as opposed to only staggered 
mixing in geometry A. The two geometries were chosen to study the effect of 
different levels of mixing and shear applied to the material as it is conveyed 
along the extruder barrel. Figure 3.12 displays the individual screw 
components used to build a screw geometry and a detailed list of the 
components used to make each screw along with their relative length is 
shown in table 3.2. Finally, figure 3.13 is an image of the extruder barrel 
where the individual barrel zones have been labelled in pen. 
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Figure 3.11 Photographs of screw geometry A and B situated in an 
open extruder barrel. 
 
Figure 3.12 Individual screw components used for screw geometries A 
and B. Forward conveying screw (Left), broad end kneading component 
(Centre), narrow end kneading component (Right). 
 
Figure 3.13 Extruder barrel zones marked in pen. Zone 1 is where the 
material is fed into the barrel. 
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Table 3.2 A list of screw components in order from zone 1 to zone 10 of 
the extruder barrel for screw geometries A and B. The relative length of 
each component is also stated. 
Screw Geometry A Screw Geometry B 
Length (D) Component Length (D) Component 
28 Forward conveying 19 Forward conveying 
2.25 30° kneading 1 30° kneading 
1.25 60° kneading 1 60° kneading 
1 90° kneading 1 90° kneading 
6 Forward conveying 2 Forward conveying 
1.5 Discharge 0.5 0° kneading 
  1 Forward conveying 
  0.5 0° kneading 
  2 Forward conveying 
  0.5 0° kneading 
  1 Forward conveying 
  0.5 0° kneading 
  2 90° kneading 
  6.5 Forward conveying 
  1.5 Discharge 
 
3.83 Screw speed 
The Pharmalab twin screw extruder can achieve speeds in excess of 200 
rpm, however for this study, a long residence time for the material was key 
for cocrystallisation, thus only slow speeds were used. Screw speeds of 10, 
20 and 30 rpm were chosen. A screw speed of 10 rpm provided a long 
residence time of the material in the extruder barrel, whereas the screw 
speed of 30 rpm provided increased shear intensity but a shorter residence 
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time. Different screw speeds were used to work out how the compromise 
between residence time and shear intensity effects the co-crystal yield. 
3.9 Near infrared spectroscopy 
A powerful characterisation technique was required for many different 
experiments throughout this study. NIR provided an accurate 
characterisation technique which could meet this goal. Off-line NIR spectra 
were collected using an Antaris II NIR spectrometer (Thermo Scientific, UK). 
Scans were carried out over the wavenumber range 4000-10,000 cm-1 
(2500-1000 nm wavelength) using the RESULT software by Thermo 
Scientific. Each scan provided an average of 32 individual spectra taken with 
a resolution of 8 cm-1. The material was loaded into a glass vial and placed 
on top of the glass window on the spectrometer. NIR was mainly used for 
characterisation purposes in chapters 4 and 5. However, it also provided an 
accurate way of predicting the co-crystal yield in the samples in chapter 6. 
The prediction models created in chapter 6 were made by using the NIR 
spectra of standard samples. For the ibuprofen – nicotinamide pair, a PLS 
regression model was designed using a set of standard samples consisting 
of a mixture of 1:1 IBU-NIC co-crystal and pure ibuprofen. The PLS model for 
the carbamazepine – nicotinamide pair was designed using a set of standard 
samples consisting of a mixture of 1:1 CBZ-NIC co-crystal and pure 
carbamazepine. The pure co-crystals used for the calibration and validation 
samples were made using the methods described in sections 3.2 and 3.3. 
The validation samples were made from a separate batch of co-crystal to the 
calibration samples for both co-crystal pairs, they were not used to create the 
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PLS models, but they were used to validate the models. The concentration of 
the calibration samples ranged from pure ibuprofen/carbamazepine (0%) to 
100% 1:1 co-crystal with standards made at concentrations of 5% 
increments in between, totalling 20 calibration samples. Validation samples 
were made at the following concentrations: 2.5, 7.5, 12.5, 17.5, 27.5, 37.5, 
52.5, 62.5, 72.5 and 92.5% 1:1 co-crystal, totalling 10 validation samples. 
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CHAPTER 4 UNDERSTANDING CO-CRYSTAL 
FORMATION 
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This chapter was designed to focus on the fundamental characteristics of co-
crystal formation for several different co-crystal pairs. It was vital to 
understand the behaviour of the physical mixtures and the co-crystal forms 
because this would provide important data to cross reference with the 
extrusion experiments in chapter 5 and future work.  
The chapter focuses on a range of characterisation techniques such as DSC, 
modulated DSC, light microscopy equipped with a hot stage and a shear cell 
mounts, and rheometry. Several different pharmaceutical pairs were chosen 
for investigation. All were previously known to form stable co-crystals. The 
following pairs that were investigated were ibuprofen – nicotinamide, 
carbamazepine – nicotinamide, nicotinamide – salicylic acid and caffeine – 
maleic acid. The pharmaceutical pairs were chosen according to their 
availability at the time and their pharmaceutical importance, particularly 
ibuprofen – nicotinamide and carbamazepine – nicotinamide. 
The knowledge gathered from the ibuprofen – nicotinamide and 
carbamazepine – nicotinamide studies was used to guide the extrusion 
experiments carried out in chapter 5, the thermal data was particularly 
important for designing the extrusion experiments. 
4.1 Carbamazepine – nicotinamide thermal analysis 
Standard DSC ramps of carbamazepine and nicotinamide were carried out at 
two different heating rates of 5°C/minute and 10°C/minute. The resulting 
thermograms for carbamazepine are shown in figure 4.1.  
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Figure 4.1 DSC thermograms of carbamazepine (Form III) using heating 
ramps of 5°C and 10°C per minute. 
The thermograms display the difference in the behavior of carbamazepine 
between the two heating rates. The 5°C/min thermogram had a broad 
endothermic peak at 163.5°C (Tm CBZ (III)) followed by a sharp endothermic 
peak at 191.0°C (Tm CBZ (I)). The 10°C/min thermogram had an 
endothermic peak at 175.8°C (Tm CBZ (III)) immediately followed by a small 
exothermic peak at 177.8°C (Crystallisation of CBZ (I)) and then displays a 
sharp endothermic peak at 192.2°C (Tm CBZ (I)). The standard DSC ramps 
for nicotinamide are shown in figure 4.2. 
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Figure 4.2 DSC thermograms of nicotinamide using heating ramps of 
5°C and 10°C per minute. 
For nicotinamide, the thermograms show very little difference when using the 
two heating rates of 5°C and 10°C per minute. The 5°C/min thermogram has 
an endothermic peak at 129.3°C (Tm NIC) and the 10°C/min thermogram has 
an endothermic peak at 131.9°C (Tm NIC). 
The impact of the heating rate on the melting temperature of carbamazepine 
is important because the melting point is significantly reduced under slower 
heating rates. Therefore slower heating rates could improve thermal 
manufacturing methods of materials where carbamazepine is present 
because they could allow for processing at lower temperatures. Processing 
materials at lower temperatures has many benefits including reduced energy 
consumption, however it may also prevent decomposition of pharmaceutical 
materials which is very important if materials are to meet acceptable 
standards for market. 
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4.2 Carbamazepine – nicotinamide modulated DSC 
Modulated DSC is a technique where the temperature is modulated 
compared to a normal linear temperature profile. The technique can locate 
and distinguish reversible and non-reversible melting and crystallisation 
events. It also provides a more realistic melting point by delivering improved 
accuracy and sensitivity compared to conventional DSC (Reading, Luget et 
al. 1994). 
Modulated DSC was used to analyse carbamazepine – nicotinamide physical 
mixture samples with the following molar ratios: 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 
7:3, 8:2 and 9:1. A standard heating rate of 5°C/min was used with a set 
modulation of 2°C every 60 seconds. The resulting thermograms are shown 
in figure 4.3. 
 
Figure 4.3 Modulated DSC thermograms of carbamazepine – 
nicotinamide physical mixtures at different molar ratios. 
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The endothermic and exothermic peak and onset temperatures are shown in 
table 4.1 along with the integrated energies. 
Table 4.1 Endothermic and exothermic events with the corresponding 
onset and peak temperatures and the integrated energies. 
 
First endotherm Second endotherm Third endotherm 
CBZ - 
NIC 
molar 
ratio 
Onset 
(°C) 
Peak 
(°C) 
Energy 
(J/g) 
Onset 
(°C) 
Peak 
(°C) 
Energy 
(J/g) 
Onset 
(°C) 
Peak 
(°C) 
Energy 
(J/g) 
1 to 9 104.1 109.1 3.13 121.8 124.1 168.40 
   
2 to 8 103.8 108.1 1.26 122.9 126.1 139.70 
   
3 to 7 103.4 107.8 1.71 122.0 126.4 106.90 143.3 154.0 26.89 
4 to 6 102.9 106.3 0.47 122.1 125.6 81.92 150.0 158.8 55.65 
5 to 5 102.9 106.5 0.63 121.3 125.1 68.65 153.4 159.1 71.77 
6 to 4 102.1 105.7 0.17 121.3 125.5 52.00 152.7 158.7 99.11 
7 to 3 103.7 106.3 0.26 120.2 125.0 20.48 150.8 154.7 98.90 
8 to 2 103.5 107.2 0.49 120.0 124.7 20.23 150.3 154.3 94.57 
9 to 1 102.4 106.1 0.09 120.4 125.9 9.96 149.9 154.6 68.60 
 
The results from the modulated DSC experiment firstly show that the 
relatively small endothermic peak between 105°C and 109°C has a higher 
integrated energy for the physical mixture ratios of 3:7, 2:8 and 1:9, 
compared to the ratios of 4:6, 5:5, 6:4. 7:3, 8:2 and 9:1. This suggests this 
endothermic event is affected by higher concentrations of nicotinamide. The 
second endothermic peak between 124°C and 126°C significantly increases 
in the integrated energy as the amount of nicotinamide is increased. This 
would make sense as this melting endotherm is the eutectic melting point 
which is thought to be heavily influenced by nicotinamide which has the 
lower melting point of the two components. The third endotherm between 
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154°C and 159°C experiences a shift towards a lower melting temperature 
from the ratio of 6:4 to the ratio of 7:3. This significant shift is caused by a 
higher concentration of carbamazepine. The modulated DSC technique 
provided important thermal data for the carbamazepine – nicotinamide pair. 
There is an additional endothermic event experienced for the ratios of 7:3, 
8:2 and 9:1 between 170-190°C. This could be due to excess 
carbamazepine which has transformed into carbamazepine form I and 
subsequently melted. 
4.3 Carbamazepine – nicotinamide phase diagram 
Following on from the modulated DSC data gathered in section 4.2, a simple 
carbamazepine – nicotinamide binary phase diagram was created using 
modulated DSC data. The eutectic melting point, 1:1 co-crystal melting point 
and carbamazepine form I melting point for each mol fraction of 
carbamazepine are plotted in figure 4.4. Also included in the graph are the 
melting points for pure carbamazepine (Form III and form I) and 
nicotinamide. 
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Figure 4.4 Modulated DSC melting temperatures for 1:1 physical 
mixture (Eutectic), 1:1 co-crystal and carbamazepine form I plotted for 
each mol fraction of carbamazepine. 
The eutectic, 1:1 co-crystal and carbamazepine form I integrated melting 
peak energies are plotted in figure 4.5. The integrated energies are directly 
influenced by the amount of material associated with each peak, so a larger 
integrated energy suggests a larger amount of material has undergone a 
transformation at that particular temperature. 
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Figure 4.5 Modulated DSC integrated melting peak energies for 1:1 
physical mixture (Eutectic), 1:1 co-crystal and carbamazepine form I 
plotted for each mol fraction of carbamazepine. 
The energies in figure 4.5 confirm that as the mol fraction of carbamazepine 
is increased, the integrated energy for the eutectic melting peak reduces. 
The integrated energy for the 1:1 co-crystal melting peak increases with the 
mol fraction of carbamazepine before reducing from 0.7 to 0.9 mol fraction of 
carbamazepine due to an increased amount of carbamazepine form I. 
Using the endotherm melting temperatures, a simple binary phase diagram 
according to the mol fraction of carbamazepine was constructed and is 
shown in figure 4.6. The phase diagram indicates the eutectic temperatures 
and each phase was labelled according to the DSC data. The curves have 
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not been calculated but are simply a prediction of where the real curves 
would lie. 
 
Figure 4.6 A simple carbamazepine – nicotinamide binary phase 
diagram plotted using the modulated DSC data. 
Phase I is where the material has experienced a full melt. Phase II is where 
solid carbamazepine form I is present plus the liquid phase. Phase III is 
where the co-crystal forms after the eutectic melting of the physical mixture. 
Phase IV is the solid physical mixture of carbamazepine and nicotinamide. It 
is interesting to note that the eutectic melting temperature is slightly raised 
between 0.4 and 0.6 mol fraction of carbamazepine. 
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4.4 Model shear deformation studies  
4.41 Introduction    
An integral part of this project was to understand the effect of shear on co-
crystal formation. Shear force is experienced by materials as they are 
extruded using twin screw extrusion. Therefore it was vital to understand the 
behaviour of co-crystal formation under shear using several different 
techniques.       
An initial hot stage microscopy technique was used to explore the hot stage 
equipment and to view individual ibuprofen and nicotinamide crystals and 
their co-crystal form. This experiment provided an opportunity to set up the 
light microscope and hot stage, and to gain knowledge for using the 
equipment. 
Secondly, an amorphous experiment was conducted using DSC and the hot 
stage in conjunction with each other. This was done to provide visual 
evidence of the material to support the DSC data and to learn how the hot 
stage performed, compared to the DSC technique. 
A shear cell investigation was carried out, supported by light microscopy, of 
three different pharmaceutical pairs. Followed by an in-depth rheometry 
study into the effect of temperature and shear on the ibuprofen – 
nicotinamide pair. 
4.42 Ibuprofen – nicotinamide Kofler method    
The Kofler method (Or thermal fusion method) is a basic technique which is 
described in section 2.5. It can provide critical information about the crystal 
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form and morphology of materials, including co-crystals, and it can give 
further insight into the thermal behaviour of the materials. 
 
In this section, the Kofler method was performed using the ibuprofen – 
nicotinamide pair. Figure 4.7 shows the bright field microscopy image of the 
resulting experiment. The image shows re-crystallised nicotinamide (Left) 
and carbamazepine (Right) with a central mixing zone where co-crystal 
needles have formed. 
 
Figure 4.7 Light microscope image of the Kofler method using 
ibuprofen and nicotinamide. 
This simple technique allowed for a first observation of the 1:1 
carbamazepine – nicotinamide co-crystal under the light microscope. The co-
crystal forms thin needle shaped crystals which coincides with the reported 
crystal morphology (Seefeldt et al. 2007, Qiao et al. 2013). 
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4.43 Carbamazepine – nicotinamide amorphous study   
In this section, a small study was conducted for the carbamazepine – 
nicotinamide pair. The 1:1 physical mixture was subjected to a heat-cool-
heat DSC method. Then, the exact same method was performed on a 
Linkam hot stage where bright field and polarised light microscopy images of 
the sample could be collected. The heating method that was utilised was as 
follows.  
1. 40°C  200°C (5°C/min)  
2. Isothermal for 1 minute at 200°C 
3. 200°C  10oC (20°C/min) 
4. Isothermal for 5 minutes at 10°C 
5. 10°C  50°C (5°C/min, isothermal for 60 minutes) 
6. 50°C  220°C (5°C/min) 
The heating method was designed to fully melt the physical mixture, then to 
rapidly cool at 20°C per minute to quench the material, then to heat the 
material to 50°C to observe any crystallisation or cocrystallisation and finally 
a standard heating ramp to determine the crystal that had formed. The DSC 
thermogram for this experiment is shown in figure 4.8. The endothermic and 
exothermic peak and onset temperatures are shown in table 4.2 along with 
the integrated energies. 
 
81 
 
 
Figure 4.8 A DSC thermogram of 1:1 carbamazepine – nicotinamide 
physical mixture using a heat-cool-heat method. Important events are 
labelled A to G. 
Table 4.2 Endothermic and exothermic events with the corresponding 
onset and peak temperatures and the integrated energies. 
Event Onset temperature  (°C) Peak temperature (°C) Energy (J/g) 
A 106.6 108.3 0.78 
B 124.4 125.6 64.12 
C 157.8 159.4 76.48 
D 24.6 27.7 1.00 
E 49.6 50.0 2.24 
F 85.3 94.7 41.68 
G 154.9 158.0 79.37 
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The bright field and polarised microscopy images taken at specific 
temperatures are displayed in figures 4.9 and 4.10 to provide visual evidence 
of the changes the material underwent. 
 
 
Figure 4.9 Bright field light microscopy images of 1:1 carbamazepine – 
nicotinamide physical mixture using a heat-cool-heat method. 
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Figure 4.10 Polarised light microscopy images of 1:1 carbamazepine – 
nicotinamide physical mixture using a heat-cool-heat method. 
The microscope images confirm the changes the sample underwent during 
the employed thermal program. Firstly, the powder was heated through event 
A where a crystal form appeared. At event B the nicotinamide crystals melted 
and subsequent cocrystallisation occurred. Event C marks the melting of the 
remaining carbamazepine and co-crystal immediately after. It is unclear from 
the images what takes place at event D because no solid phase was 
observed before or after, the event may be caused by short range order 
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within the amorphous phase relaxing and molecules moving further apart 
upon heating.  
During the isothermal period where event E is situated, three separate 
crystal seeds form. This crystal form then proceeds to grow as the 
temperature is increased. At event F, another crystal form is observed within 
the initial crystal, and eventually takes over the initial crystal to become the 
thermodynamically preferred crystal form at temperatures above 94.7°C. The 
melting point of this crystal form, event G, has a similar melting temperature 
to the 1:1 co-crystal. 
The results from this study directly match those conducted by Seefelt et al. 
(2007). They observed a birefringent crystal forming from the amorphous 
phase which is then transformed into another crystal form. The researchers 
provided evidence from several characterization techniques which confirmed 
the first crystal form is an intermediate co-crystal form which they referred to 
as CBZ-NCT (Form II). They concluded that a relatively slow heating rate 
increases the chance of forming the intermediate co-crystal phase compared 
to forming the individual components. 
4.44 Shear cell investigation 
The shear cell (Linkam Scientific) was another technology which was utilised 
in this study. It provided the combined capability of applying rotational shear 
and hot stage microscopy. Three different co-crystal pairs were chosen for 
the study; ibuprofen – nicotinamide, nicotinamide – salicylic acid and caffeine 
– maleic acid. The main reason these co-crystal pairs were chosen was to 
link up with synchrotron studies that were planned by our research team. The 
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data gathered from the ibuprofen – nicotinamide study was beneficial for 
other sections and chapters in this project. Characterisation of the samples 
was performed using PXRD and light microscopy images were collected at 
various stages during each run. 
4.441 Ibuprofen – nicotinamide 
For the ibuprofen – nicotinamide pair, a gap size of 50 µm and rotary velocity 
of 5 rad/s were used. For both runs that were carried out, the 1:1 physical 
mixture was heated from RT to 85/90°C at 5°C/min. It was held at 85/90°C 
for 10 minutes before shear was applied to ensure the material had reached 
the desired temperature. The shear was applied in 1 minute long bursts for a 
total of 8 minutes of shear. The sample was then cooled to RT at 5°C/min. 
The PXRD spectra of the samples are shown in figure 4.11 along with the 
1:1 physical mixture and co-crystal spectra for the ibuprofen – nicotinamide 
pair. 
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Figure 4.11 PXRD spectra of 1:1 ibuprofen – nicotinamide physical 
mixture (PM) and the samples for Tmax 85°C (Run 1) and Tmax 90°C (Run 
2). 
The study by Kelly et al. (Kelly et al. 2012) was used as a guide for 
identifying the 1:1 co-crystal peaks. The sample for run 1 which reached 
85°C produced a 1:1 co-crystal spectrum, showing the standard co-crystal 
peaks at 3.1°, 9.3° and 12.45° (2θ). The sample for run 2 which reached 
90°C had the 1:1 co-crystal peak at 3.1° (2θ), however the other 1:1 co-
crystal peaks were largely missing, suggesting that some of the powder had 
potentially become amorphous when subjected to the higher temperature. 
Light microscopy images were collected throughout the two runs and are 
showing in figures A.1 and A.2 in appendix A. It was difficult to determine 
exactly when co-crystal formation initiated for run 1, however the images 
suggest a large proportion of the final co-crystal crystallised upon cooling, 
after the shear had been applied. The sample for run 2 exhibited significant 
melting when the temperature reached 85°C and above, with a small number 
of co-crystals visible before shear was applied. After shearing and then 
cooling, the images for the sample for run 2 indicated that an amorphous 
phase had formed, again with some short co-crystal needles visible. 
4.442 Nicotinamide – salicylic acid  
For the nicotinamide – salicylic acid pair, a gap size of 50 µm and rotary 
velocity of 5 rad/s were used. For the experiments that were carried out, the 
1:1 physical mixture was heated from RT to 115/120°C at 5°C/min. It was 
held at 115/120°C for 10 minutes before shear was applied to ensure the 
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material had reached the desired temperature. The shear was applied in 1 
minute long bursts for a total of 8 minutes of shear. The sample was then 
cooled to RT at 5°C/min. A third experiment was also conducted using the 
same conditions as the second run, but instead, a faster rotary velocity of 10 
rad/s was used. 
The PXRD spectra of the samples and their physical mixture are shown 
below in figure 4.12. 
 
Figure 4.12 PXRD spectra of 1:1 nicotinamide – salicylic acid physical 
mixture (PM) and the samples for Tmax 115°C (Run 1), Tmax 120°C (Run 2) 
and Tmax 120°C 10 rad/sec (Run 3). 
The reported PXRD peaks for 1:1 nicotinamide – salicylic acid are 7.4°, 8.4° 
and 9.4° (2θ) (Berry et al. 2008). These peaks are present for all three runs 
completed for this co-crystal pair using the shear cell. Although the co-crystal 
was present in all samples, there was also some remaining salicylic acid. It 
was difficult to determine the co-crystal purity because the spectra for all 
runs exhibited relatively small diffraction peaks. The salicylic acid peak at 
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10.8° (2θ) was present for all samples. There were very few differences 
between the spectra for run 2 and 3, however the peaks at approximately 
17.3° (2θ) was much more prominent in the spectra for the sample of run 3. 
This peak is also associated with salicylic acid. This may suggest that a 
faster rotational velocity does not necessarily increase the extent of mixing of 
the material, or indeed promote further cocrystallisation. 
Light microscopy images were collected for the samples for all three runs 
and are shown in figures A.3, A.4 and A.5 in appendix A. The sample for run 
1 exhibited co-crystal formation upon the application of shear and after 8 
minutes of applied shear, a significant amount of co-crystals could be 
viewed. There were issues with the images that were collected after any 
amount of shear had been applied for runs 2 and 3 because the resulting 
material was opaque. This may have been caused by the agglomeration of 
cocrystallised particles at the higher temperature of 120°C when shear was 
applied. The images collected during the isothermal period at 120°C for runs 
2 and 3 indicated the formation of some co-crystals had begun during this 
stage. This was interesting because 120°C is well below the melting points 
for salicylic acid (159.83°C) (Elbagerma et al. 2010) and nicotinamide 
(132.1°C). 
4.443 Caffeine – maleic acid   
For the caffeine – maleic acid pair, a gap size of 50 µm and rotary velocity of 
5 rad/s were used. For the experiments that were carried out, the 1:1 
physical mixture was heated from RT to 90/100/110°C at 5°C/min. It was 
held at 90/100/110°C for 10 minutes before shear was applied to ensure the 
material had reached the desired temperature. The shear was applied in 1 
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minute long bursts for a total of 8 minutes of shear. The sample was then 
cooled to RT at 5°C/min. For some of the runs, the shear direction was 
alternated for each 1 minute burst of shear. Additionally, for run 5, the 2:1 
physical mixture was used. The PXRD spectra of the samples and their 
physical mixture are shown below in figure 4.13. 
 
Figure 4.13 PXRD spectra of 1:1 caffeine – maleic acid physical mixture 
(PM) and the samples for Tmax 90°C (Run 1), Tmax 100°C (Run 2) Tmax 
100°C with alternating shear direction (Run 3), Tmax 110°C (Run 4) and 
2:1 PM initial material Tmax 100°C (Run 5). 
The study by Guo et al. (Guo et al. 2009) was used as a guide for identifying 
1:1 and 2:1 co-crystal peaks. The PXRD spectra for run 1 indicated that the 
sample was still mostly 1:1 physical mixture, showing a large caffeine peak 
at approximately 12° (2θ), however, low intensity 1:1 co-crystal peaks were 
observed at 13.3°, 14.1° and 15.2° (2θ) also. The spectrum for run 2 
exhibited 2:1 co-crystal peaks at 8.9° 10.2° 13.5° and 15.9° (2θ) along with a 
reduced caffeine peak at 12° (2θ) compared to run 1. The spectrum for run 3 
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indicates that a high yield of 2:1 co-crystal was obtained, displaying the main 
2:1 co-crystal peaks as previously discussed, and an absence of the 12° (2θ) 
caffeine peak. 
The spectrum for run 4 exhibited 1:1 co-crystal peaks at 11.2°, 13.3°, 14.1° 
and 15.2° (2θ), and 2:1 co-crystal peak at 10.2° (2θ). The spectrum for run 5 
displays 2:1 co-crystal peaks 8.9° 10.2° 13.5° and 15.9° (2θ). Both samples 
for runs 4 and 5 have residual caffeine, indicated by the peak at 12° (2θ). 
The PXRD findings suggest the alternating shear direction method promotes 
more sufficient mixing and is able to increase the purity of the 2:1 co-crystal 
form at 100°C compared to the single shear direction method. Additionally, 
the presence of 1:1 co-crystal in the sample for run 4 was surprising 
considering the melting point of the 1:1 co-crystal is approximately 104°C 
(Guo et al. 2009). Run 5, which used the same conditions as run 2, albeit 
starting with a 2:1 physical mixture, yielded a similar material composition to 
run 2. 
The light microscopy images are shown in figures A.6 to A.10 in appendix A. 
The images show that needle shaped crystals formed typically after 2 
minutes of shear had been applied for all shear cell runs apart from run 1, 
where it was clear that the bulk material had not undergone any 
transformations and exhibited a similar morphology to the starting material. 
The sample for run 3 had a more uniform co-crystal morphology and size 
compared to the sample for run 2. This strengthens the case that the 
alternating shear direction promotes good quality mixing. Finally, the sample 
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for run 4 experienced significantly more melting than the other runs, however 
this was expected at the higher temperature used. 
4.45 Ibuprofen – nicotinamide rheometry investigation  
Model shear deformation studies were carried out for the ibuprofen 
nicotinamide system to show the effect of shear and temperature on 1:1 co-
crystal formation. All samples, that were processed using an Anton Paar 
rheometer, were heated and cooled at a rate of 20°C/min and held at the 
maximum temperature for 10 minutes to mimic the time the material would 
spend, on average, inside the extruder barrel during extrusion. Different 
strain limits were applied during the heating, hold and cooling of the sample 
and the direction of shear was set to oscillation mode. The shear cell study in 
the previous section concluded that the oscillating mode provided improved 
mixing of the material. The oscillation mode was programmed to reverse the 
direction once a pre-set strain value had been reached. The oscillatory mode 
was also chosen over the continuous direction mode in an attempt to keep 
as much of the material in contact with the upper and lower rheometer plates 
as possible during the applied shear. Both the upper and lower plates were 
standard parallel plates and unless otherwise specified, the downwards force 
applied to the material was programmed to stay at 1 N throughout the 
duration of the experiments. 
Figure 4.14 shows PXRD spectra of the 1:1 physical mixture heated and held 
at 70°C for 10 minutes before being cooled to room temperature. No shear 
was applied to one of the samples and the others had shear applied with the 
strain set to 25%, 50%, 75% and 100%. The resulting PXRD spectra 
indicated that at 70°C and no shear, there are new peaks formed at 14.9°, 
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16.7°, 17.2° and 24.2° (2θ). These new peaks are associated with the 1:1 co-
crystal. When the strain is increased from 25% to 100%, the intensity of the 
ibuprofen peak at 6° (2θ) decreases and the new peaks at 14.9°, 16.7°, 17.2° 
and 24.2° (2θ) experience no significant changes in intensity. The 1:1 co-
crystal peak situated at 3.1° (2θ) appears at 75% and 100% strain. 
 
Figure 4.14 PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
no shear, 25% strain, 50% strain, 75% strain and 100% strain and held 
at 70°C for 10 minutes with a heating and cooling rate of 20°C/min. The 
1:1 physical mixture spectrum is also shown (PM). 
Figure 4.15 shows PXRD spectra of the 1:1 physical mixture heated and held 
at 80°C for 10 minutes before being cooled to room temperature. No shear 
was applied to one of the samples and the others had applied strain of 25%, 
50%, 75% and 100%. The spectra indicated that at 80°C and no shear, the 
1:1 co-crystal peaks are present at 14.9°, 16.7°, 17.2° and 24.2° (2θ). The 
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1:1 co-crystal peak situated at 3.1° (2θ) had a relatively high intensity for the 
50% strain sample. The ibuprofen peak at 6° (2θ) suggested that there was 
residual ibuprofen present in the majority of the samples, including the 
sample at 50% strain. 
 
Figure 4.15 PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
no shear, 25% strain, 50% strain, 75% strain and 100% strain and held 
at 80°C for 10 minutes with a heating and cooling rate of 20°C/min. The 
1:1 physical mixture spectrum is also shown. 
Figure 4.16 shows PXRD spectra of the 1:1 physical mixture heated and held 
at 90°C for 10 minutes before being cooled to room temperature. No shear 
was applied to one of the samples and the others had applied strain of 25%, 
50%, 75% and 100%. The spectra indicated that 1:1 co-crystal had formed in 
all the samples. The 1:1 co-crystal peak situated at 3.1° (2θ) appeared at all 
levels of strain and it had the highest intensity for the 50% strain sample. The 
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ibuprofen peak at 6° (2θ) was not observed in any samples, however the 
nicotinamide peak at 14.7° (2θ) can be observed in the majority of the 
samples suggesting there was some residual nicotinamide. 
 
Figure 4.16 PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
no shear, 25% strain, 50% strain, 75% strain and 100% strain and held 
at 90°C for 10 minutes with a heating and cooling rate of 20°C/min. The 
1:1 physical mixture spectrum is also shown. 
The samples from figures 4.14 to 4.16 above were subjected to DSC 
analysis. The DSC data is shown in figures 4.17 and 4.18. Thermal analysis 
of the samples provided another characterisation approach. All samples 
were heated to 175°C with a standard heating rate of 10°C/min. Figure 4.17 
shows the DSC thermograms of the samples which experienced no shear 
and shear with 25% and 50% strain limits. Figure 4.18 shows the DSC 
95 
 
thermograms of the samples which experienced shear with 75% and 100% 
strain limits. 
The 90°C samples exhibited the largest co-crystal melting peaks situated at 
approximately 91.1°C compared to samples processed at lower 
temperatures. This may suggest that 90°C was the optimal temperature for 
1:1 co-crystal formation during the model shear deformation experiments, 
even when no shear was applied. However, for this particular pharmaceutical 
pair, the 1:1 co-crystal is known to form from the 1:1 physical mixture during 
a 10°C/min DSC ramp from RT to 200°C. Therefore it is difficult to determine 
the effect any remaining unreacted ibuprofen or nicotinamide will have on the 
DSC thermograms, in figures 4.17 and 4.18, because some additional co-
crystals could form during the DSC heating. The DSC results show no 
obvious correlation between the amount of applied strain and the yield of the 
1:1 co-crystal. 
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Figure 4.17 DSC thermograms of the model shear deformation samples. 
Temperatures: 70, 80 and 90°C. Strain: 0, 25 and 50%. 
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Figure 4.18 DSC thermograms of the model shear deformation samples. 
Temperatures: 70, 80 and 90°C. Strain: 75 and 100%. 
During the application of shear with varying strain limits, contact between the 
material and the upper and lower rheometer plates was an important factor. 
Little or no contact can lead to significantly lower levels of shear force that 
the material experiences during the model rheology method. An additional 
experiment was carried out where a force of 5 N was applied directly onto 
each sample during heating, holding and cooling. Each sample was heated 
to 70°C, 80°C and 90°C with a 25% strain limit for the oscillating shear 
98 
 
mode. The PXRD spectra for these samples are shown in figure 4.19. Both 
the 1:1 co-crystal peak at 3.1° (2θ) and the ibuprofen peak at 6° (2θ) were 
present in the 70°C and 80°C samples, however, the 90°C sample spectrum 
did not show these two peaks. The presence of peaks at 9.3°, 12.4° and 
14.7° (2θ) indicated the 90°C sample was a mixture of 1:1 co-crystal and 
nicotinamide. During this experiment, the rheometer was unable to apply a 
downward force of 5 N onto the sample at all times, particularly when the 
material had experienced melting. 
 
Figure 4.19 PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
25% strain and held at 70°C, 80°C and 90°C for 10 minutes with a 
heating and cooling rate of 20°C/min and an applied force of 5 N. 
In an attempt to increase the 1:1 co-crystal yield, the strain limit was 
increased to 200% to potentially increase the chance of the carbamazepine 
and nicotinamide molecules coming into contact with one another. The 
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samples were run at 70, 75, 80, 85 and 90°C with a force of 1 N applied 
throughout each experiment. Figure 4.20 shows the PXRD spectra for these 
samples. All the samples shown in figure 4.20 exhibited the 3.1° (2θ) peak, 
even at the lowest temperature of 70°C. The 80°C sample produced the 
highest intensity 1:1 co-crystal peak at 3.1° (2θ) compared to the other 
samples. The increased yield of the 1:1 co-crystal may have been caused by 
the larger strain limit providing more efficient mixing. The samples run at 
85°C and 90°C exhibited a small 3.1° (2θ) peak compared to the sample at 
80°C, this may have been caused by a loss of contact between the material 
and the rheometer plates as it melted, therefore leading to reduced mixing 
and shear force experienced by the samples. 
 
Figure 4.20 PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
200% strain and held at 70°C, 75°C, 80°C, 85°C and 90°C for 10 minutes 
with a heating and cooling rate of 20°C/min and an applied force of 1 N. 
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An additional experiment was conducted using a 300% strain limit and the 
PXRD spectra are shown in figure 4.21. It is unclear whether increasing the 
strain from 200% to 300% caused the 1:1 co-crystal yield to increase. 
However, the 80°C sample had an increased intensity 3.1° (2θ) peak 
compared to the other samples which was a similar result compared to the 
200% strain limit experiment.
 
Figure 4.21 PXRD spectra of IBU-NIC 1:1 physical mixture subjected to 
300% strain and held at 70°C, 75°C, 80°C, 85°C and 90°C for 10 minutes 
with a heating and cooling rate of 20°C/min and an applied force of 1 N. 
The conclusion from the ibuprofen – nicotinamide model shear deformation 
study is that shear does have a role in the 1:1 co-crystal formation at 70°C, 
80°C and 90°C. However, temperature is the most important factor for 
cocrystallisation of the ibuprofen – nicotinamide pair. 
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4.5 Conclusion 
This chapter set out to explore the behaviour of pharmaceutical co-crystals 
under different conditions using a wide array of techniques to probe and 
characterise the materials. The results show that temperature and shear play 
different roles in co-crystal formation and in some techniques; the shear 
force provided a form of mixing to facilitate further cocrystallisation. 
The model shear experiments that were carried out provided a unique insight 
into the behaviour of co-crystal pairs subjected to different quantities of shear 
force at high temperatures. The shear cell microscope stage is a promising 
technology that can be used to apply defined amounts of shear force to a 
small amount of material whilst accurately controlling the temperature. The 
shear cell provided an enclosed space for the material that was being 
analysed; this was not the case for the larger scale rheometer where some 
material could potentially spill over the side of the parallel plates.  
Light microscopy was an important characterisation tool, particularly when 
combined with temperature control capabilities. It provided a key insight into 
changes and events that occurred to the material during a range of different 
experiments with a selection of pharmaceutical pairs which are able to form 
stable co-crystals. Key information was gathered about different crystal forms 
of the pharmaceutical materials and cocrystallisation was able to be 
observed in situ in real time. 
The thermal behaviour of the physical mixtures of the pharmaceutical pairs in 
chapter 4 was found to be in conjunction with relevant studies in the 
literature. The data gathered in this chapter was directly used for designing 
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the extrusion experiments in chapter 5 and also provided important 
knowledge, particularly for the carbamazepine – nicotinamide pair. 
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CHAPTER 5 HOT MELT EXTRUSION OF CO-
CRYSTAL PAIRS 
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Hot melt extrusion of two co-crystal pairs was investigated in this chapter. 
The ibuprofen – nicotinamide pair was chosen initially because it is a 
relatively well-understood co-crystal and it has already been proven to 
cocrystallise during hot melt extrusion (Dhumal et al. 2010). The 
carbamazepine – nicotinamide pair was also investigated. Carbamazepine – 
nicotinamide had not been successfully produced by hot melt extrusion so it 
was selected to be investigated using this method. 
A thorough analysis of the extruded samples was carried out in this chapter. 
This included using X-ray diffraction, differential scanning calorimetry, near 
infrared spectroscopy and scanning electron microscopy techniques. XRD, 
DSC and NIR all gave insight into the purity and composition of the extruded 
samples. SEM provided crucial morphological information and was also used 
to estimate the size of some extruded particles. 
5.1 Ibuprofen – nicotinamide 
5.11 Extrusion study 
The purity of the individual components was determined using powder X-ray 
diffraction. The diffraction spectra for ibuprofen, nicotinamide, IBU-NIC 1:1 
physical mixture and IBU-NIC 1:1 co-crystal are shown in figure 5.1. The key, 
standalone ibuprofen peak is situated at 6° (2θ). This can be used to 
determine whether ibuprofen is present in a sample. Similarly, the peak at 
14.7° (2θ) is a distinguishable peak associated with nicotinamide. The co-
crystal exhibits a major peak at 3.1° (2θ) and has two more peaks situated at 
9.3° and 12.4° (2θ) which can be used to help identify co-crystal present in 
experimental samples. 
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Figure 5.1 PXRD spectra of A. ibuprofen, B. nicotinamide, C. IBU-NIC 
1:1 physical mixture and D. IBU-NIC 1:1 co-crystal (Microwave method 
section 3.2). 
Extrusion was carried out using the ibuprofen – nicotinamide system to 
evaluate if this process can be used for manufacturing the co-crystal. 
Thermal information about the pair was critical for optimising the temperature 
of extrusion and for selecting the temperature profiles that were used. 
Differential scanning calorimetry provided this information and the 
thermograms for ibuprofen, nicotinamide, IBU-NIC 1:1 physical mixture and 
IBU-NIC 1:1 co-crystal are shown in figure 5.2. The melting temperatures of 
ibuprofen and nicotinamide were found to be 78.0°C and 132.1°C 
respectively. The physical mixture eutectic melting point of the pair was 
72.8°C and the co-crystal melting point was 91.1°C. 
The thermal data that was gathered from the DSC results was used to 
decide what temperature profiles were chosen for the HME of ibuprofen – 
nicotinamide. It is thought that cocrystallisation can occur from the melt 
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phase of the physical mixture. The physical mixture for ibuprofen – 
nicotinamide has a eutectic melting point of 72.8°C. So the temperature 
profiles were based around this temperature and were increased until pure 
co-crystal was obtained. 
 
Figure 5.2 DSC thermograms of A. ibuprofen, B. nicotinamide, C. IBU-
NIC 1:1 physical mixture and D. IBU-NIC 1:1 co-crystal (Microwave 
method section 3.2) heated at 10°C/min from 40°C to 220°C. 
Extrusion was carried out by feeding a pre-mixed 1:1 physical mixture of 
ibuprofen and nicotinamide into the first zone of the extruder barrel. The 
temperature codes of T80 and T90 are the temperature profiles that were 
used and which are described in section 3.81. The maximum temperatures 
achieved along the extruder barrel were 80°C for T80 and 90°C for T90. The 
high shear screw geometry, SGB (Described in section 3.82), was used to 
provide sufficient mixing and shear which is thought to aid cocrystallisation. 
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Two screw speeds were selected; 20 rpm and 30 rpm. The 20 rpm screw 
speed provided a longer residence time and caused the material in the 
extruder barrel to experience a longer period of thermal exposure whereas 
the 30 rpm screw speed provided higher shear forces experienced by the 
material. The extrudates were collected and PXRD spectra of the samples 
were obtained for investigation purposes. The spectra are shown in figure 
5.3 and are stacked to help identify subtle differences. The IBU-NIC 1:1 
physical mixture and IBU-NIC 1:1 co-crystal spectra were included to display 
the peaks of interest. 
 
Figure 5.3 PXRD spectra of A. IBU-NIC 1:1 physical mixture, B. 
extrudate T80 30 rpm, C. extrudate T80 20 rpm, D. extrudate T90 30 rpm, 
E. extrudate T90 20 rpm, F. IBU-NIC 1:1 co-crystal (Microwave method 
section 3.2). 
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The 20 rpm extrudates both exhibited the co-crystal peak situated at 3.1° 
(2θ), indicating significant cocrystallisation had occurred when using this 
screw speed. The ibuprofen peak at 6° (2θ) is present in both samples 
processed using the T80 temperature profile but is absent in the T90 
samples. This would suggest that temperature also played a key role in 
cocrystallisation and ensuring the remaining ibuprofen is able to form the co-
crystal. The T90 20 rpm extrudates exhibited all 3 previously mentioned co-
crystal peaks at 3.1°, 9.3° and 12.45° (2θ), however it also had the 
nicotinamide peak situated at 14.7° (2θ) suggesting there was still some 
remaining nicotinamide. 
Extrusion carried out at temperatures higher than 90°C ended in degradation 
of the powder which formed a light green colour. However, this degradation 
was not investigated further. 
5.12 Seeding study 
Seeding of IBU-NIC 1:1 co-crystal was done to determine if it was possible to 
extrude the co-crystal using a low shear screw geometry (SGA) described in 
section 3.82. The other conditions for extrusion were T90 temperature profile 
and a 20 rpm screw speed. The pure 1:1 co-crystal seed was pre-mixed into 
the physical mixture before being fed into the extruder barrel. The total co-
crystal seed added was 15% w/w. The extruded samples were characterised 
using NIR spectroscopy. The normal spectra for ibuprofen, nicotinamide, 1:1 
physical mixture, 1:1 co-crystal and the extruded batch (Original and ground 
powder) are shown in figure 5.4. 
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Figure 5.4 NIR spectra of ibuprofen, nicotinamide, 1:1 IBU-NIC physical 
mixture, 1:1 IBU-NIC co-crystal (Microwave method section 3.2), 
extrudate T90 20 rpm 15% seed, extrudate T90 20 rpm 15% seed, 
ground powder. All the spectra shown have been treated with SNV 
baseline correction. 
Each region of the spectra in figure 5.4 was examined. Firstly, the spectra 
showed that the extruded samples were very similar to the pure co-crystal, 
exhibiting stand-alone co-crystal bands at approximately 4466, 4794, 6445 
6688 and 8451 cm-1 (Black arrows in figure 5.4). There was no observed 
band shifting between the extruded sample and the ground powder version. 
The ibuprofen band at 6426 cm-1 was present in the extruded samples 
spectra, which suggests there was some residual ibuprofen however this 
was the only point where the extruded sample spectra deviated from the 
pure co-crystal spectra. The second derivative spectra were calculated to 
see if there were any other subtle differences between the extruded sample 
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and the pure co-crystal. The spectra are shown as 3 separate regions in 
figure 5.5. 
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Figure 5.5 Second derivative NIR spectra of ibuprofen, nicotinamide, 
IBU-NIC 1:1 physical mixture, IBU-NIC 1:1 co-crystal (Microwave 
method section 3.2), extrudate T90 20 rpm 15% seed, extrudate T90 20 
rpm 15% seed, ground powder. All the spectra shown have been 
treated with SNV baseline correction and Norris smoothing. 
The second derivative spectra improved the resolution of the overlapping 
bands which provided an insight into whether the extruded samples were 
pure co-crystal as it was able to find small differences in the spectral data. 
When observing the second derivative spectra, there was no discernible 
difference between the original extruded sample and the ground powder 
sample. There are many examples throughout the second derivative NIR 
spectrum (4000-10000 cm-1) where the extruded samples had bands which 
aligned with those for the pure co-crystal. However there were a number of 
extruded sample bands which had experienced a pull towards the ibuprofen 
spectra. This would suggest that there was a residual amount of ibuprofen in 
the extruded samples. The presence of ibuprofen in the extruded samples 
may have been caused by some of the initial (Within the first 10 minutes of 
extrusion) ibuprofen coating the extruder barrel, which then may have 
dislodged from the barrel during the extrusion process.  
In conclusion, the 1:1 ibuprofen – nicotinamide co-crystal was successfully 
manufactured by hot melt extrusion. The screw speed was an important 
factor for co-crystal purity as well as the temperature profile that was used. 
Interestingly, the highest co-crystal yield was achieved using the temperature 
profile which provided a maximum temperature which was closest to the 
melting point of the 1:1 co-crystal. NIR analysis of 1:1 co-crystal seeded 
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extruded samples suggested that a high co-crystal purity could be achieved 
when using the low shear screw geometry A. 
5.2 Carbamazepine – nicotinamide  
A large proportion of the HME investigation was carried out using 
carbamazepine and nicotinamide with the general objective of producing 1:1 
co-crystals. This section includes the initial study, the extruder barrel zone 
analysis, NIR characterisation and SEM particle analysis. 
5.21 Extruder Study 
The purity of the individual components was determined using powder X-ray 
diffraction. The diffraction spectra for carbamazepine, nicotinamide, CBZ-NIC 
1:1 physical mixture and CBZ-NIC 1:1 co-crystal are shown in figure 5.6. The 
more prominent carbamazepine peaks are situated at approximately 12.8°, 
14.9° and 15.7° (2θ). They can indicate whether any carbamazepine is 
present in a sample. Nicotinamide has a peak at 14.7° (2θ) which is useful 
for identifying nicotinamide in a sample. The co-crystal exhibits three major 
peaks at 6.6°, 8.8° and 10.2° (2θ) which can be used to reveal if any co-
crystal is present in samples. 
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Figure 5.6 PXRD spectra of A. carbamazepine (Form III), B. 
nicotinamide, C. CBZ-NIC 1:1 physical mixture and D. CBZ-NIC 1:1 co-
crystal (Solvent evaporation method section 3.3). 
Thermal information about the carbamazepine – nicotinamide pair was 
important for optimising the temperature of extrusion and for selecting the 
temperature profiles that were used. Differential scanning calorimetry 
provided this information and the thermograms for carbamazepine, 
nicotinamide, CBZ-NIC 1:1 physical mixture and CBZ-NIC 1:1 co-crystal are 
shown in figure 5.7. The melting temperatures of carbamazepine and 
nicotinamide were found to be 175.0°C and 132.1°C respectively. The 
physical mixture eutectic melting point of the pair was 125.8°C and the co-
crystal melting point was 162.4°C. 
The thermal data that was gathered from the DSC results was used to 
decide what temperature profiles were chosen for the HME of 
carbamazepine – nicotinamide. It is thought that cocrystallisation can occur 
from the melt phase of the physical mixture. The physical mixture for 
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carbamazepine – nicotinamide has a eutectic melting point of 125.8°C. The 
temperature profiles for extrusion were based around this eutectic melting 
point, temperature and other parameters were investigated to increase the 
co-crystal purity. 
 
Figure 5.7 DSC thermograms of A. carbamazepine (Form III), B. 
nicotinamide, C. CBZ-NIC 1:1 physical mixture and D. CBZ-NIC 1:1 co-
crystal (Solvent evaporation method section 3.3) heated at 10°C/min 
from 40°C to 220°C. 
Extrusion was carried out by feeding a pre-mixed 1:1 physical mixture of 
carbamazepine and nicotinamide into the first zone of the extruder barrel. 
More details of the set-up are found in section 3.8. The temperature codes, 
such as T140, indicate the temperature profiles that were used and each 
code is described in section 3.81. The code indicates the maximum 
temperature achieved along the extruder barrel, so for T140 the maximum 
temperature was 140°C. Two screw geometries were explored, SGA and 
SGB (Described in section 3.82). The screw geometries directly influence the 
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degree of mixing and shear which are thought to aid the cocrystallisation 
process. Two screw speeds were selected; 20 rpm and 30 rpm. The 20 rpm 
screw speed provided a longer residence time and caused the material in the 
extruder barrel to experience a longer period of thermal exposure whereas 
the 30 rpm screw speed provided higher shear forces experienced by the 
material. 
The first set of extrusion runs were carried out using SGA and a 20 rpm 
screw speed. The temperature was increased from T125 to T140 with 5°C 
intervals in between. The extrudates were collected and PXRD spectra of the 
samples were obtained for investigation purposes. The spectra are shown in 
figure 5.8 and are stacked to help identify subtle differences. The CBZ-NIC 
1:1 physical mixture and CBZ-NIC 1:1 co-crystal spectra were included to 
display the peaks of interest. 
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Figure 5.8 PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. 
extrudate T125 20 rpm, C. extrudate T130 20 rpm, D. extrudate T135 20 
rpm, E. extrudate T140 20 rpm, F. CBZ-NIC 1:1 co-crystal (Solvent 
evaporation method section 3.3). 
The  extrudates PXRD spectra, shown in figure 5.8, all exhibited the first 
three co-crystal peaks situated at 12.8°, 14.9° and 15.7° (2θ), indicating 
cocrystallisation had occurred when using this screw speed. The 
carbamazepine peak at 12.8° (2θ) is present in all extruded samples, 
suggesting there was some pure carbamazepine remaining after extrusion. 
There were very subtle differences between the spectra for the extruded 
samples with no significant indications that an increase in temperature has 
an impact on the co-crystal purity when using 20 rpm screw speed and SGA. 
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The second set of extrusion runs were carried out using SGB and a screw 
speed of 20 rpm. The number of different temperature profiles was increased 
to accommodate the lower temperatures of T110 and T120. The extrudates 
were collected and PXRD spectra of the samples were obtained and are 
shown in figure 5.9 and are stacked to help identify subtle differences. The 
CBZ-NIC 1:1 physical mixture and CBZ-NIC 1:1 co-crystal spectra were 
included to display the peaks of interest. 
 
Figure 5.9 PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. 
extrudate T110 20 rpm, C. extrudate T120 20 rpm, D. extrudate T125 20 
rpm, E. extrudate T130 20 rpm, F. extrudate T135 20 rpm, G. extrudate 
T140 20 rpm, H. CBZ-NIC 1:1 co-crystal (Solvent evaporation method 
section 3.3). 
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The  extrudates PXRD spectra, shown in figure 5.9, all exhibited the first 
three co-crystal peaks situated at 12.8°, 14.9° and 15.7° (2θ), these peaks 
appear more prominent compared to the extrudates in figure 5.8, particularly 
for the extruded samples at T130, T135 and T140. The carbamazepine peak 
at 12.8° (2θ) was present in all extruded samples, suggesting there was 
some pure carbamazepine remaining after extrusion. The increase in 
temperature did have a small impact on the co-crystal yield, particularly from 
T110 through to T130. 
Two additional extrusion runs were carried out using the 10 rpm screw speed 
at T135 and T140 using SGB. The objective was to reduce the screw speed 
and increase the residence time of the material in the extruder barrel to 
increase the co-crystal yield. The resulting extruded samples were subjected 
to PXRD and are shown in figure 5.10 along with the corresponding samples 
extruded at 20 rpm, the physical mixture and the pure co-crystal. 
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Figure 5.10 PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. 
extrudate T135 20 rpm, C. extrudate T140 20 rpm, D. extrudate T135 10 
rpm, E. extrudate T140 10 rpm, F. CBZ-NIC 1:1 co-crystal (Solvent 
evaporation method section 3.3). 
The PXRD spectra in figure 5.10 showcase the 20 rpm extrudates (B and C) 
and the 10 rpm extrudates (D and E). The carbamazepine peak at 12.8° (2θ) 
had a reduced intensity for the 10 rpm spectra compared to the 20 rpm 
spectra. This indicated that the increased residence time allowed for more of 
the remaining carbamazepine to form the co-crystal. From observing the 
PXRD spectra, the T135 10 rpm SGB extrudate sample had the least 
amount of remaining carbamazepine and nicotinamide. 
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In conclusion, the hot melt extrusion technique was able to successfully 
produce the 1:1 co-crystal of carbamazepine and nicotinamide. With often 
small differences between the PXRD spectra when comparing the extruded 
samples it was difficult to determine the true purity. Both screw geometries 
(SGA and SGB) were able to provide enough shear and mixing for 
cocrystallisation to occur and the co-crystal yield increased when the 
temperature was increased from T110 to T130. Samples extruded at higher 
temperatures between T130 and T140 had very small differences in the 
PXRD spectra when compared with one another. 
The increased residence time that the 10 rpm screw speed provided, 
enabled further cocrystallisation to take place, which in turn reduced the 
amount of residual carbamazepine and nicotinamide in the extruded 
samples. It was observed that under the conditions of T135 10 rpm SGB, the 
extruded sample had a relatively good co-crystal yield with very low amounts 
of residual carbamazepine and nicotinamide. This temperature profile 
reached the maximum temperature of 135°C along the extruder barrel, this 
was approximately 10°C above the eutectic melting point of the 1:1 physical 
mixture of carbamazepine and nicotinamide. 
5.22 Extruder barrel zone investigation 
To further understand cocrystallisation via hot melt extrusion, it was 
necessary to explore where along the extruder barrel cocrystallisation was 
occurring. The extruder barrel zone investigation was carried out for the 
carbamazepine – nicotinamide pair. A series of extrusion runs, carried out at 
different temperatures and screw speeds, were selected according to the 
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results from section 5.21. Each extrusion run was allowed to mature for 10 
minutes before the extruder was switched off. This was done to ensure that 
the extruder barrel was as full as possible with the pre-mixed carbamazepine 
– nicotinamide physical mixture and to make sure the process had reached 
full maturity regarding cocrystallisation. Samples were immediately collected 
from along the barrel and PXRD analysis was carried out. It is important to 
note that zone 1 of the extruder barrel is behind where the pre-mixed 
physical mixture is fed into the extruder, therefore there was no point of 
collecting the zone 1 sample as it is irrelevant to the extrusion process. 
Initially, a test extrusion run was carried out to determine if it was possible to 
collect the samples from the extruder barrel. It was difficult to locate exactly 
where each zone began and finished along the extruder barrel when the 
barrel was full of material, this test run also highlighted concerns about 
handling the material next to a high temperature extruder barrel. Due to an 
issue with locating the barrel zones between zone 2 and zone 6, the samples 
from these zones were discarded. Figure 5.11 shows the PXRD spectra from 
this test run which was carried out under the conditions of temperature profile 
T130, screw geometry B and 20 rpm screw speed. 
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Figure 5.11 PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. zone 2 
sample, C. zone 6 sample, D. zone 7 sample, E. zone 8 sample, F. zone 
9 sample, G. extrudate sample, H. CBZ-NIC 1:1 co-crystal (Solvent 
evaporation method section 3.3). 
The PXRD spectra in figure 5.11 indicated that cocrystallisation had occurred 
by at least zone 6 of the extruder barrel. There was remaining 
carbamazepine in the samples from zones 2, 6 and 7 and also in the 
extruded sample. The temperature of the extruder barrel at zone 6 was set to 
125°C. The eutectic point of the carbamazepine – nicotinamide physical 
mixture is 125.8°C. This may suggest that the eutectic point plays an 
important role in the cocrystallisation process. However, to explore this, 
samples from each extruder barrel zone would be required.  
The issue regarding locating the extruder barrel zones was solved by 
marking the start of each zone on the side of the extruder barrel. This did not 
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interfere with the extrusion process and provided a simple way of 
determining the location of each zone. Two more extrusion runs were carried 
out under the conditions of screw geometry B, 20 rpm screw speed and 
temperature codes T135 and T140. Samples were collected from all extruder 
zones (Zone 2 to the extruded sample). The PXRD spectra are shown in 
figure 5.12 and figure 5.13 for T135 and T140 respectively. 
 
Figure 5.12 PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. zone 2 
sample, C. zone 3 sample, D. zone 4 sample, E. zone 5 sample, F. zone 
6 sample, G. zone 7 sample, H. zone 8 sample, I. zone 9 sample, J. zone 
10 sample, K. extrudate sample, L. CBZ-NIC 1:1 co-crystal (Solvent 
evaporation method section 3.3). 
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Figure 5.13 PXRD spectra of A. CBZ-NIC 1:1 physical mixture, B. zone 2 
sample, C. zone 3 sample, D. zone 4 sample, E. zone 5 sample, F. zone 
6 sample, G. zone 7 sample, H. zone 8 sample, I. zone 9 sample, J. zone 
10 sample, K. extrudate sample, L. CBZ-NIC 1:1 co-crystal (Solvent 
evaporation method section 3.3). 
For the T135 extrusion run in figure 5.12, the three main co-crystal PXRD 
peaks appear at zone 6 of the extruder barrel. The temperature of zone 6 for 
the T135 temperature profile was 130°C, and the temperature of zone 5 was 
120°C. For the T140 extrusion run, the PXRD spectra in figure 5.13 indicate 
that cocrystallisation first occurs at zone 5 of the extruder barrel. For the 
T140 temperature profile, the temperature of zone 5 is 125°C. Therefore, the 
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eutectic melting point of the carbamazepine – nicotinamide physical mixture 
is very important for cocrystallisation of this pair. Although it is unclear from 
the PXRD spectra which extrusion run produced the best co-crystal yield, the 
higher temperature of T140 may provide a more optimal environment for 
cocrystallisation because the co-crystals start to form earlier along the 
extruder barrel, allowing the co-crystals to form and grow for the remainder 
of the residence time. 
5.23 NIR analysis 
An alternative characterisation method was chosen to analyse the extruded 
material. NIR spectroscopy was believed to provide key molecular 
information about the material as well as the capability to provide more detail 
about the co-crystal yield, particularly when chemometric techniques were 
applied, such as the second derivative. The rapid scanning time for the 
offline, reflection NIR spectroscopy mode, ensured that the NIR spectra gave 
a more accurate characterisation of the extruded materials than PXRD, this 
is because the time it took for PXRD of some samples was several hours, in 
which time, more co-crystal may have formed. 
Firstly, the original and second derivative NIR spectra for carbamazepine, 
nicotinamide, CBZ-NIC 1:1 physical mixture and the CBZ-NIC 1:1 co-crystal 
are shown in figure 5.14.  
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Figure 5.14 Original (Top) and second derivative (Bottom) NIR spectra 
of carbamazepine (Form III), nicotinamide, CBZ-NIC 1:1 physical 
mixture and CBZ-NIC 1:1 co-crystal (Solvent evaporation method 
section 3.3). All the spectra shown have been treated with SNV baseline 
correction. 
Extrusion runs were carried out at different screw speeds of 10 rpm and 20 
rpm and with different temperature profiles. Screw geometry B was used for 
all the runs. The NIR spectra collected from the extruded samples are shown 
in figure 5.15.  
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Figure 5.15 Original NIR spectra of A. 1:1 CBZ-NIC physical mixture, B. 
T120 SGB 20 rpm sample, C. T125 SGB 20 rpm sample, D. T130 SGB 20 
rpm sample, E. T135 SGB 20 rpm sample, F. T140 SGB 20 rpm sample, 
G. T130 SGB 10 rpm sample, H. T135 SGB 10 rpm sample, I. T140 SGB 
10 rpm sample, J. 1:1 CBZ-NIC co-crystal (Solvent evaporation method 
section 3.3). 
The NIR spectra of the extruded samples in figure 5.15 show a large 
reduction of the intensity of the carbamazepine NIR bands situated at 4555, 
5045, 5064, 6576, 6807 and 8358 cm-1. The intensity of these bands 
reduced further when the screw speed was decreased to 10 rpm (Spectra G, 
H and I). This is a clear indication of the impact the 10 rpm screw speed has 
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on the co-crystal yield of the extruded samples. The unique co-crystal bands 
at 4073, 4478, 4771, 5002, 6503, 6680 cm-1 are indicated by the black 
arrows in figure 5.15. The NIR spectra suggest that all extruded samples 
have a relatively high co-crystal yield, and this yield increased when the 
screw speed was decreased. To extract more information from the spectra, 
the second derivative spectra for the extruded samples are shown in figure 
5.16. 
The second derivative NIR spectra in figure 5.16 have been colour 
coordinated to orange/red colours for 20 rpm samples and blue/purple 
colours for 10 rpm samples to make the graphs clearer. The samples 
processed at 10 rpm have more NIR bands in line with the bands for the 1:1 
co-crystal compared to the 20 rpm samples. However, a smaller region was 
required to observe differences in the spectra of the extruded samples.  
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Figure 5.16 Second derivative NIR spectra of 1:1 CBZ-NIC physical 
mixture, T130 SGB 20 rpm sample, T135 SGB 20 rpm sample, T140 SGB 
20 rpm sample, T130 SGB 10 rpm sample, T135 SGB 10 rpm sample, 
T140 SGB 10 rpm sample, 1:1 CBZ-NIC co-crystal (Solvent evaporation 
method section 3.3). 
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Figure 5.17 shows second derivative NIR spectra for the region of 4930 cm-1 
to 5150 cm-1 taken from figure 5.16. This region provided the clearest 
indication of how the co-crystal yield increased when the samples were 
processed at a 10 rpm screw speed compared to the 20 rpm.  
 
Figure 5.17 Second derivative NIR region 4930 cm-1 to 5150 cm-1 spectra 
of 1:1 CBZ-NIC physical mixture, T130 SGB 20 rpm sample, T135 SGB 
20 rpm sample, T140 SGB 20 rpm sample, T130 SGB 10 rpm sample, 
T135 SGB 10 rpm sample, T140 SGB 10 rpm sample, 1:1 CBZ-NIC co-
crystal (Solvent evaporation method section 3.3). 
NIR spectra were also collected for the extruded samples from the 
experiments in section 5.22. The original spectra for the extruded samples, 
taken from the barrel zones and the final extruded sample under the 
conditions of T135 SGB 20 rpm, T140 SGB 20 rpm and T140 SGB 10 rpm 
are plotted in figure 5.18. The spectra for all three extrusion runs displayed 
observable changes in the spectra between zone 5 and zone 8.  
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Figure 5.18 NIR spectra of samples taken from along the extruder barrel 
from zone 2 to the extruded material. A) T140 SGB 10 rpm, B) T140 SGB 
20 rpm, C) T135 SGB 20 rpm. The arrows indicate the samples starting 
at zone 2 and finishing at the extruded material. The 1:1 carbamazepine 
nicotinamide physical mixture is also included (The grey spectrum). 
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Between these four zones, carbamazepine bands reduced in intensity, and 
co-crystal bands significantly increased in intensity. The carbamazepine 
band at 6807 cm-1 indicated the amount of pure carbamazepine left in each 
sample, this band exhibited a significant reduction in intensity at zone 8 for 
the T135 SGB 20 rpm run, and at zone 7 for the T140 SGB 20 rpm and 10 
rpm runs. 
Again, the second derivative spectra were observed to find any small 
variations between the three extrusion runs. The second derivative spectra 
are plotted in figure 5.19 for the same samples as viewed in figure 5.18. Four 
small regions were selected, 5850 to 6000 cm-1, 6780 to 6890 cm-1, 4050 to 
4150 cm-1 and 4600 to 4700 cm-1 which showed clear differences between 
the second derivative spectra. 
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Figure 5.19 Second derivative NIR regions: 5850 to 6000 cm-1, 6780 to 
6890 cm-1, 4050 to 4150 cm-1 and 4600 to 4700 cm-1. Spectra of 1:1 CBZ-
NIC physical mixture, zone 2 to zone 10 and extruded samples and 1:1 
CBZ-NIC co-crystal (Solvent evaporation method section 3.3) for three 
extrusion runs of T140 SGB 10 rpm (A), T140 SGB 20 rpm (B) and T135 
SGB 20 rpm (C). 
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The second derivative spectra in figure 5.19 showed band ‘reversal’ in 
intensity and also band shifting. The region of 5850 to 6000 cm-1 exhibited 
the bands changing their intensity from positive to negative and vice versa, 
as the co-crystal yield increased. This was also the case for the region of 
6780 to 6890 cm-1. For the regions of 4050 to 4150 cm-1 and 4600 to 4700 
cm-1, the band at approximately 4092 cm-1 shifted to 4077 cm-1 and the band 
at approximately 4663 cm-1 shifted to 4640 cm-1 with increasing co-crystal 
yield. The spectra for the samples taken from zone 6 for all three extrusion 
runs show a greater change in intensity, or greater shift towards the pure co-
crystal spectrum, as the temperature profile is increased from T135 to T140, 
and the screw speed is reduced from 20 rpm to 10 rpm. For the two 
temperature codes, the increase in temperature at zone 6 of the extruder 
barrel is from 130°C to 135°C when going from T135 to T140. As the 
carbamazepine – nicotinamide physical mixture eutectic melting point of 
125.8°C is reached earlier along the extruder barrel, as a higher temperature 
profile is used, the co-crystal begins to form earlier along the barrel.  
This section provided a clear insight into the effect of different parameters on 
co-crystal formation by hot melt extrusion. Samples taken and analysed from 
along the extruder barrel indicated that the eutectic temperature was an 
important factor for co-crystal formation as presented by PXRD and NIR 
characterisation techniques. 
5.24 SEM analysis 
Scanning electron microscopy (SEM) was an important technique used to 
support the extrusion chapter. It was viewed as a powerful technique which 
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can determine particle morphology information including particle size. In this 
section, SEM was used for analysing pure carbamazepine and nicotinamide, 
1:1 carbamazepine nicotinamide physical mixture and 1:1 carbamazepine – 
nicotinamide co-crystal. Secondly, it was employed for analysing selected 
carbamazepine nicotinamide extrusion samples. 
SEM images of pure carbamazepine and nicotinamide are shown in figure 
5.20 at 400X and 200X magnification respectively. The carbamazepine 
particles ranged from 10 µm to 100 µm in diameter and the nicotinamide 
particles ranged from 50 µm to 400 µm in diameter. 
 
Figure 5.20 SEM image of carbamazepine (Form III) 400X (Left). SEM 
image of nicotinamide 200X (Right). 
The SEM images for the 1:1 carbamazepine nicotinamide physical mixture 
are shown in figure 5.21. In the 200X image, the contrasting sizes of the 
carbamazepine and nicotinamide particles can be observed next to one 
another. Under further magnification of 2000X, carbamazepine particles can 
be seen coating the nicotinamide particle surface. 
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Figure 5.21 SEM images of 1:1 carbamazepine nicotinamide physical 
mixture at 200X magnification (Left) and 2000X magnification (Right). 
 
Figure 5.22 SEM images of 1:1 carbamazepine nicotinamide co-crystal 
(Solvent evaporation method section 3.3) at 500X magnification (Left) 
and 3000X magnification (Right). 
Figure 5.22 displays the SEM images of the 1:1 pure co-crystal made using 
the solvent evaporation technique described in section 3.3. The co-crystal is 
shown at 500X and 3000X magnification. In solution, the co-crystals grew 
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following a needle shaped morphology. The co-crystal needles had a width 
between 2 µm and 5 µm and a length between 10 µm and 300 µm. 
Selected extrusion samples from section 5.2 were analysed using SEM. The 
images for the extruded sample for the extrusion run carried out under the 
conditions T135 SGB 20 rpm are shown in figure 5.23. At the magnifications 
of 500X and 1000X, 1:1 co-crystal needles were observed. The needles had 
a width between 2 µm and 10 µm and the needle lengths were between 5 
µm and 80 µm. The needles were generally shorter than the co-crystal 
needles produced using solution evaporation in figure 5.22. There was also 
evidence of hollow co-crystal needles in the 1000X magnification image 
(Circled in red), the unique conditions of twin screw extrusion could have 
caused this morphology to occur. 
 
Figure 5.23 SEM images of the carbamazepine nicotinamide extruded 
sample: T135 SGB 20 rpm at 500X magnification (Left) and 1000X 
magnification (Right). 
SEM images of the extruded sample, using conditions T140 SGB 10 rpm, 
are shown in figure 5.24. There were no hollow co-crystal needles located in 
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the section of the sample that was viewed under the microscope. The SEM 
images do however show co-crystal needles which were slightly shorter than 
those found in figure 5.23. The image of 3000X magnification was displayed 
because it exhibited a large co-crystal needle, with a width of approximately 
5 µm adjacent to a much thinner co-crystal needle. It was evident, that the 
unique ‘journey’ of the material through the extruder barrel had a significant 
impact on co-crystal morphology. It may also be the case that co-crystals 
which formed at an early extruder barrel zone, had a longer residence time, 
and may have experienced more growth than those which formed later along 
the barrel. 
 
Figure 5.24 SEM images of the carbamazepine nicotinamide extruded 
sample: T140 SGB 10 rpm at 1000X magnification (Left) and at 3000X 
magnification (Right).  
To investigate observable differences between the samples taken from the 
extruder barrel zones, SEM images were collected for zone 8 to zone 10 
samples for the T140 SGB 10 rpm extrusion run. Figure 5.25 shows the SEM 
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images for the samples from zones 8 and 9. Figure 5.26 shows SEM images 
for the samples from zone 10 and a selected image from zone 8.  
 
Figure 5.25 SEM images of carbamazepine nicotinamide extruded 
sample: T140 SGB 10 rpm zone 8 at 3000X magnification (Left) and 
zone 9 at 3000X magnification (Right). 
 
Figure 5.26 SEM images of carbamazepine nicotinamide extruded 
sample: T140 SGB 10 rpm zone 10 at 3000X magnification (Left) and a 
selected image from zone 8 at 1000X magnification (Right). 
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It is difficult to determine co-crystal yield from examining the SEM images in 
figures 5.25 and 5.26, however there is a clear presence of the co-crystal 
needles. Many are short, however some of the surface needles appear to 
have a longer morphology. The number of co-crystal needles with a longer 
motif on the surface of the agglomerated particles from zone 9 to zone 10 
increased. This could indicate that the co-crystals undergo further growth 
between zones 9 and 10, or alternatively it could suggest that the larger co-
crystal needles are formed at zone 10 in the early stages of the extrusion 
process which are then “picked up” by the agglomerated co-crystal particles 
when the extrusion process has been running for longer period of time. The 
image in figure 5.26 from the zone 8 sample shows a particularly long needle 
that was located with an approximate length of 300 µm, however it must be 
noted that the majority of the bulk agglomerated co-crystals typically had a 
length of no longer than 10 µm. 
To conclude this section, it was found that the carbamazepine particles had a 
smaller diameter than the nicotinamide particles. The carbamazepine 
particles were seen to coat the nicotinamide particles after physical mixing. 
The co-crystal forms needle shaped crystals which have a small width of 2-5 
µm and a length which can vary significantly between 10 µm and 300 µm. 
The length of the co-crystal needles are restricted more by the extrusion 
process compared to the solvent evaporation method and more co-crystal 
needles with a longer length appear at zone 10 of the extruder barrel. 
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5.3 Degradation study 
In this section, the extrusion of pure carbamazepine and nicotinamide was 
carried out to investigate if any transformations take place when they are 
extruded at high temperatures. Characterisation and analysis of the extrusion 
products was conducted. Finally, a HPLC study was carried out to determine 
the amount of iminostilbene present in samples containing carbamazepine to 
determine the extent of degradation which can occur during hot melt 
extrusion.  
5.31 Overview 
Extrusion was carried out with pure carbamazepine and nicotinamide. It was 
important to investigate the behaviour and transformations, if any, that the 
pure materials underwent during extrusion. The materials were extruded 
using the high shear screw geometry, SGB, 10 rpm screw speed and at high 
temperatures to exaggerate any polymorphic transformations and to 
determine if any degradation had occurred. 
The extrusion of carbamazepine was carried out under the conditions of 
T150, SGB 10 rpm. PXRD and DSC techniques were used for sample 
analysis and characterisation. Firstly, the PXRD spectra in figure 5.27 
confirm the extruded carbamazepine had transformed into carbamazepine 
form I. The peaks at approximately 3.6°, 5.4°, 6.0°, 7.7°, 8.4° and 9.2° (2θ) 
are good indicators of carbamazepine form I and are present in the extruded 
carbamazepine spectrum. Upon heating in a DSC chamber at 10°C/min, 
carbamazepine usually transforms into form I at approximately 179°C. 
However under the high shear and mixing of screw geometry B used for the 
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extrusion run, the carbamazepine transformed into form I using a 
temperature profile with a maximum temperature of 150°C reached along the 
extruder barrel. 
 
Figure 5.27 PXRD spectra of carbamazepine (Form III) and extruded 
carbamazepine using screw geometry B, 10 rpm screw speed and 
temperature profile T150. 
The DSC results are shown in figure 5.28. The pure carbamazepine 
thermogram displays the melting point of carbamazepine form III, the 
crystallisation of carbamazepine form I and the subsequent melting point of 
carbamazepine form I. The extruded sample thermogram exhibits an 
endothermic peak at approximately 154.3°C which could be caused by the 
melting of some remaining carbamazepine form III and then an endothermic 
peak at 192.1°C which signifies the melting of carbamazepine form I. 
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Figure 5.28 DSC thermograms of carbamazepine (Form III) and 
extruded carbamazepine using screw geometry B, 10 rpm screw speed 
and temperature profile T150. 
Pure nicotinamide was extruded using the screw geometry B, 10 rpm and 
temperature profiles of T140 and T150. The PXRD spectra are shown in 
figure 5.29 for the pure nicotinamide and the two extruded samples. Although 
it appears some shifting has occurred this may have been caused by 
instrumental error, the powder not being level or by crystal morphological 
differences. The extruded samples exhibited all of the common XRD peaks 
associated with nicotinamide; there was no evidence to suggest any 
transformations had occurred. 
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Figure 5.29 PXRD spectra of nicotinamide and extruded nicotinamide 
using screw geometry B, 10 rpm screw speed and temperature profiles 
T140 and T150. 
 
Figure 5.30 DSC thermograms of nicotinamide and extruded 
nicotinamide using screw geometry B, 10 rpm screw speed and 
temperature profiles T140 and T150. 
The DSC thermograms for pure nicotinamide and the two extruded samples 
are shown in figure 5.30. The melting peak for nicotinamide is exhibited for 
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both extruded samples and there was no evidence of any impurities or any 
transformations which may have occurred. 
To conclude this section, carbamazepine transformed into form I after it was 
extruded using the temperature profile of T150. This was unexpected 
because the XRD peaks for form I were not present in the extruded samples 
when carbamazepine was extruded with nicotinamide. The carbamazepine 
nicotinamide 1:1 co-crystal could be thermodynamically or kinetically 
favoured to form compared to carbamazepine form I when carbamazepine is 
extruded in the presence of nicotinamide, even at higher temperatures. The 
extruded nicotinamide did not indicate any impurities or transformations after 
it was extruded at high temperature profiles of T140 and T150. 
5.32 HPLC results 
The analysis of iminostilbene was carried out using HPLC. The results are 
shown in figure 5.31 for the following extrusion samples: extruded 
carbamazepine using T130 temperature profile, extruded carbamazepine 
using T140 temperature profile and extruded carbamazepine nicotinamide 
using T140 temperature profile. 
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Figure 5.31 HPLC iminostilbene analysis results. 
Interestingly, the sample for the extruded carbamazepine nicotinamide 
physical mixture had the highest amount of iminostilbene present. The 
presence of iminostilbene indicates the degradation of carbamazepine 
molecules. Degradation could be caused by the high temperature, high shear 
conditions within the extruder barrel. The relatively long residence time of the 
material in the extruder barrel is also a factor which can cause degradation to 
occur. The presence of nicotinamide may alter the powder flow during the 
extrusion process, compared to extruding carbamazepine on its own. This 
difference in powder flow may explain why there is a slightly higher amount 
of iminostilbene found in the CBZ NIC T140 sample. The presence of 
nicotinamide also causes a partial melt of the physical mixture at the 
previously discussed eutectic melting point. This melting event could also be 
a factor in the degradation of carbamazepine. 
Considering the HPLC results in figure 5.31, all of the analysed samples 
presented a relatively small amount of iminostilbene. The United States 
Pharmacopeial Convention (USPC) held in 2015 updated the acceptance 
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criteria for carbamazepine related degradation compounds in carbamazepine 
tablets (Convention 2015). The revised criteria, for any degradation products 
of carbamazepine, was a limit of 0.2%. The HPLC results presented 
iminostilbene concentrations well below this limit. 
5.4 Conclusion 
Chapter 5 presented a solvent-free hot melt extrusion method for the 
extrusion of two pharmaceutical co-crystal pairs. The effect of temperature, 
shear and screw speed on co-crystal yield was investigated. The results 
directly link up with chapter 4, where the temperature was found to be the 
most important parameter for cocrystallisation. However, the level of shear 
(Screw configuration) and the residence time (Screw speed) played 
important roles in attempting to optimise the co-crystal yield. Temperatures 
above the physical mixture eutectic points provided higher co-crystal yields, 
whilst higher shear and reduced residence times improved the co-crystal 
yield further. 
The degradation study conducted for one of the co-crystal pairs provided 
crucial information and helped to reassure the potential of the solvent-free 
hot melt extrusion technique. The degradation of carbamazepine was 
minimal and the extruded samples would meet FDA standards if produced in 
tablet form. 
NIR spectroscopy proved to be an effective characterisation technique which 
delivered rapid and accurate information for the extruded samples. Its ease 
of use and its ability to distinguish between small differences in the samples 
made the technology the favourite choice for material characterisation. 
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Overall, this chapter showcased the potential of extrusion technology in the 
pharmaceutical sector. Pharmaceutical co-crystals were successfully 
manufactured using this technology however it was unclear if 100% co-
crystal yield was achieved. Further extrusion experiments are required in 
order to fully optimise the technology; however this study helped to provide 
information on the effect of different parameters on cocrystallisation. 
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CHAPTER 6 A CO-CRYSTAL QUANTIFICATION 
METHOD 
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An in-depth investigation of the use of NIR spectroscopy for qualitative and 
quantitative purposes within the pharmaceutical field was carried out in 
chapter 2, section 2.92. The literature review revealed NIR spectroscopy was 
increasingly being used for analysing pharmaceutical materials, including 
pharmaceutical co-crystals. In chapter 5, it was demonstrated that NIR 
spectroscopy can distinguish between a co-crystal and its individual 
components and it was a useful characterisation technique.  
In this chapter, NIR spectroscopy was used to predict the concentration of 
two pharmaceutical co-crystals; 1:1 ibuprofen – nicotinamide (IBU-NIC) and 
1:1 carbamazepine – nicotinamide (CBZ-NIC). The mathematical spectral 
analysis was carried out using partial least squares (PLS) regression. A PLS 
model was developed for both co-crystal pairs using sets of standard 
samples to create calibration and validation data sets with which to build and 
validate the models.  
To evaluate each model that was created, the root mean square error of 
calibration (RMSEC), root mean square error of prediction (RMSEP) and 
correlation coefficient were used to assess the accuracy and linearity of the 
models. The objective of this chapter was to create accurate PLS regression 
models for both co-crystal pairs which can be used to predict the co-crystal 
concentration in a powder mixture of the co-crystal and the active 
pharmaceutical ingredient (API). In the following sections, the PLS analysis 
of each co-crystal pair is discussed along with an in-depth look at the NIR 
regions and chemometric pre-treatments that were used. 
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6.1 Ibuprofen – nicotinamide 
In this section, the Ibuprofen – nicotinamide pair have been fully analysed 
and discussed. The NIR regions, chemometric pre-treatments and the results 
from the PLS analysis are presented in the following sub-sections. 
6.11 NIR region selection   
To select the NIR regions used for the PLS regression model, the whole 
spectra was examined in the original state (Figure 6.1). The 1:1 IBU NIC CC 
spectrum had unique bands at approximately 4794, 5087, 6460, 6676, 8285 
and 8393 cm-1, compared to ibuprofen, nicotinamide and their physical 
mixture. 
 
Figure 6.1 NIR spectra for ibuprofen, nicotinamide, IBU-NIC 1:1 physical 
mixture (PM) and IBU-NIC 1:1 co-crystal (CC) (Microwave method 
section 3.2). For this figure, the spectra were pre-treated using SNV 
across the whole region 10000-4000 cm-1. 
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The spectra were also examined in the second derivative and are shown in 
figure 6.2. The second derivative was able to extract more detail from the 
NIR spectra and importantly, it is an effective tool for distinguishing NIR 
spectra of materials which are very similar to one another at the molecular 
level. 
 
Figure 6.2 Second derivative NIR spectra for ibuprofen, nicotinamide, 
IBU-NIC 1:1 physical mixture (PM) and IBU-NIC 1:1 co-crystal (CC) 
(Microwave method section 3.2). For this figure, the spectra were pre-
treated using SNV and Norris smoothing across the whole region 
10000-4000 cm-1. 
We were only able to identify six unique bands when viewing the normal co-
crystal spectra in figure 6.1. However, in figure 6.2, there was a much larger 
number of unique second derivative NIR bands associated with the 1:1 
ibuprofen – nicotinamide co-crystal compared to the individual components 
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and their physical mixture. This ability to differentiate between the materials 
much more effectively in the second derivative was promising for NIR 
prediction purposes. This is because the PLS regression uses the spectral 
data for predicting the co-crystal yield. 
Many different NIR regions were evaluated for the ibuprofen – nicotinamide 
PLS model. The RMSEC, RMSEP and correlation coefficient values were 
used to determine the performance of each region. The TQ Analyst software 
which was used to create the PLS models was able to suggest regions 
according to the covariance of the spectral data. However, when the 
suggested regions were used for the PLS model, the aforementioned error 
values were worse than those for the models which used manually selected 
regions. 
The manually selected NIR regions were reviewed, and in total, nine different 
NIR regions were chosen for further investigation based on their 
performance. Firstly, the whole NIR region (10000-4000 cm-1 wavenumber) 
was selected, and then relatively large regions to avoid areas that can be 
affected by noise were chosen. Next, medium sized regions of interest were 
selected followed by small sized regions which generally covered a small 
number of bands of interest. The nine NIR regions were as follows: 10000-
4000, 10000-5400, 9000-4700, 7450-7000, 6100-5600, 6820-6620, 9000-
8000, 6080-6030, 5100-4910 cm-1 (Wavenumber). 
Standard samples were formulated to make the calibration and validation 
sets. The samples for the ibuprofen – nicotinamide pair were made by 
another PhD student, Abdolati Alwati. Refer to section 3.9 for more 
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information about the standard samples. The NIR spectra for the standard 
samples were collected. The nine different NIR regions trialled for the PLS 
models are shown in figure 6.3 in the second derivative for ibuprofen, 25% 
CC, 50% CC, 75% CC and the pure 1:1 co-crystal (100% CC). 
 
 
 
 
A 10000-4000 cm-1 
B 10000-5400 cm-1 
C 9000-4700 cm-1 
D 7450-7000 cm-1 
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E 6100-5600 cm-1 
F 6820-6620 cm-1 
G 9000-8000 cm-1 
H 6080-6030 cm-1 
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Figure 6.3 A to I show the nine different NIR regions. Second derivative 
NIR spectra for ibuprofen, 25%CC, 50%CC, 75%CC and 100%CC. All 
spectra were pre-treated using SNV and Norris smoothing across the 
whole region 10000-4000 cm-1. 
The NIR regions in figure 6.3 are shown in the second derivative for two 
reasons; it is easier to observe the spectral shifting and the differences in the 
absorbance intensity are more distinct. As the co-crystal yield is increased in 
the standard samples, the second derivative NIR bands shift towards the 1:1 
co-crystal bands. This was expected because as the co-crystal concentration 
is increased, the co-crystal NIR bands will have more influence over the 
resulting spectral pattern. 
6.12 Chemometric treatments 
For each of the nine NIR regions discussed in section 6.11, different levels of 
chemometric pre-treatments were carried out to determine their effect on the 
RMSEP and RMSEC values for the PLS analysis. 
Five types of chemometric pre-treatments were used for both co-crystal pairs 
which included the standard normal variate (SNV) first and second 
Wavenumber (cm-1) 
I 5100-4910 cm-1 
Ibuprofen 25%CC 50%CC 75%CC 100%CC
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derivatives, Savitzky-Golay smoothing (SGS) and Norris smoothing (NS) 
algorithms. SNV pre-treatment was used to compensate for differences in 
sample pathlength. The SNV was carried out over the full spectral range 
(4000-10000 cm-1 wavenumbers) and effectively minimised any scaling or 
offset effects which may have occurred. 
First and second derivatives were used to improve the resolution of 
overlapping bands, whilst also acting as a linear baseline correction method. 
It was also beneficial to view individual spectra in the second derivative as 
discussed in section 6.11. 
Smoothing techniques were applied to reduce noise. SGS was carried out 
using 7 data points and a polynomial order of 3. NS was carried out using a 
segment length of 5 and a gap between segments length of 5. Both 
smoothing techniques can affect the performance of a PLS model. 
The RMSEC, RMSEP and correlation coefficient values were recorded for 
each NIR region. Table 6.1 and table 6.2 display the RMSEC and RMSEP 
values for each PLS model respectively. The results suggest that the level of 
chemometrics applied to the spectra had a significant impact on both the 
calibration and prediction error values. The most significant reduction of the 
RMSEC and RMSEP values was caused by applying the SNV. The SNV 
baseline correction algorithm compensates for differences in the pathlength 
and the PLS regression is heavily influenced by the spectral band intensities 
in comparison with one another. Therefore, the SNV pre-treatment played a 
crucial role in improving the model accuracy and prediction capabilities. After 
applying the SNV, the evaluated regions then reacted differently to the 
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various levels of other chemometric techniques. The ten models with the 
lowest RMSEC values in table 6.1 and table 6.2 are in bold text to help 
visualise their distribution in relation to the different chemometrics that were 
applied. 
Table 6.1 IBU-NIC model: A matrix of RMSEC values of the PLS 
regression models when using different regions and different levels of 
chemometrics (Bold text = top ten models). 
Region 
(Wavenumber 
cm-1) 
RMSEC Values (%) 
Original SNV 
SNV 
1st 
Dev. 
SNV 
1st 
Dev.  
SGS 
SNV 
1st 
Dev.  
NS 
SNV 
2nd 
Dev. 
SNV 
2nd 
Dev.  
SGS 
SNV 
2nd 
Dev.  
NS 
10000-5400 7.17 1.20 1.08 1.08 0.97 1.11 1.13 1.10 
10000-4000 2.21 1.14 1.67 1.67 1.38 1.83 1.79 1.54 
9000-8000 6.07 2.60 0.87 0.90 1.07 0.89 0.96 1.11 
9000-4700 1.96 1.05 1.03 1.03 0.92 1.10 0.96 1.06 
7450-7000 6.17 3.04 1.01 0.99 1.85 1.22 0.99 0.77 
6820-6620 4.99 2.98 2.93 2.94 3.10 3.22 2.66 2.94 
6100-5600 5.12 1.09 1.17 1.17 1.16 1.20 1.19 1.21 
6080-6030 3.36 1.96 0.92 0.95 1.56 1.95 1.41 1.45 
5100-4910 2.40 1.47 2.90 2.91 2.82 2.66 2.90 2.81 
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Table 6.2 IBU-NIC model: A matrix of RMSEP values of the PLS 
regression models when using different regions and different levels of 
chemometrics (Bold text = top ten models). 
Region 
(Wavenumber 
cm-1) 
RMSEP Values (%) 
Original SNV 
SNV 
1st 
Dev. 
SNV 
1st 
Dev. 
SGS 
SNV 
1st 
Dev.  
NS 
SNV 
2nd 
Dev. 
SNV 
2nd 
Dev.  
SGS 
SNV 
2nd 
Dev.  
NS 
10000-5400 11.80 0.91 1.52 1.52 1.37 1.88 1.73 1.64 
10000-4000 4.61 1.74 3.13 3.12 2.29 3.57 3.38 2.69 
9000-8000 12.50 1.84 1.54 1.59 1.48 1.60 1.80 1.93 
9000-4700 3.57 1.10 1.78 1.78 1.42 1.93 1.74 1.70 
7450-7000 9.82 4.34 1.28 1.26 1.77 1.57 1.52 0.95 
6820-6620 4.64 2.99 2.18 2.17 2.50 4.72 2.69 2.47 
6100-5600 4.58 1.96 1.67 1.68 1.44 1.88 1.80 1.56 
6080-6030 3.03 1.52 0.92 0.94 1.20 1.69 1.62 1.48 
5100-4910 2.86 1.60 3.23 3.23 3.33 2.86 2.92 3.00 
 
After examining the RMSEC and RMSEP values it was clear that certain 
chemometric pre-treatments had significantly different effects on both error 
values when used on different regions. For example, when applying the first 
derivative, SNV and Norris smoothing the RMSEC value for the region 9000-
4700 cm-1 was 0.92%, however for the region 6820-6620 cm-1 the RMSEC 
value was 3.10% under the same conditions. This was expected to be the 
case because the regions shown in figure 6.3 have different characteristics, 
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and where one region is greatly affected by a derivative or smoothing 
technique, another will not necessarily respond in the same way. 
The error of calibration was chosen to be a good indicator of the 
performance of the PLS models. Table 6.3 shows the ten PLS regression 
models which exhibited the lowest RMSEC values. The correlation 
coefficient values for the models indicated that they were all well-correlated 
linear models because they were all 0.999 to three decimal places. Also 
shown in table 6.3 was the difference between the RMSEC and RMSEP 
values, this value gave an indication of the variance between the calibration 
and validation data sets with the optimal value of 0% meaning that the 
calibration and validation data sets were identical when subjected to PLS 
regression. 
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Table 6.3 IBU-NIC model: The top ten PLS regression models in order 
of RMSEC value. The RMSEP and the difference between RMSEC and 
RMSEP are also shown along with the regions and chemometrics used. 
Model 
Region 
(cm-1) 
Chemometrics 
RMSEC 
(%) 
RMSEP 
(%) 
RMSEC 
– 
RMSEP 
(%) 
Corr. 
Coef. 
1 7450-7000 
SNV, 2nd Dev., 
NS 
0.77 0.95 -0.18 0.9997 
2 9000-8000 SNV, 1st Dev. 0.87 1.54 -0.67 0.9996 
3 9000-8000 SNV, 2nd Dev. 0.89 1.60 -0.71 0.9996 
4 9000-8000 
SNV, 1st Dev., 
SGS 
0.90 1.59 -0.69 0.9996 
5 9000-4700 
SNV, 1st Dev., 
NS 
0.92 1.42 -0.50 0.9995 
6 6080-6030 SNV, 1st Dev. 0.92 0.92 +0.00 0.9995 
7 6080-6030 
SNV, 1st Dev., 
SGS 
0.95 0.94 +0.01 0.9995 
8 9000-8000 
SNV, 2nd Dev., 
SGS 
0.96 1.80 -0.84 0.9995 
9 9000-4700 
SNV, 2nd Dev., 
SGS 
0.96 1.74 -0.78 0.9995 
10 10000-5400 
SNV, 1st Dev., 
NS 
0.97 1.37 -0.40 0.9995 
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The wavenumber region of 7450-4700 cm-1 provided the smallest calibration 
error of 0.77%, when the 2nd Dev., SNV and NS algorithms were applied, 
compared to any other region and level of chemometric pre-treatment used 
in this study for the ibuprofen – nicotinamide pair. This region provided a 
model with relatively low error values which can accurately predict the 
percentage yield of 1:1 IBU-NIC CC in samples where there is a mixture of 
ibuprofen and the 1:1 IBU-NIC CC. This model (Model 1) exhibited a small 
RMSEP value of 0.95% and the difference between the RMSEC and RMSEP 
values was only 0.18%. A small difference was a good indicator of the 
accuracy and predictability of the model. 
6.13 Selected model overview   
The selected model shown in table 6.3 (Model 1) is plotted in figure 6.4. The 
predicted co-crystal yield values for the calibration and validation samples 
are shown against the measured co-crystal yield. This model had a 
correlation coefficient of 0.9997 and no outlying points were observed. 
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Figure 6.4 IBU-NIC model: PLS regression Model 1. Using the region 
7450-7000 cm-1 and chemometrics second derivative, SNV and Norris 
smoothing. Both the calibration and validation data sets are plotted. 
In figure 6.5, the cross-validation error for Model 1 was analysed and the 
RMSECV value did not significantly improve when using more than 2 factors 
for the PLS regression. Since the models were created using 20 calibration 
samples, using more than 2 factors could have caused over-fitting of the 
curves which could have resulted in poor co-crystal yield prediction 
capabilities. 
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Figure 6.5 IBU-NIC model: PLS regression Model 1. RMSECV values 
according to the number of factors used in the PLS regression. 
The spectral and concentration factor loadings for both PLS factors were 
calculated and are plotted in figure 6.6. The factor loadings are the numerical 
loading values for the spectral and concentration contribution of the 
calibration standards for the selected factor. The first factor describes the 
majority of the variation in the calibration set, the second factor describes 
most of the remaining variation. An ideal factor loading will have evenly 
distributed points along a line that is 45 degrees from both axes. The higher 
the spectral and concentration loading values are for a given standard, the 
more significant the standard is to the selected factor. 
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Figure 6.6 IBU-NIC model: PLS regression Model 1. First and second 
factor loadings for the spectral and concentration contribution of the 
calibration standards. 
The first factor used 99.1% spectral information and 99.7% concentration 
information. The second factor used 0.5% spectral and 0.2% concentration 
information. Therefore the total spectral information used was 99.6% and the 
total concentration information from the calibration set was 99.9%. 
The data point observed in figure 6.6 with 0.19 spectral loading and 5.22 
concentration loading in the second factor plot was the calibration standard 
for pure ibuprofen, it was expected that this standard would have some 
influence to the loading values due to it being pure ibuprofen. 
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The residual values for Model 1 were plotted against the measured co-crystal 
yield in figure 6.7. The residuals are the measured co-crystal yield values 
subtracted from the predicted co-crystal yield values. 
 
Figure 6.7 IBU-NIC model: Model 1 residuals plot. Using the region 
7450-7000 cm-1 and chemometrics second derivative, SNV and Norris 
smoothing. 
Upon inspection of the residual plot, the points appear to be randomly 
dispersed around the horizontal axis for both the calibration and validation 
sets. This implies that the linear regression model was appropriate for Model 
2, as opposed to a non-linear model. 
The NIR region, 7450-7000 cm-1, used for Model 1 is shown in figure 6.8 in 
the second derivative. In this region, the spectra exhibited a clear and 
predictable trend, with the majority of the second derivative NIR bands 
increasing in intensity as the 1:1 co-crystal concentration was decreased 
from 100% co-crystal to 0% (Pure ibuprofen). The only exception to this 
trend was the band located between 7247 cm-1 and 7239 cm-1 (Red arrow, 
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figure 6.8), where the band increased in intensity along with the co-crystal 
concentration. 
It was difficult to identify individual bands within the NIR spectra because 
most are overtone or combination bands. The hydrogen bonding involved in 
forming the 1:1 co-crystal may have caused some of the observed band 
shifting. The most significant shift in this region is from 7108 cm-1 to 7128 cm-
1 (Black arrow, figure 6.8). Two other relatively large shifts are seen from 
7070 cm-1 to 7081 cm-1 and from 7378 cm-1 to 7367 cm-1 (Black arrows, 
figure 6.8).  
 
Figure 6.8 IBU-NIC model:  second derivative NIR spectra over the 
region 7450-7000 cm-1 with Norris smoothing of ibuprofen and the 
calibration samples with 25, 50, 75 and 100% 1:1 IBU-NIC CC.  
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6.2 Carbamazepine – nicotinamide 
In this section, the carbamazepine – nicotinamide model has been fully 
analysed and reviewed. In the same order as the ibuprofen – nicotinamide 
section, the NIR regions, chemometric pre-treatments and the results from 
the PLS analysis are presented in the following sub-sections. 
6.21 NIR region selection 
To select the NIR regions used for the PLS regression model, the whole 
spectra was observed in the original state (Figure 6.9). The 1:1 CBZ NIC CC 
spectrum had unique bands at approximately 4636, 5002, 6495 and 6696 
cm-1, compared to carbamazepine, nicotinamide and their 1:1 physical 
mixture. 
 
Figure 6.9 NIR spectra for carbamazepine, nicotinamide, CBZ-NIC 1:1 
physical mixture and CBZ-NIC 1:1 co-crystal (Solvent evaporation 
method section 3.3). For this figure, the spectra were pre-treated using 
SNV across the whole region 10000-4000 cm-1. 
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The spectra were also viewed in the second derivative and they are shown in 
figure 6.10. As explained in section 6.8, the second derivative spectra 
allowed more detail to be extracted and it was an effective tool for 
distinguishing NIR spectra of materials which are molecularly very similar. 
 
Figure 6.10 Second derivative NIR spectra for carbamazepine, 
nicotinamide, CBZ-NIC 1:1 physical mixture and CBZ-NIC 1:1 co-crystal 
(Solvent evaporation method section 3.3). For this figure, the spectra 
were pre-treated using SNV and Norris smoothing across the whole 
region 10000-4000 cm-1. 
In figure 6.9, we were only able to identify four unique bands when viewing 
the normal co-crystal spectra. However, in figure 6.10, there are an 
increased number of unique second derivative NIR bands associated with 
the 1:1 carbamazepine – nicotinamide co-crystal compared to the individual 
components and their physical mixture. The second derivative spectra 
allowed for effective differentiation of the materials, this was promising for 
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NIR prediction purposes because the PLS regression uses the spectral data 
for predicting the co-crystal yield. 
Just like the ibuprofen – nicotinamide pair, many different NIR regions were 
evaluated for the carbamazepine – nicotinamide PLS model using the TQ 
analyst software. The RMSEC, RMSEP and correlation coefficient values 
were used to determine the performance of each region. The TQ Analyst 
software suggested regions according to the covariance of the spectral data. 
However, the PLS model calibration and prediction error values were worse 
than those for the models which used manually selected regions. 
The manually selected NIR regions were reviewed, and in total, nine different 
NIR regions were selected for further investigation by PLS regression. The 
whole region (10000-4000 cm-1 wavenumber) was selected, and then 
relatively large regions to avoid areas affected by noise were chosen. Next, 
medium sized regions of interest were selected followed by small sized 
regions which generally covered a small number of bands of interest. The 
nine NIR regions were as follows: 10000-4000, 10000-5400, 9000-5300, 
10000-9646, 9000-8500, 7200-5400, 6881-6696, 6684-6457, 6075-5827 cm-
1 (Wavenumber). It is important to note that only two of the nine regions were 
used for the ibuprofen – nicotinamide pair; 10000-4000 and 10000-5400 cm-
1. 
Standard samples were formulated to create the calibration and validation 
sets (Refer to section 3.9 for more details). The NIR spectra for the standard 
samples were collected. The nine selected NIR regions used for the PLS 
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models are shown in figure 6.11 in the second derivative for carbamazepine, 
25% CC, 50% CC, 75% CC and the pure 1:1 co-crystal (100% CC). 
 
 
 
 
A 10000-4000 cm-1 
B 10000-5400 cm-1 
C 9000-5300 cm-1 
D 10000-9646 cm-1 
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E 9000-8500 cm-1 
F 7200-5400 cm-1 
G 6881-6696 cm-1 
H 6684-6457 cm-1 
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Figure 6.11 A to I show the nine different NIR regions. Second 
derivative NIR spectra for carbamazepine, 25%CC, 50%CC, 75%CC and 
100%CC. All spectra were pre-treated using SNV and Norris smoothing 
across the whole region 10000-4000 cm-1. 
6.22 Chemometric treatments 
For each of the nine NIR regions discussed in section 6.21, different levels of 
chemometric pre-treatments were carried out to determine their effect on the 
RMSEP and RMSEC values for the PLS analysis. The chemometrics are 
exactly the same as those described in section 6.11 for the ibuprofen – 
nicotinamide pair. The chemometric pre-treatments used were the SNV, first 
and second derivatives, SGS and NS 
The RMSEC, RMSEP and correlation coefficient values were calculated for 
each NIR region. Table 6.4 and table 6.5 display the RMSEC and RMSEP 
values for each regression model respectively. The results suggested that 
the level of chemometrics used had a significant impact on both error values; 
this was the same for the ibuprofen – nicotinamide pair. The most significant 
reduction of the RMSEC and RMSEP values was caused by applying the 
Wavenumber (cm-1) 
I 6075-5827 cm-1 
Carbamazepine 25%CC 50%CC 75%CC 100%CC
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SNV. After using the SNV, the evaluated regions then reacted differently to 
the various levels of chemometrics. The ten models with the lowest RMSEC 
values are highlighted in bold text to help visualise their distribution related to 
the different chemometrics that were applied. 
Table 6.4 CBZ-NIC model: A matrix of RMSEC values of the PLS 
regression models when using different regions and different levels of 
chemometrics (Bold text = top ten models). 
Region 
(Wavenumber 
cm-1) 
RMSEC Values (%) 
Original SNV 
SNV 
1st 
Dev. 
SNV 
1st 
Dev.  
SGS 
SNV 
1st 
Dev.  
NS 
SNV 
2nd 
Dev. 
SNV 
2nd 
Dev.  
SGS 
SNV 
2nd 
Dev.  
NS 
10000-9646 5.01 3.16 1.55 1.54 2.37 1.51 1.63 2.67 
10000-5400 6.99 2.40 3.42 2.49 2.49 2.23 3.29 2.46 
10000-4000 6.46 2.76 2.84 2.84 2.77 2.86 2.94 2.80 
9000-8500 7.10 3.28 2.28 2.30 2.42 1.18 1.23 2.32 
9000-5300 6.88 2.60 2.52 2.52 2.51 2.44 2.55 2.49 
7200-5400 6.35 2.68 2.58 2.58 2.58 2.59 2.62 2.56 
6881-6696 5.26 3.18 2.68 2.68 2.66 2.70 2.68 2.57 
6684-6457 5.58 2.52 2.58 2.58 2.58 2.56 2.59 2.60 
6075-5827 6.25 3.21 3.26 3.26 3.33 2.82 2.95 3.31 
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Table 6.5 CBZ-NIC model: A matrix of RMSEP values of the PLS 
regression models when using different regions and different levels of 
chemometrics (Bold text = top ten models). 
Region 
(Wavenumber 
cm-1) 
RMSEP Values (%) 
Original SNV 
SNV 
1st 
Dev. 
SNV 
1st 
Dev.  
SGS 
SNV 
1st 
Dev.  
NS 
SNV 
2nd 
Dev. 
SNV 
2nd 
Dev.  
SGS 
SNV 
2nd 
Dev.  
NS 
10000-9646 3.29 3.59 3.92 4.00 3.04 5.49 4.73 3.71 
10000-5400 5.03 2.71 4.22 3.09 3.11 3.07 4.52 3.00 
10000-4000 5.59 3.51 4.20 4.21 3.91 4.58 4.51 4.09 
9000-8500 4.26 4.28 3.32 3.32 3.30 4.26 3.53 3.33 
9000-5300 4.97 3.00 3.13 3.13 3.15 3.04 3.08 3.03 
7200-5400 4.87 3.12 3.18 3.18 3.20 3.09 3.13 3.10 
6881-6696 4.44 3.95 3.41 3.41 3.36 3.41 3.33 3.11 
6684-6457 4.08 2.99 3.00 3.00 2.98 3.15 3.07 2.99 
6075-5827 5.05 4.23 4.12 4.12 4.34 3.42 3.69 4.34 
 
After examining the RMSEC and RMSEP values it was clear that certain 
chemometric pre-treatments had significantly different effects on both error 
values when used on different regions.  
The error of calibration was a good indicator of the performance of the PLS 
models. Table 6.6 shows the ten PLS regression models which exhibited the 
lowest RMSEC values. The correlation coefficient values for the models were 
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0.99 to two decimal places and the top two models were 0.999 to three 
decimal places. This provided evidence that they were all well correlated 
linear models. Table 6.6 also displays the difference between the RMSEC 
and RMSEP values to give an indication of the variation between the 
calibration and validation data sets with the optimal value of 0% for the 
identical performance of the calibration and validation data sets. 
Table 6.6 CBZ-NIC model: The top ten PLS regression models in order 
of RMSEC value. The RMSEP and the difference between RMSEC and 
RMSEP are also shown along with the regions and chemometrics used. 
 
Model 
Region 
(cm-1) 
Chemometrics 
RMSEC 
(%) 
RMSEP 
(%) 
RMSEC 
– 
RMSEP 
(%) 
Corr. 
Coef. 
1 9000-8500 SNV, 2nd Dev. 1.18 4.26 -3.08 0.9992 
2 9000-8500 
SNV, 2nd Dev., 
SGS 
1.23 3.53 -2.30 0.9992 
3 10000-9646 SNV, 2nd Dev. 1.51 5.49 -3.98 0.9988 
4 10000-9646 
SNV, 1st Dev., 
SGS 
1.54 4.00 -2.46 0.9987 
5 10000-9646 SNV, 1st Dev. 1.55 3.92 -2.37 0.9987 
6 10000-9646 
SNV, 2nd Dev., 
SGS 
1.63 4.73 -3.10 0.9985 
7 10000-5400 SNV, 2nd Dev. 2.23 3.07 -0.84 0.9973 
8 9000-8500 SNV, 1st Dev. 2.28 3.32 -1.04 0.9972 
9 9000-8500 
SNV, 1st Dev., 
SGS 
2.30 3.32 -1.02 0.9971 
10 9000-8500 
SNV, 2nd Dev., 
NS 
2.32 3.33 -1.01 0.9971 
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The first and second smallest calibration errors (RMSEC) of 1.18% (Model 1) 
and 1.23% (Model 2) were found when using the wavenumber region of 
9000-8500 cm-1. Therefore, this particular region provided models with 
relatively low error values which could be used to accurately predict the 1:1 
co-crystal yield in samples where there is a mixture of carbamazepine and 
the 1:1 co-crystal. 
The best overall performing model was determined as Model 2. Model 2 was 
chosen because it exhibited a smaller RMSEP value of 3.53% compared to 
4.26% for Model 1. The difference between the RMSEC and RMSEP values 
were only -2.3% for Model 2 where as it was significantly larger for Model 1, -
3.08%. 
6.23 Selected model analysis 
Model 2 is plotted in figure 6.12 where both the averaged calibration and 
validation samples are shown to compare the measured co-crystal yield to 
the PLS regression predicted co-crystal yield. This model had a correlation 
coefficient of 0.9992. 
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Figure 6.12 CBZ-NIC model: PLS regression Model 2. Using the region 
9000-8500 cm-1 and chemometrics second derivative, SNV and SG 
smoothing. 
In figure 6.13, the cross-validation error for Model 2 was analysed. The 
RMSECV value did not significantly improve when using more than 2 factors 
for the PLS regression. Considering the possibility of curve over-fitting due to 
the limited number of standard samples, it was decided that the model 
should only use 2 factors. 
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Figure 6.13 CBZ-NIC model: PLS regression Model 2. RMSECV values 
according to the number of factors used in the PLS regression. 
The spectral and concentration factor loadings for both PLS factors were 
calculated and are plotted in figure 6.14. The factor loadings are the 
numerical loading values for the spectral and concentration contribution of 
the calibration standards for the selected factor. The first factor describes the 
majority of the variation in the calibration set, the second factor describes 
most of the remaining variation. 
The first factor used 95.1% spectral information and 99.4% concentration 
information. The second factor used 0.6% spectral and 0.4% concentration 
information. The total spectral information used was 95.6% and the total 
concentration information gathered was 99.8%. 
The factor loadings in figure 6.14 were well-distributed for the first factor. 
Unlike the ibuprofen – nicotinamide model, the pure carbamazepine 
calibration standard did not have a strong influence over the second PLS 
factor for the carbamazepine – nicotinamide model. 
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Figure 6.14 CBZ-NIC model: PLS regression Model 2. First and second 
factor loadings for the spectral and concentration contribution of the 
calibration standards. 
The residual values for Model 2 were plotted against the measured co-crystal 
yield in figure 6.15. The residuals are the measured co-crystal yield values 
subtracted from the predicted co-crystal yield values. 
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Figure 6.15 CBZ-NIC model: Model 2 residuals plot. Using the region 
9000-8500 cm-1 and chemometrics second derivative, SNV and SG 
smoothing.  
In the residual plot, the points appear to be randomly dispersed around the 
horizontal axis, particularly for the calibration set. This indicates that the 
linear regression model was also appropriate for the carbamazepine – 
nicotinamide Model 2, as opposed to a non-linear model. 
For the carbamazepine – nicotinamide selected model, the validation sample 
data point with a 52.5% measured co-crystal yield in figures 6.12 and 6.15 
could be an outlier as it deviates from the linear model significantly more 
than any other data point. Table 6.7 shows the SUM of the squared residuals 
for the calibration set, validation set, and validation set excluding the point at 
52.5% measured co-crystal yield. 
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Table 6.7 CBZ-NIC model: Model 2. The SUM of the squared residuals 
for the calibration set, validation set and validation set excluding the 
point at 52.5% measured co-crystal yield. 
CBZ-NIC Selected Model (Model 2) (%) 
SUM squared residual calibration 31.59 
SUM squared residual validation 124.61 
SUM squared residual validation excl. 52.5% 36.62 
 
The squared residual for the point at 52.5% measured co-crystal yield was 
87.98%. This was 2.4 times larger than the sum of the squared residuals for 
the validation set when excluding the outlier (36.62%). If this data point is 
removed from the validation set, the RMSEP value improves from 3.53% to 
2.02% when using all of the same conditions: SNV, second derivative, SGS, 
NIR region 9000-8500 cm-1. This would bring the carbamazepine – 
nicotinamide model closer to the 1:1 IBU-NIC model when comparing their 
prediction error. 
The NIR region used for Model 2 of 9000-8500 cm-1 is shown in figure 6.16 
in the second derivative. The majority of the second derivative NIR bands in 
this region exhibited an increase in intensity as the 1:1 co-crystal 
concentration was decreased from 100% to 0% (Pure carbamazepine). 
However there were two notable exceptions to this rule at 8751 cm-1 and 
8624 cm-1 (Red arrows, figure 6.16), where the bands increased in intensity 
with an increase in the co-crystal concentration. 
It may be possible that the hydrogen bonding involved in forming the 1:1 co-
crystal may have caused some of the observed band shifting. The second 
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derivative NIR spectra for the carbamazepine – nicotinamide pair were more 
complex compared to the ibuprofen – nicotinamide pair. Some of the more 
exaggerated band shifting was observed from 8690 cm-1 to 8713 cm-1, 8663 
cm-1 to 8670 cm-1 and 8879 cm-1 to 8886 cm-1 (Black arrows, figure 6.16). 
The most prominent second derivative band associated with the co-crystal in 
this region was situated at 8751 cm-1.  
 
Figure 6.16 CBZ-NIC model:  second derivative NIR spectra over the 
region 9000-8500 cm-1 with SG smoothing of carbamazepine and the 
calibration samples with 25, 50, 75 and 100% 1:1 CBZ-NIC co-crystal. 
6.24 Quantification of co-crystal samples 
The selected model (Model 2) discussed in section 6.23 was created with the 
purpose of predicting the co-crystal yield in samples. In this section, several 
samples from the hot melt extrusion experiments outlined in chapter 5 were 
selected for 1:1 carbamazepine – nicotinamide co-crystal yield prediction 
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using this model. The full spectrum fit, measurement region fit, predicted co-
crystal concentration and prediction uncertainty were calculated for the 
extruded samples shown in table 6.8, table 6.9, table 6.10 and table 6.11. 
Table 6.8 Hot melt extrusion samples, processed at temperatures T120 
to T140, screw geometry B and screw speeds 10 rpm and 20 rpm. Their 
full spectrum fit, measurement region fit, predicted co-crystal 
concentration and prediction uncertainty values. 
Sample 
Full 
spectrum 
fit (%) 
Measurement 
region fit (%) 
Predicted co-
crystal 
concentration 
(%) 
Prediction 
uncertainty (%) 
T120 SGB 
20 rpm 
95.6 60.8 81.0 15.7 
T125 SGB 
20 rpm 
91.9 90.9 99.4 9.8 
T130 SGB 
20 rpm 
87.1 72.8 82.4 9.9 
T135 SGB 
20 rpm 
88.2 91.6 84.9 5.5 
T140 SGB 
20 rpm 
85.7 87.4 89.2 7.0 
     
T130 SGB 
10 rpm 
86.9 90.4 91.6 7.7 
T135 SGB 
10 rpm 
90.5 92.9 95.3 7.7 
T140 SGB 
10 rpm 
87.3 93.2 94.3 6.3 
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In table 6.8, the full spectrum fit values were relatively high for all extruded 
samples; this is an indication that the computed predicted co-crystal 
concentration values were accurate. The predicted co-crystal yield values 
provided evidence that as the screw speed was reduced from 20 rpm to 10 
rpm, the co-crystal yield increased. The predicted value of 99.4% for the 
T125 SGB 20 rpm sample was unexpected as this result was not supported 
by the X-ray diffraction and thermal data in chapter 5. 
Table 6.9 Hot melt extrusion samples from along the barrel, processed 
at temperature T135, screw geometry B and screw speed 20 rpm. Their 
full spectrum fit, measurement region fit, predicted co-crystal 
concentration and prediction uncertainty values. 
T135 SGB 
20 rpm 
sample 
Full 
spectrum 
fit (%) 
Measurement 
region fit (%) 
Predicted co-
crystal 
concentration 
(%) 
Prediction 
uncertainty 
(%) 
Z2 95.7 46.1 47.4 24.6 
Z3 95.1 48.0 49.2 25.1 
Z4 97.6 44.6 67.4 23.8 
Z5 92.7 47.5 51.6 21.6 
Z6 87.6 51.4 57.7 17.4 
Z7 89.9 56.9 69.7 12.5 
Z8 88.6 89.5 89.8 7.1 
Z9 89.6 94.6 91.9 7.1 
Z10 98.5 84.4 100.0 10.5 
EX 88.2 91.6 84.9 5.5 
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Table 6.10 Hot melt extrusion samples from along the barrel, processed 
at temperature T140, screw geometry B and screw speed 20 rpm. Their 
full spectrum fit, measurement region fit, predicted co-crystal 
concentration and prediction uncertainty values. 
T140 SGB 
20 rpm 
sample 
Full 
spectrum 
fit (%) 
Measurement 
region fit (%) 
Predicted co-
crystal 
concentration 
(%) 
Prediction 
uncertainty 
(%) 
Z2 97.9 47.1 59.0 24.2 
Z3 91.6 50.2 40.8 25.0 
Z4 96.9 46.9 50.4 22.9 
Z5 90.6 46.5 49.9 21.2 
Z6 87.9 58.9 69.6 11.9 
Z7 87.8 81.6 88.0 7.3 
Z8 89.7 88.3 89.2 8.1 
Z9 84.6 92.8 94.7 6.5 
Z10 87.2 91.9 92.5 6.2 
EX 85.7 87.4 89.2 7.0 
 
 
 
 
 
 
 
 
187 
 
Table 6.11 Hot melt extrusion samples from along the barrel, processed 
at temperature T140, screw geometry B and screw speed 10 rpm. Their 
full spectrum fit, measurement region fit, predicted co-crystal 
concentration and prediction uncertainty values. 
T140 SGB 
10 rpm 
sample 
Full 
spectrum 
fit (%) 
Measurement 
region fit (%) 
Predicted co-
crystal 
concentration 
(%) 
Prediction 
uncertainty 
(%) 
Z2 97.3 52.3 48.8 22.7 
Z3 95.1 47.1 50.4 25.4 
Z4 96.9 51.9 53.0 23.5 
Z5 94.1 45.3 63.4 20.1 
Z6 85.4 67.8 81.9 9.2 
Z7 86.5 85.5 88.3 6.5 
Z8 88.7 94.1 94.0 6.2 
Z9 85.6 92.7 93.1 6.9 
Z10 98.8 85.6 99.1 10.0 
EX 87.3 93.2 94.3 6.3 
 
In tables 6.9, 6.10 and 6.11, the full spectrum fit values were relatively high 
for all samples that were analysed. The predicted co-crystal concentration 
values indicated that the co-crystal yield increased steadily along the 
extruder barrel. The reduced co-crystal yield for the extruded samples was 
expected, as discussed in chapter 5. The prediction uncertainty values were 
relatively high for the samples Z2 to Z5. Due to these high uncertainty values 
it is possible the model has over-predicted the co-crystal yield for the 
samples for the first 4 extruder barrel zones. This scenario would make the 
most sense because the characterisation techniques used in chapter 5 
determined that there were very low levels of co-crystal at these initial zones. 
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This over-prediction could be caused by the presence of pure nicotinamide in 
the samples which is not factored into the prediction model. 
6.3 Discussion and conclusion 
To compare the PLS models for both co-crystal pairs, the selected model 
details are shown in table 6.12. The correlation coefficient, RMSEC and 
RMSEP values were compared. Both co-crystal pairs achieved linear models 
with relatively low error values. In summary, the ibuprofen – nicotinamide 
model had lower RMSEC and RMSEP values than the carbamazepine – 
nicotinamide model and a slightly higher correlation coefficient. 
Table 6.12 A comparison of the selected 1:1 IBU-NIC model (Model 1) 
and 1:1 CBZ-NIC model (Model 2), including the region, number of 
factors, chemometrics, RMSEC, RMSEP and correlation coefficient. 
Co- 
Crystal 
Pair 
Region 
(cm-1) 
PLS 
Factors 
Chemo- 
metrics 
RMSEC 
(%) 
RMSEP 
(%) 
Corr. 
Coef. 
IBU-NIC 7450-7000 2 
SNV, 2nd 
Dev., NS 
0.77 0.95 0.9997 
CBZ-NIC 9000-8500 2 
SNV, 2nd 
Dev., SGS 
1.23 3.53 0.9992 
 
The second derivative NIR spectra shown in figures 6.11 and 6.19 for both 
co-crystal pairs exhibited an increase in the second derivative NIR band 
intensity for the majority of the NIR bands in the selected model regions, as 
the co-crystal concentration decreased. This could suggest the PLS models 
have reduced error values when using a region where the intensity of most 
second derivative NIR bands directly correlates to a decrease in the co-
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crystal concentration. Regarding the size of the NIR regions, there was no 
clear indication that a particular region size had a large effect on the PLS 
regression performance. 
The second derivative NIR spectra used to create the carbamazepine – 
nicotinamide model were relatively complex and exhibited less distinct 
differences between each co-crystal concentration, compared to the 
ibuprofen – nicotinamide spectra. The complexity of the NIR spectra could be 
caused by the different arrangement of hydrogen bonding associated with 
the 1:1 CBZ-NIC co-crystal compared to the 1:1 IBU-NIC co-crystal. The 
different hydrogen bonding arrangements have been discussed in chapter 4. 
The complex spectra could have impacted the PLS regression performance 
and may have been the reason why the error values were higher for the 
selected carbamazepine – nicotinamide model. 
The demonstrated PLS models in this chapter were able to quantify unknown 
samples from extrusion experiments discussed in chapter 5 with a high 
accuracy. However, the prediction uncertainty values were relatively high for 
samples which may have had increased concentrations of pure nicotinamide. 
This is a downside to the models as they do not take account of pure 
nicotinamide. 
The PLS models presented in this chapter will facilitate future applications of 
NIR spectroscopy for quantifying pharmaceutical co-crystals. The results 
suggest that NIR spectroscopy could be used as a PAT tool for many 
different co-crystal manufacturing methods and could be used to improve the 
understanding of the cocrystallisation of pharmaceutical materials. 
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Chapter 4 provided evidence of how temperature and shear force effects 
cocrystallisation and the thermal events involved with forming co-crystals. 
Key crystal morphology information was also presented for the 
carbamazepine – nicotinamide pair. The light microscopy images for 
carbamazepine – nicotinamide pair were useful as the discovered 
morphologies could be directly compared to the SEM images shown in 
chapter 5. The thermal data acquired for ibuprofen – nicotinamide and 
carbamazepine – nicotinamide was also beneficial for designing the 
extrusion experiments conducted in chapter 5.  
In chapters 4 and 5, in figures 4.3 and 5.7, it was found that there was a 
relatively small endothermic melting peak during DSC heating of 
carbamazepine – nicotinamide at between 105°C and 109°C. This peak is 
not observed for nicotinamide on its own or for nicotinamide in the presence 
of any other material. The light microscopy images in figures 4.9 and 4.10 
clearly show a new crystal form appears after this melting event has taken 
place; however it is still unclear what is causing the initial endothermic peak. 
In the literature, a nicotinamide polymorph has been reported which is 
metastable and has been crystallised in solution in the presence of the API 
isoxyl (Li et al. 2011). This reported polymorph has a melting point of 
approximately 105°C. 
A study by Hino et al. (Hino et al. 2001) discovered four potential 
nicotinamide polymorphs by DSC. They found the melting points for form III 
and form IV were between 107-111°C and 101-103°C respectively. Further 
investigation would be required to characterise the phase which is causing 
the endothermic peak observed in figures 4.3 and 5.7. However there is a 
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possibility, that in the presence of carbamazepine, small quantities of 
nicotinamide form III or form IV are present under heating conditions. The 
melting of this phase may induce the crystallisation that is observed in the 
microscope images in figures 4.9 and 4.10. 
The model shear experiments in chapter 4 used several techniques to apply 
small quantities of shear to the selected pharmaceutical pairs. However, a 
new piece of technology has recently been developed which will help to 
bridge the gap between the model shear experiments and full scale hot melt 
extrusion. It is called a mini mixer and has been developed by Anton Paar 
GmbH (Model: Anton Paar Physica MCR501). It consists of an enclosed 
chamber which can be loaded to a certain fill factor of the material to be 
analysed and it also has the capability to heat and cool the material. Inside 
the chamber is a small scale screw configuration which can be designed to 
mimic a full scale extruder screw. The mini mixer can then be attached to an 
Anton Paar rheometer such as the one used in chapter 4. This piece of 
equipment is able to feedback real-time rheological measurements whilst the 
chosen material is undergoing shear conditions. This technology has the 
potential to provide key data for investigating scale-up effects of hot melt 
extrusion in the near future. 
Chapter 5 presented a solvent free continuous cocrystallisation method for 
ibuprofen – nicotinamide and carbamazepine – nicotinamide co-crystals. NIR 
spectroscopy was the favoured mode of characterisation which provided 
detailed insight into where cocrystallisation was occurring along the extruder 
barrel. The results from the extrusion experiments confirmed that 
temperature and shear play important roles in cocrystallisation and additional 
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parameters such as the screw speed can be used to increase the co-crystal 
yield. SEM analysis provided information about the agglomeration of 
extruded particles. 
The design of the extrusion experiments in chapter 5, with regards to the 
explored parameters of temperature, screw geometry and screw speed, 
provided a strong case for the relationship between the parameters and the 
co-crystal yield. However, the experimental design process itself could be 
improved using a design of experiment (DoE) methodology. To determine 
the optimum parameters for extrusion, DoE could have been implemented at 
the earliest stage of the hot melt extrusion experimental design process 
(Alagumurthi et al. 2006). 
Classical DoE and Taguchi’s DoE are common methodologies which can be 
used to optimise process variables to deliver improved product quality (Roy 
2001). In the case of extrusion, these approaches would allow for a multi-
dimensional approach to experiment design where each experiment 
performed is a point on a multi-dimensional axis. This is particularly 
important for efficiently optimizing a process because each data point or 
experiment would contribute to the optimisation of all parameters that are 
being investigated. This is very different to examining one parameter at a 
time and DoE would benefit future extrusion studies conducted in the 
pharmaceutical field. 
A small degradation study was conducted in chapter 5 which monitored the 
degradation of carbamazepine. There was a slightly raised amount of 
iminostilbene found in the extruded sample when carbamazepine was 
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extruded with nicotinamide compared to when pure carbamazepine was 
extruded. However, the level of degradation was relatively small and was not 
considered to be a detrimental factor to the technique due to the measured 
levels of iminostilbene being well below the recommended limit for 
carbamazepine tablets of 0.2%. 
Chapter 6 presented accurate co-crystal yield prediction models for the 1:1 
ibuprofen – nicotinamide and 1:1 carbamazepine – nicotinamide co-crystals, 
which can predict the 1:1 co-crystal yield in a mixture of the co-crystal and 
the API. Both models will provide a platform for in-line PAT technologies 
used in future studies. PAT technology can be used to monitor 
pharmaceutical manufacturing processes, including hot melt extrusion and 
can provide vital real-time information about a process. NIR spectroscopy is 
commonly employed as a PAT tool due to its ease of use, robustness and its 
ability to rapidly characterise materials. It is a technique which will continue 
to be developed and implemented as a PAT tool over the forthcoming years, 
specifically in the pharmaceutical industry, and it is believed that the results 
presented in chapter 6 have demonstrated the powerful advantages of this 
technique. 
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CHAPTER 8 PROJECT CONCLUSION 
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8.1 Conclusion 
The presented project was able to provide important information about 
pharmaceutical co-crystal formation and behaviour under a variety of 
conditions using several different techniques. A SFCC technique was 
successfully explored and NIR spectroscopy was deemed to be an important 
characterisation technique which provided qualitative and quantitative 
information about co-crystals and their components. Understanding the 
behaviour of the materials on the small scale, provided vital knowledge which 
was subsequently used for designing the large scale hot melt extrusion 
experiments. NIR spectroscopy was also proven to be an accurate 
characterisation tool for predicting pharmaceutical co-crystal yields. Two 
pharmaceutical co-crystal models were created using PLS which can be 
used to predict co-crystal yield. The models will facilitate future in-line PAT 
studies of pharmaceutical co-crystals. 
8.2 Future work 
Future work will include in-line NIR measurements of cocrystallisation of 
pharmaceutical co-crystals with real-time monitoring during the hot melt 
extrusion process. This in-line data will provide crucial information about 
crystallisation events during hot melt extrusion and other techniques. 
Mini mixer experiments will be conducted in order to provide small scale 
rheological data for pharmaceutical co-crystal pairs and the effect of scale on 
the outcome of hot melt extrusion. This unique technology will deliver data on 
the mixing properties of materials and the effect of small scale mixing on 
cocrystallisation. 
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Synchrotron data will be fully analysed for experiments conducted at 
Diamond Light Source and ESRF. The data will provide key knowledge on 
co-crystal formation and will link up with the shear cell data that was 
presented in chapter 4. Synchrotron X-ray data is more accurate than the 
conventional PXRD presented in this study and will provide information on 
the early stages of cocrystallisation of pharmaceutical pairs. 
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Figure A.1 Light microscopy images of 1:1 ibuprofen – nicotinamide physical mixture shear cell run 1. Showing the 
starting material (Left), after 8 minutes of shear (Centre) and post shear 33°C (Right). 
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Figure A.2 Light microscopy images of 1:1 ibuprofen – nicotinamide physical mixture shear cell run 2. Showing the 
starting material (Left), the material at 85°C pre shear (Centre) and post shear 30°C (Right). 
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Figure A.3 Light microscopy images of 1:1 nicotinamide – salicylic acid physical mixture shear cell run 1. Showing the 
starting material (Left), after 2 minutes of shear (Centre) and after 8 minutes of shear (Right). 
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Figure A.4 Light microscopy images of 1:1 nicotinamide – salicylic acid physical mixture shear cell run 2. Showing the 
starting material (Left), after 2 minutes isothermal at 120°C (Centre) and after 8 minutes of shear (Right). 
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Figure A.5 Light microscopy images of 1:1 nicotinamide – salicylic acid physical mixture shear cell run 3. Showing the 
starting material (Left), after 2 minutes isothermal at 120°C (Centre) and after 8 minutes of shear (Right). 
 
 
 
 
224 
 
 
 
Figure A.6 Light microscopy images of 1:1 caffeine - maleic acid physical mixture shear cell run 1. Showing the starting 
material (Left), after 6 minutes of shear (Centre) and post shear 35°C (Right). 
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Figure A.7 Light microscopy images of 1:1 caffeine - maleic acid physical mixture shear cell run 2. Showing the starting 
material (Left), after 2 minutes of shear (Centre) and after 8 minutes of shear (Right). 
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Figure A.8 Light microscopy images of 1:1 caffeine - maleic acid physical mixture shear cell run 3. Showing the starting 
material (Left), after 2 minutes of shear (Centre) and after 8 minutes of shear (Right). 
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Figure A.9 Light microscopy images of 1:1 caffeine - maleic acid physical mixture shear cell run 4. Showing the starting 
material (Left), after 2 minutes of shear (Centre) and after 8 minutes of shear (Right). 
228 
 
 
Figure A.10 Light microscopy images of 2:1 caffeine - maleic acid physical mixture shear cell run 5. Showing the starting 
material (Left), after 2 minutes of shear (Centre) and after 8 minutes of shear (Right). 
 
 
 
 
